Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Version:  June 23, [ADDRESS_913445] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  Lung Function  Improvement  after Bronchoscopic Lung Volum e 
Reduction with Pulmonx Endobronchial V alves used in Treatment of 
Emphysema  
(LIBERATE STUDY ) 
U.S. I nvestigational Device Exemption (IDE)  Clinical Investigational Plan 
#630 -0012 _H 
ECO# 4000
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913446] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  Table of Contents  
CLINICAL INVESTIGATION PLAN AGREEMENT FORM  ................................ ....................... 10 
1.0 Background  ................................ ................................ ................................ ......11 
1.1 Pathophysiology of Emphysema  ................................ ................................ ........ 11 
1.2 Management of Emphysema:  Lung Volume Reduction Surgery (LVRS)  ........... 11 
1.3 Bronchoscopic Lung Volume Reduction (BLVR)  ................................ ................ 11 
1.4 BLVR with the Pulmonx Endobronchial Valve (EBV)  ................................ .......... 12 
1.5 Pi[INVESTIGATOR_675657]:  The VENT Study (IDE#G020230)  .................. 12 
1.6 Learnings from the VENT Study  ................................ ................................ ......... 12 
1.7 Collateral Ventilation Impacts Lung Volume Reduction  ................................ ......12 
1.8 Measurement of Collateral Ventilation  ................................ ................................ 13 
1.9 Conclusion from the Prior Studies  ................................ ................................ ......14 
2.0 Study device and intended use  ................................ ................................ .......14 
3.0 Study device / technology description  ................................ ........................... [ADDRESS_913447]-bronchoscopy PULMONARY REHABILITATION  ................................ ...25 
10.1 Pulmonary Rehabilitation Program  ................................ ................................ .....26 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913448]-Bronchoscopy Recovery Period Procedures for Stud y Treatment Arm  ......29 
11.7 Procedures Prior to Discharge  ................................ ................................ ........... 31 
12.0 Secondary Valve Procedures  ................................ ................................ ..........32 
12.1 Valve Removal  ................................ ................................ ................................ ...32 
12.2 Valve Replacement  ................................ ................................ ............................ 32 
12.3 Valve Adjustment  ................................ ................................ ............................... 32 
13.0 Clinical Effectiveness Outcomes  ................................ ................................ ....33 
13.1 Spi[INVESTIGATOR_038]  ................................ ................................ ................................ ......... 33 
13.2 Patient -Reported Health Status Measures  ................................ ......................... 33 
13.3 Body Plethysmography Testing  ................................ ................................ .......... 35 
13.4 Diffusing Capacity Testing  ................................ ................................ ................. 35 
13.5 Medication Use  ................................ ................................ ................................ ..36 
13.6 Daily Diary  ................................ ................................ ................................ ......... 36 
13.7 Six-Minute Walk Distance (6MWD) Test  ................................ ............................ [ADDRESS_913449] X -Ray ................................ ................................ ................................ ......38 
13.10  Physical Exam  ................................ ................................ ................................ ...38 
13.11  High Resolution Computed Tomography  ................................ ........................... 38 
13.12  BODE Index  ................................ ................................ ................................ .......38 
14.0 Sequence for Testing ................................ ................................ ....................... 39 
14.1 Screening Assessment – within [ADDRESS_913450] ≤ 120 days following screening eligibility  ......... 40 
14.3 Bronchoscopy Procedure – Should occur ≤ [ADDRESS_913451] Procedure  ................................ ................................ ................................ ..41 
14.5 Prior to Discharge  ................................ ................................ .............................. 41 
14.6 Daily Follow Up Phone Call for 10 Days after Discharge (up to 11:59 pm)  ......... 42 
14.7 Day 7 after Discharge Visit (+ 1 business day)  ................................ ................... 42 
14.8 Day 30 Visit (+/ - 5 days)  ................................ ................................ ..................... 42 
14.9 Day 45 Visit (+/ - 5 days)  ................................ ................................ ..................... 42 
14.10  3 Month Visit (+/ - 14 days)  ................................ ................................ ................. 42 
14.11  6 Month Visit (+/ - 21 days)  ................................ ................................ ................. 43 
14.12  9 Month Visit (+/ - 21 days)  ................................ ................................ ................. 43 
14.13  1 Year Visit (+/ - 45 days)  ................................ ................................ ................... 43 
14.14  Annual Visits (+/ - 60) only for Study Participants treated with EBV  .................... 44 
15.0 Safety Elements  ................................ ................................ ............................... 44 
15.1 Adverse Events  ................................ ................................ ................................ ..44 
15.2 Serious Adverse Events  ................................ ................................ ..................... 46 
15.3 Management of Selected Anticipated Adverse Events  ................................ .......46 
15.4 Events Anticipated to Precipi[INVESTIGATOR_675658]  ................................ ............... 47 
16.0 Risk - benefit evalauation  ................................ ................................ ................ 48 
16.1 Potential Benefits  ................................ ................................ ............................... 48 
16.2 Potential Risks  ................................ ................................ ................................ ...48 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913452] (IRB) Approval  ................................ ......................... 48 
17.2 Confidentiality  ................................ ................................ ................................ ....48 
17.3 Ethical Considerations  ................................ ................................ ....................... 49 
17.4 Methods to Eliminate Bias  ................................ ................................ .................. 49 
17.5 Early Termination of the Clinical Investigation  ................................ .................... 49 
18.0 Clinical Site Training  ................................ ................................ ....................... 49 
18.1 Clinical Study Staff Training  ................................ ................................ ............... 49 
18.2 Procedure and Training Videos  ................................ ................................ .......... 50 
18.3 Physician Hands -on Training:  Endobronchial Valve  ................................ .......... 50 
18.4 Physician Hands -on Training:  Chartis Assessment System  .............................. [ADDRESS_913453] (DSMB)  ................................ ........................ 51 
19.2 Clinical Events Committee  ................................ ................................ ................. 52 
19.3 Operations Committee  ................................ ................................ ....................... 52 
19.4 Core Radiology Laboratory  ................................ ................................ ................ 52 
19.5 Core Spi[INVESTIGATOR_675659]  ................................ ................................ ............... 52 
19.6 Daily Diary Data Acquisition  ................................ ................................ ............... 52 
20.0 Data analysis overview  ................................ ................................ .................... 52 
20.1 Populations for Effectiveness and Additional Measures  ................................ .....52 
20.2 Safety Analysis Population  ................................ ................................ ................. 53 
20.3 Primary Effectiveness Endpoint  ................................ ................................ ......... 53 
20.4 Safety Endpoint  ................................ ................................ ................................ .54 
20.5 Secondary Effectiveness Measures  ................................ ................................ ...54 
20.6 Additional Measures  ................................ ................................ .......................... 55 
20.7 Interim Analysis  ................................ ................................ ................................ .55 
20.8 Long -Term Follow -up ................................ ................................ ......................... 55 
20.9 Time Points for Data Analysis  ................................ ................................ ............ 55 
20.10  Statistical Analysis Plan  ................................ ................................ ..................... 56 
21.0 Regulatory and Reporting Requirements  ................................ ....................... 56 
21.1 Adverse Events and Reporting  ................................ ................................ ........... 56 
21.2 Serious Adverse Events and Reporting  ................................ .............................. 56 
21.3 Unanticipated Adverse Device Effects (UADE) and Reporting  ........................... 57 
21.4 Informed Consent Violation Reporting  ................................ ................................ 57 
21.5 Protocol Deviation Reporting  ................................ ................................ ............. 57 
21.6 Investigator Reporting  ................................ ................................ ........................ 57 
22.0 Study Data Reporting and Processing  ................................ ........................... 58 
22.1 Study Data Collection  ................................ ................................ ........................ 58 
22.2 Site Data Monitoring and Quality Control  ................................ ........................... 58 
22.3 Communication  ................................ ................................ ................................ ..58 
22.4 Recruitment Tracking  ................................ ................................ ......................... 58 
22.5 Data Processing and Quality Control  ................................ ................................ .58 
22.6 Monitoring, Audits and Inspections  ................................ ................................ ....59 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913454] (IRB) Approval  ................................ ......................... [ADDRESS_913455]  ................................ ................................ ................................ ..66 
25.8 Progress Reports  ................................ ................................ ............................... 66 
25.9 Recall and Device Disposition  ................................ ................................ ............ 66 
25.10  Final Reports  ................................ ................................ ................................ .....66 
26.0 Glossary of terms  ................................ ................................ ............................ 66 
27.0 References  ................................ ................................ ................................ .......68 
 
Appendices  
Appendix 1  Study Participant Flow  
Appendix 2  Study Participant Screening and Enrollment Flowchart  
Appendix 3  Example Informed Consent Form: Study Screening  
Appendix [ADDRESS_913456]  Scan Acquisition Protocol  
Appendix 7  Baseline Eligibility Criteria  
Appendix 8  Example Informed Consent: Study Participation  
Appendix 9  Bronchoscopy Procedure Planning: Radiologic Identification  of Target Treatment 
Lobe (s)  
Appendix [ADDRESS_913457]-bronchoscopy Pulmonary Rehabilitation In -Clinic Log  
Appendix 14  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913458]- EBV Procedure Discharge Instructions for the Study Treatment Arm  
Appendix 18  Management of Pneumothorax  
Appendix 19  Statistical Analysis Plan  
Appendix 20  Example Informed  Consent: Crossover Participant   
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913459] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx   
Executive Summary  
 
Study Device and 
Intended Use   
The Pulmonx Zephyr Endobronchial Valve (EBV) is an implantable 
bronchial valve intended to decrease volume in targeted regions of 
the lung . It is indicated for the treatment of  patients with 
hyperinflation associated with severe heterogeneous emphysema  in 
regions of the lung that have little or no collateral ventilation as 
assessed by [CONTACT_675748] .  
  
Study Purpose   
The purpose  of this study is to assess the safety and effectiveness 
of bronchoscopic lung volume reduction (BLVR) using  the Pulmonx 
Endobronchial Valve (EBV)  in treated study participants compared 
to control  participants  to support a premarket approval application to 
FDA.  
  
Study Design  
This will be a multi -center , prospective, randomized, controlled  study 
with EBV treatment statistically evaluated using Intent -to-Treat (ITT) 
analyses. A maximum of [ADDRESS_913460] -approval.   
  
Study Population   
The study population will be comprised of 1 83 study participants with 
severe heterogeneous emphysema as defined by [CONTACT_675749].  The study participants will be randomly assigned at a 2:1 
ratio to the study treatment along with optimal medical therapy  or to 
optimal medical therapy alone . 
     
Study Objective   
The objective  of the study will be  to evaluate lung function changes  
and adverse events after BLVR using the Pulmonx EBV .  
     
Primary Effectiveness 
Endpoint   
The percentage of study participants in the EBV t reatment arm 
meeting the clinically significant threshold of >15% improved forced 
expi[INVESTIGATOR_31737] (FEV 1), obtained immediately 
following bronchodilator therapy, as compared to the percentage in 
the control arm at [ADDRESS_913461]-procedure . 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913462] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx   
Safety Endpoint   
Evaluation of the short - and long -term adverse events  profile of the 
EBV t reatment arm during the treatment period, defined as the day 
of the study procedure until 45 days  after the study procedure  
(short) , and in the post -treatment period, defined as 46 days after 
the study procedure until the 1-year follow -up visit  (long) .  
   
Secondary Effectiveness 
Measures   
Treatment Lobe Volume Reduction (TLVR) for the Treatment Arm  
• TLVR, measured as the ‘ absolute  change from baseline’ 
for treated lobe volume as seen via HRCT (high 
resolution computed tomography), will be evaluated at 45 
days  and 1 year.   
• TLVR, measured as the ‘percent age change from 
baseline’ for treated lo be volume as seen via HRCT , will 
be evalua ted at [ADDRESS_913463]. George’s Respi[INVESTIGATOR_6015] (SGRQ)  
• Difference between study arms in ‘absolute change from 
baseline’ for SGRQ score at 1 year.   
 
FEV 1  
• Persistence of treatment effect will be evaluated  by 
[CONTACT_675750] d ifference between study arms for 
‘absolute  change from baseline’ for FEV 1 at 45 days, 6 
months, and 1 year.  
• Persistence of treatment effect will be evaluated by 
[CONTACT_395569] d ifference between study arms for 
‘percent age change from baseline’ for FEV 1 at 45 days, 6 
months, and 1 year.   
 
6-Minute Walk Distance  (6MWD)  
• Difference between study arms in ‘absolute change from 
baseline’ for 6MWD at 1 year .  
• Difference between study arms in ‘percent age change 
from baseline’ for 6MWD at 1 year .  
 
Additional Measures   
Mean changes and/or changes measured using responder analyses 
for:  
• Spi[INVESTIGATOR_038] , including FEV 1, forced vital capacity ( FVC) and 
the ratio of FEV 1/FVC  
• Body ple thysmography , including residual volume ( RV), 
inspi[INVESTIGATOR_14008] (IC) , functional residual capacity (FRC), 
total lung capacity ( TLC), and the ratio s of RV/TLC  and 
IC/TLC  
• SGRQ global and domain (i.e. ‘symptoms’, ‘activity’, and 
‘impacts on daily life’) scores  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913464] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  • Modified Medical Research Council (mMRC) dyspnea scale  
score  
• BODE Index  
• Transitional Dyspnea Index (TDI)  from Baseline Dyspnea 
Index (BDI)  
• COPD Assessment Test (CAT)  
• SF-36 Health Survey  
• EQ-5D Health Survey  
• Health Care Utilization Questionnaire  
• 6 minute walk distance  
• Borg scale dyspnea scores before and after 6MWD test  
• Change in  use of ‘maintenance’ medications, including 
bronchodilators, corticosteroids, antibi otics, and anti -
inflammatories  
• Daily diary (EXACT -PRO, p ulmonary rehabilitation 
compliance , health status changes )  
• Carbon Monoxide Diffusing Capacity (DL CO) 
• Lung radiographic features  
• Blood chemistry measures  
 
Crossover of Control 
Study Participants  
  
After completing the 1 year visit, if a control study participant 
continues to qualify for the study treatment, (s)he will be permitted to 
crossover to the study tre atment.   
 
Interim Data Analysis   
An interim data analysis designed to evaluate effectiveness for 
continuing crossover of control arm study participants after the [ADDRESS_913465] completed the 1-year follow -up.  If crossover 
of control arm study participants is found to be justified by [CONTACT_675751] s after (s)he 
has reached the [ADDRESS_913466] of FEV 1 and adverse  events.  
    
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913467] the investigation according to 
the procedures specified herein.  
 
 
Site No.:  
Principal Clinical Investigator  
Name:  
 
[INVESTIGATOR_7496]: _____________________  Date: ______________  
 
 
 
 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913468] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  1.0    BACKGROUND  
1.1 Pathophysiology  of Emphysema  
Emphysema is a debilitating and progressive disease that presents a major  health 
problem globally .  It is characterized by [CONTACT_355771], irreversible destruction of lung tissue and 
loss of elastic recoil within the lungs, causing loss of ability to expel air and efficiently 
absorb oxygen.  Emphysema dramatically reduces a person’s expi[INVESTIGATOR_4806], lead ing 
to dyspnea (breathlessness), lessened capacity for performing daily living activities, and 
reduced quality of life.   
Breathlessness in emphysema is thought to result from three primary problems: 1) loss of 
parenchymal tissue for gas exchange, 2) gas t rappi[INVESTIGATOR_675660] , and 3) 
altered breathing mechanics of the chest wall and diaphragm as a result of hyperinflation. 
Breathlessness during exercise worsens as patients must breathe at even higher lung 
volumes to exchange sufficient air (dynam ic hyperinflation).  As emphysema progresses, 
the diseased, hyperinflated areas of the lung eventually fill the chest cavity, leaving less 
room for functioning lung tissue  and preventing adequate diaphragmatic and chest wall 
function .   
1.2 Management  of Emphy sema:  Lung Volume Reduction Surgery (LVRS)  
The goals of therapy for emphysema are to slow the progressive decline in lung function, 
prevent and shorten exacerbations of the disease, improve exercise capacity and quality  
of life, and prolong survival [1] .  Medical treatment for palliating symptoms associated with 
emphysema is well established and widely used but  is of limited efficacy [2,3] .  
Lung volume reduction surgery (LVRS) has been shown to offer relief to patients suffering 
from emphysema when other treatment options fail  [4-10].  The physiologic basis of LVRS 
is direct ly tied to the pathophysiology of emphysema.  With LVRS, the physician aims to 
reduce hyperinflation by [CONTACT_675752], leaving the 
remaining lung room to expand and therefore function more efficiently  and allo w improved 
breathing mechanics .  The National Emphysema Treatment Trial (NETT) compared LVRS 
to optimal medical management in 1,218 patients with advanced emphysema of various 
morphologies  [10].  Clear clinical benefits  were observed with LVRS over optimal medical 
management.   
After  LVRS, improvement in dyspnea and increases in exercise tolerance correlate best 
with reduced hyperinflation and increased transdiaphragmatic pressure resulting from  
repositioning of the diaphragm and recruitment of inspi[INVESTIGATOR_675661]  [11,12] .  
An additional mechanism  is increase d elastic recoil of the lung, probably because the most 
severely hyperinflated part of the lung  is resected .  These changes ofte n result in marked 
improvement of lung function, commonly reported using f orced expi[INVESTIGATOR_118780] (FEV 1).  Moreover, LVR S has also been found to lengthen  survival  in patients with 
heterogeneous e mphysema [ 13,14].  Nevertheless, the reported risks of procedure -related 
morbidity and mortality with LVRS are of substantial  concern  [15].   
1.3 Bronchoscopic Lung Volume Reduction (BLVR)  
A less invasive approach to LVRS using the bronchoscope has long been so ught.  The 
goal of  bronchoscopic  lung volume reduction (BLVR) is to obtain similar p hysiologic 
benefit s as LVRS, without the risk of chest surgery. The aim in BLVR procedures is to 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913469] of hyperinflated lung tissue on adjoining higher functioning  
lung tissue.  
1.4 BLVR with the Pulmonx Endobronchial Valve (EBV)  
Pulmonx has developed a one -way valve that can be implanted during bronchoscopy, 
where the aim is to block inspi[INVESTIGATOR_675662], hyperinflated regions of the lung, 
while permitting  exhaled gas to escape. When an endobronchial valve is placed in a 
bronchial lumen and is performing as intended , air is restricted from going through or 
around the valve during inspi[INVESTIGATOR_675663].  The 
Pulmonx  Zeph yr valve has been  previously studied  in a large multi -center,  prospective, 
randomized trial [ 16,17 ]. At that time , the Zephyr valve was manufactured by [CONTACT_675753]. (Redwood City, CA).   
1.5 Pi[INVESTIGATOR_675664]:  The VENT Study (IDE#G020230)  
The Endobronchial Valve for Emphysema Palliation Trial ( VENT study ) was a prospective, 
randomized, controlled study conducted in the United  States to evaluate the Zephyr EBV 
in comparison with  optimal medical treatment in patients with heterogeneous  emphy sema.  
The Zephyr EBV is a silicone covered stent -like device with a built -in one -way valve that 
lets air out of, but not into, targeted regions of the lung.  The valve was placed 
bronchoscopi[INVESTIGATOR_675665].   
The VENT study results were reviewed by [CONTACT_675754] P070025 and were 
presented at a meeting of the Anesthesiology and Respi[INVESTIGATOR_675666] r 2008.  While the effectiveness outcomes for the EBV -treated study 
group were significan tly improved  over the control group, and the results of the study 
successfully met the pre -determined primary endpoints, the Advisory Panel and FDA 
concluded  that the mean results did not reach minimally important clinical difference.  
However, it was recognized that outcomes with EBV appeared to be clinically meaningful  
in a discrete subgroup of patients .   
1.6 Learnings from the VENT Study  
As presented to FDA during the PMA review of the Zephyr endobronchial valve,  analyses 
of VENT study  participant subgroups indicat ed that the Zephyr EBV had higher 
effectiveness in study participants who had certa in lung radiographic features.  Key 
findings of the VENT study data indicated that EBV therapy was optimized in patients who 
had high resolution computed tomography (HRCT) findings suggestive of a complete 
fissure between the EBV -treated lobe and the adjacent lobe [16,17].   
Complete fissure, as determined via qualitative assessment of H RCT scans, is thought to 
correspond to lack of inter -lobar collateral ventilation (CV) [1 8].  Researchers in the clinical 
community have theorized that presence of lobar CV  is likely to mitigate clinical response 
to EBV treatment [ 19,20 ].  
1.7 Collateral Ventilation  Impacts Lung Volume Reduction  
During the 1930’s, Van Allen and Lindskog [21] were the first to demonstrate 
experimentally that presence of CV allows inter -lobar communication of air.  As the use of 
surgical treatments for emphysema grew  and direct observation of  the in vivo  tissue 
condition was possible, collateral air flow was found to be linked to the regional over -
distention and air trappi[INVESTIGATOR_675667] [22] .  Collateral channels were 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913470] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  found to occur more frequently in emphys ema patients than in normal subjects and the 
channels were wider and less resistant d uring exhalation  [23].   
Understanding CV pathways in endobronchial lung volume reduction candidates and 
having the ability to selectively target treatment effectively has become an important 
clinical goal .  It has been hypothesized by [CONTACT_675755] a primary reason for the infrequency of observing clinically significant lung 
volume reduction in patients participating in the  VENT study. Assessment of inter -lobar 
CV, as described below,  will be performed in the proposed trial as a means to select  study 
participants  who are likely to experience significant lung volume reduction  with the 
Pulmonx Zephyr EBV.   
1.8 Measurement of Collateral Ventilation  
In 2005, Pulmonx, Inc. developed an integrated system for CV assessment now known as 
the Chartis® Catheter and Chartis® Console.  The Chartis System is a catheter -based 
device that allows sealing of a lung compartment and measuremen t of air pressure and 
flow from the sealed compartment ( K111522 for Chartis Catheter and K111764 for Chartis 
Console1).  Based on these measurements, CV within a lobe targeted for endobronchial 
treatment  can be identified .   
Safety and feasibility of obtaining measurements predictive of atelectasis after EBV 
treatment using the Chartis syste m has been previously reported [24]  ([STUDY_ID_REMOVED] ).  
Gompelmann and colleagues observ ed that i n 18/20 (90 %) of the EBV treated cases, 
post-procedure atelectasis response, as visualized using chest X -ray, matched the Chartis 
system prediction of presence or absence of collateral ventilation.  No adverse events  
associated with use of the Chartis system were obser ved.   
In a later, larger,  prospective multi -center study conducted in [LOCATION_013], t he Netherlands, 
and Sweden , the Chartis System was used successfully as a tool to identify  emphysema 
patients who would achieve clinically significant lung volume reduction after EBV treatment  
[25] ([STUDY_ID_REMOVED] ).  Patients were prospectively classified using the Chartis System 
during the bronchoscopy procedure —prior to EBV placement —as having or not having CV 
in the targeted treatment lobe . The patients who were classified as  having  little or no lobar 
CV had significant target lobe volume reduction and significantly  improved respi[INVESTIGATOR_2606], exercise performance, and quality of life measures  after EBV treatment  whereas 
those who were identified as having CV did not .   
The secondary objective of the Chartis multicenter study was to compare the accuracy of 
the Chartis System and visual assessment of HRCT fissure completeness for assessing 
CV status by [CONTACT_675756]. Diagnostic accuracy of the Chartis System for prospectively classifying 
presence or absence of CV in a lobe targeted for EBV treatment, when compared to the 
observed response to the EBV procedure as measured using volumetric reduction seen 
with HRCT, was found to be similar  to HRCT fissure analysis .   
                                                 
1 Cleared indications for use: The Chartis System is indicated for use by [CONTACT_675757][INVESTIGATOR_675668] a diagnostic 
bronchoscopy in adult patients in a bronchoscopy suite. The system, composed of the Chartis Catheter and Chartis 
Console, is designed to measure pressure and flow in order to calculate resistance to airflow and quantify collateral 
ventilation in isolated lung compartments. The Chartis Catheter is used through the working channel of a 
bronchoscope and connects to the Chartis Console. The Chartis Console is a re -usable pi[INVESTIGATOR_675669].  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913471] that BLVR performed using the 
Pulmonx Zephyr EBV may induce regional lung volume reduction  associated with 
improved clinical condition  in patients identified as having little or no CV.    
2.0    STUDY DEVICE AND INTENDED USE  
The Pulmonx Zephyr Endobronchial Valve (EBV) is an implantable bronchial valve 
intended to decrease volume in targeted region s of the lung .  It is indicated for the 
treatment of  patients with hyperinflation associated with severe heterogeneous 
emphysema  in regions of the lung that have little or no collateral ventilation as assessed 
by [CONTACT_675748] .     
 
3.0   STUDY DEVICE / TECHNOLOGY DESCRIPTI ON 
The Pulmonx Zephyr Endobronchial Valve (EBV) is a device that incorporates  a one -way 
valve that is implanted in a bronchial lumen.  A stent -like self -expanding retainer that 
secures the implanted EBV in place  supports the one -way valve .  The implanted EBV is 
designed to allow  air to be vented from the isolated lung segment while preventing air 
from refilling the isolated lung during inhalation.   It is not anticipated that the study device 
will require modifica tion during execution of the study.    
3.[ADDRESS_913472] components:  a one -way valve and a retainer.   
3.1.[ADDRESS_913473] polymer valve is mounted inside the retainer.  The valve vents during 
exhalation and c loses when flow is reversed (inhalation).  
3.1.[ADDRESS_913474] 
stents.  The EBV is compressed into the retractable distal housing.  The EBV is 
deployed by [CONTACT_675758], which retracts the distal housing and 
releases the EBV to expand  inside the target lumen.  The delivery c atheter can then be 
retracted from the EBV and removed from the patient.  
 
4.0    STUDY PURPOSE  
The purpose  of this study is to assess the safety and effectiveness  of BLVR  using  the 
Pulmonx Endobronchial Valve (EBV) in treated study participants compared to control 
participants  to support a premarket approval application to FDA .   
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913475] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx   
5.0    STUDY DESIGN  
This will be a multi -center prospective, randomized, controlled  study with EBV treatment 
statistically evaluated using Intent -to-Treat (ITT) analyses. Random assignment will be 
conducted using an allocation ratio of 2:1; two study participants will be randomized to 
the EBV Treatment arm for every one participant randomized to the Control arm.  A 
maximum of [ADDRESS_913476] -approval.  The flow of study participants through the study 
protocol is shown in Appendix 1. 
 
6.0    STUDY POPULATION  
The study population will be comprised of 183 study participants with  severe 
heterogeneous emphysema as defined by [CONTACT_145914] .  The study 
participants will be randomly assigned to the study treatment along with optim al medical 
therapy  or optimal medical therapy alone .   
6.1 Optimal Medical Therapy  
All study participants will receive optimal medical therapy, defined fo r the purposes of this 
protocol  as maximal medical treatment for stable COPD as indicated by [CONTACT_941] 20 11 
NIH/WHO GOLD guidelines  [26].  The optimal medical therapy  will be initiated, if not 
begun previously, upon a study candidate’s enrollment into the study.  The GOLD 
recommend ations for optimal medical therapy consist of smoking cessation support, 
oxygen supplementation, pharmacological treatment s, and pulmo nary rehabilitation .  All 
enrolled s tudy participants will be provided access to a smoking cessation support 
program and will receive oxygen supplementation as medically indicated  during their 
participation in the study.  Pharmacological treatments and pulmonary rehabilitation 
therapy are described in detail in Section 9.0 and Section 10.0, respectively.  All study 
participants will meet the study eligibility criteria for having current Pneumococc us and 
Influenza vaccinations.   
      
7.0    STUDY OBJECTIVE  
The objective of the study will be to evaluate lung function changes and adverse events  
after BLVR using the Pulmonx EBV.     
7.1 Primary Effectiveness Endpoint  
The percentage of EBV Treatment a rm study participants meeting the threshold of >15% 
improved forced expi[INVESTIGATOR_31737] (FEV 1), obtained immediately following 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913477]-
procedure.   
7.2 Safety Endpoint  
Evaluation of the short - and long -term adverse events  profile  of the EBV Treatment arm 
during the treatment period, defined as the day of the study procedure until 45 days  after 
the study procedure  (short) , and in the post -treatment period, defined as 46 days after 
the study procedure until the 1-year follow -up visit  (long) .   
7.[ADDRESS_913478] of the following:    
 
1) Treatment Lobe Volume Reduction (TLVR) for the EBV Treatment Arm  
i. TLVR, measured as the ‘ absolute change from baseline’ for treated 
lobe volume as seen via HRCT, will be evaluated at 45 days and 1 
year.   
ii. TLVR, measured as the ‘ percentage change from baseline’ for treated 
lobe volume as seen via HRCT, will be evaluated at 45 days and 1  
year.   
 
2) St. George’s Respi[INVESTIGATOR_6015] (SGRQ)  
i. Difference between study arms in ‘absolute change from baseline’ for 
SGRQ score at 1 year.  
 
3) FEV [ADDRESS_913479] will be evaluat ed by [CONTACT_675759] ‘absolute change from baseline’ for 
FEV [ADDRESS_913480] will be evaluated by [CONTACT_675760] ‘percentage change from baseline’ 
for FEV 1 at 45 days, 6 months, and 1 year.  
 
4) 6-Minute Walk Distance  
i. Difference between study arms in ‘absolute change from baseline’ for 
6MWD at 1 year .   
ii. Difference between study arms in ‘ percentage  change from baseline’ 
for 6MWD at 1 year.   
7.4 Additional Measures  
Mean changes and/or changes measured using responder analyses for:   
• Spi[INVESTIGATOR_038] , including FEV 1, forced vital capacity ( FVC) and the ratio of FEV 1/FVC  
• Body ple thysmography , including residual volume ( RV), inspi[INVESTIGATOR_14008] (IC),  
functional  residual capacity (FRC), total lung capacity ( TLC), and the ratio s of 
RV/TLC  and IC/TLC  
• SGRQ global and domain (i.e. ‘symptoms’, ‘activity’ and ‘impacts on daily life’) 
score  
• Modified Medical Research Council (mMRC) dyspnea scale  score  
• BODE Index  
• Transitional Dyspnea Index (TDI)  from Baseline Dyspnea Index (BDI)  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913481] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  • COPD Assessment Test (CAT)  
• SF-36 Health Survey  
• EQ-5D Health Survey  
• Health Care Utilization Questionnaire  
• 6 minute walk distance  
• Borg scale dyspnea scores before and after 6MWD test  
• Change in  use of ‘maintenance’ medications, including bronchodilators, 
corticosteroids, antibiotics, and anti -inflammatories  
• Daily diary (EXACT -PRO, p ulmonary rehabilitation compliance , health status 
changes )  
• Carbon Monoxide Diffusing Capacity (DL CO) 
• Lung radiographic features  
• Blood chemistry measures  
   
7.5 Crossover of Control Study Participants  
After completing the 1 -year visit, a control arm participant may be permitted to crossover 
to the study treatment if (s)he continues to qualify for the study treatmen t. In order to 
qualify for crossover, a control arm participant must have been foll owed up successfully 
through [ADDRESS_913482] be sch eduled to occur within the 60 days  after the 1 year visit .  After 
treatment, t he follow -up visits and testing at each visit will be identical to the study 
schedule for treatment arm participants.  
 
Note:  Per Revision H of this protocol, the requirement of a heterogeneity score  of 15% 
between lobe s is not applicable for any remaining crossover subjects. The most diseased 
target can be treated regardless of heterogeneity, provided that  the target lobe is  
collateral ventilation negative (CV -).  
 
Patients treated after approval of this Amendment wil l fall outside of the original 60 day 
window from the 1 -year visit date. This delay will not be marked as a deviation from the 
protocol.  
7.6 Interim Analysis  
An interim data analysis designed to evaluate effectiveness for continuing  crossover of 
Control arm study participants after the 1 year follow -up visit to EBV treatment will be 
performed when 74 (50% of the required minimum of  147) study participants have 
completed the 1 year follow -up.  If crossover of Control arm study participants is found to 
be justified by [CONTACT_675761] s after 
(s)he has reached the [ADDRESS_913483] not crossed over will exit from the study protocol  after the 1 -year 
visit.      
 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913484] of FEV 1 and adverse events.  
 
8.0    STUDY PARTICIPANT  MANAGEMENT   
8.1 Clinical Site Study Team  
The Principal Investigator [INVESTIGATOR_675670].  The clinical site study team will 
be responsible for executing all study -related activities .     
8.2 Clinical Study Site Training  
Prior to enrolling any study participants, the site Principal Investigator(s) and the Study 
Coordinator(s) will complete  the Pulmonx Clinical Study Training Program .  An overview 
of the training program is provided in Section [ADDRESS_913485] (IRB) overseeing their site , 
patients at the site may be approached by [CONTACT_675762].  
Clinical sites will be encouraged to advertise for local recruitment and web -links to study 
information may be provided to relevant organizat ions.  Additionally, study i nvestigators  
will be provided with written and electronic study -related materials that they may provide 
to referring care providers in their regions.   
8.4 Study Candidate Selection   
Any clinic patient may be considered for study ca ndidacy while receiving routine care for 
emphysema.  The screening flow for study candidates, with timing of study participant 
enrollment, is shown  in Appendix 2.   
 
Prior to initiating any study screening -related activities  with individual patients , all study 
candidates  will sign a Screening  Informed Consent  Form  (Appendix 3), or similar , to 
acknowledge their willingness to participat e in study screening activities.   A screening 
log that shows all screened patients who sign the Informed Consent will be maintained .  
The intent of the s creening log (Appendix 4) is to capture the reasons that chronic 
obstructive pulmonary disease (COPD) patients who are interested in the study are not 
eligible  to participate .     
8.4.1  Informed Consent and HIPAA Authorization  
The informed consent process will be conducted  in accordance with the 
Declaration of Helsinki, International Congress of Harmonization (ICH) Good 
Clinical Practice guidelines  (to the extent that they are consistent with U.S. 
Federal regulations) , and the U.S.  Federal Code of Regulations, Section 21, Part 
50. The Principal Investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a member of his/her staff should approach study 
candidates who meet study eligibility criteria to obtain informed consent.  The 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913486] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  Investigator or his/her designee will explain t he purpose of the study and the 
anticipated benefits and associated risks of study participation.  
 
The s tudy candidate will be given a n Informed Consent Form .  This form(s) (or 
modification s) must have prior approval of the study site’s Institutional Review 
Board (IRB) before use.  The study candidate will be given adequate time to 
review the Informed Consent Form.   Study candidates may not be consented 
after receiving any medication (e.g. se datives, narcotics, etc.) that might alter 
their ability to comprehend the informed consent.  After the study candidate has 
had the opportunity to read the form and discuss the study information with study 
site personnel, they will be asked to make a decis ion regarding participation in 
the study.  
 
All study candidates who choose to participate in the study will sign the Informed 
Consent Form prior to commencement of any study -specific testing . Failure to 
provide informed consent renders the study candidate  ineligible for the study.  
The signed Informed Consent Form will be retained at the investigational site, 
and copi[INVESTIGATOR_675671].  Study participants may 
voluntarily withdraw from the study at any time following enrollment in to the 
study.  
 
The HIPAA Authorization (Health Insurance Portability and Accountability Act) 
adds to protections already provided by [CONTACT_675763].  These additions 
state that the study participant must be informed that they can withdraw 
authorizati on to use data or samples not already submitted to the study sponsor 
and that the request must be in writing.  If the study participant allows samples to 
be used after withdrawal from the study, this permission may be withdrawn at a 
later date.  The HIPAA authorization specifies who may review confidential 
medical information, to whom test results will be submitted , and that test results 
obtained solely for r esearch will not be part of the study participant’s  medical 
record.   A copy of the study participant ’s information , including the signed 
consent form and HIPAA Authorization , must be provided to the study participant . 
8.[ADDRESS_913487] signed a study Screening or Study Procedure Informed 
Consent form  prior to undergoing any testing to determine study eligibility.  The 
screen ing eligibility  criteria are given in Appendix 5. It is recommended that screening 
eligibility criteria testing be conducted sequentially in the order shown here:  medical 
history collection and physical examination , an echocardiogram,  volumetric high 
resolution  computed tomography (CT) (see Section 8.5.1 below ), electrocardiography 
(ECG), spi[INVESTIGATOR_038], body plethysmography, diffusing capacity (DL CO), 6MWD, arterial 
blood gases (ABGs), complete blood count (CBC), alpha 1 -antitrypsin deficiency 
detection,  plasma cotinine level (or arterial carboxyhemoglobin if using nicotine 
products)  and serum fibrinogen .   
 
If the study candidate has had a CT within the last three  months prior to sign ing the 
screening consent and  the images were obtained in accordance with the CT scan 
protocol  then a repeat CT scan will not be necessary . Of note, screening of CT scan 
records of clinic patients seen previousl y for medical care at the study site is permitted.   
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913488] scans  will be  standardized across clinical sites  by [CONTACT_675764].  The protocol will include volume 
acquisition thin section obtained at suspended breath hold at full inspi[INVESTIGATOR_1516] 
(TLC)  and full expi[INVESTIGATOR_1516] (RV) .  Images will be reconstructed using a smooth or 
standard filter; the protocol is detailed in  Appendix 6.  The radiology 
technologists  at the clin ical sites will be trained to the HR CT data collection 
protocol.   
 
The clinical site will evaluate  HRCT images to determin e screening eligibility of 
the study candidate .  The grading system used by [CONTACT_675765].  The 
HRCT  eligibility criteria will be assessed by [CONTACT_675766] l destruct ion 
and emphysema heterogeneity  scores using the total lung capacity (TLC) scan 
and the definitions  below (Section s [IP_ADDRESS]  and [IP_ADDRESS] ). The sit e will use FDA 
cleared software, which may include VCAR (GE Medical Systems, Milwaukee, 
WI), Apollo (VIDA, Coralville, IA), syngo Lung Care CT (Siemens  Healthcare 
Solutions , Deerfield, IL), MeVis Visia CT Lung System (MeVis M edical Solutions, 
Milwaukee, WI) , Myrian (Intrasense, Montpellier, [LOCATION_009]), or other 510k cleared 
software  to measure lung density to determine parenchymal destruction .   
 
The site reader will use the parenchyma l destruction scores provided by [CONTACT_675767] a provided worksheet .  
The CT study must exhibit sufficient landmarking to be evaluated using the 
software as it is intended for delineating lobar parenchymal destruction.  
[IP_ADDRESS]   Definition of Parenchymal Destruction S core 
Lobar parenchymal destruction scores will be determined , on thin section 
volumetric series,  using specialized software to calculate the proportion of 
image voxels within a lobe that fa ll below a pre -defined Hounsfield unit 
threshold.  These scores will be reported as a  parenchymal destruction  
score for each lung lobe.  F or example, a parenchymal destruction score 
of 50% means that 50% of the volume of that lobe meet ing the Hounsfield 
threshold and will be considered destroyed by [CONTACT_325011] . 
[IP_ADDRESS]   Definiti on of Emphysema Heterogeneity  Score  
Emphysema heterogeneity score will be defined as the difference (in 
percent) between the parenchymal destruction  scores of the target lobe 
and the ipsilateral non -target lobe (s).   
 
For the left lung, emphysema heterogeneity  will be quantified by 
[CONTACT_675768] (left upper 
lobe [LUL] or left lower lobe [LLL]) parenchymal destruction  score and the 
ipsilateral non -target lobe parenchymal destruction  score.  
 
 
 
 
 
 
  
Parenchymal  
Destruction 
Score for LUL  Parenchymal  
Destruction 
Score for LLL  
 compared to 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913489] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  For the right lung, emphysema heterogeneity will be quantified by 
[CONTACT_675769] s for 
all three lobes separately  (right upper lobe [RUL], right middle lobe [RML], 
and right lower lobe [RLL]) .    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Study Bronchoscopy Plan described in Section 8.[ADDRESS_913490] eight visits will 
not be eligible to enter the study.   
  
Parenchymal  
Destruction 
Score  for RUL  Parenchymal  
Destruction 
Score for RLL 
 compared to  
 
Parenchymal  
Destruction 
Score  for RUL  Parenchymal  
Destruction 
Score for RML  
 compared to  
 
Parenchymal  
Destruction 
Score  for RLL  Parenchymal  
Destruction 
Score for RML  
 compared to  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913491] ing to 
support assessment of the baseline eligibility criteria  (Appendix 7). The baseline 
eligibility determination must be made < [ADDRESS_913492] signed the Study  Informed Consent  Form  (Appendix 8) or similar prior to 
undergoing the bronchoscopy procedure to assess study procedure eligibility .  Study 
candidates who have met the screening and baseline eligibility criteria but who are no 
longer interested in participating in the study or wh o do not sign the Study Informed 
Consent Form will be recorded  on the screening log.  
 
Study -related testing should not be conducted if the study participant is having an active 
COPD exacerbation at the time of baseline testing . If a study participant has a COPD 
exacerbation, the baseline testing  should be postponed until the exacerbation is 
resolved as determined by [CONTACT_16541].  
 
8.7 Bronchoscopy Plan  for CV Assessment  and Determining Study Eligibility  
A bronchoscopy  procedure  plan will be created by [CONTACT_675770] . The goal of bronchoscopy planning is to determine whether the study 
candidate meets the emphysema  heterogeneity eligibility criterion and to pre-identify the 
lobe(s) most appropriate for study treatment ( EBV placement ).  The bronchoscopy plan 
will be developed using  the CT scan collected during the study participant’s eligibility 
screening (see Section 8.5.1 ).  The pre-identified lobe(s) will be assessed for CV  using 
the Chartis System  during the bronchoscopy procedure .  The bronchoscopy plan will be 
documented using the appropriate Case Report Form.   
8.7.1  Algorithm for Radiologic Determination of Emphysema Heterogeneity and 
Identification of Target Treatment Lobe(s)   
The bronchoscopy plan will be completed  using    the flowchart algorithm 
provided in Appendix 9.  Lobes in both lungs may be eligible to undergo 
treatment but only one lung will be treated.    
 
Note:  Per Revision H of this protocol, the requirement of a heterogeneity score of 15% 
between lobes is not applicable for any remaining crossover subjects.  The most diseased 
target can be treated regardless of heterogeneity, provided that the target lobe is c ollateral 
ventilation negative (CV -). 
 
8.8 Study Procedure Eligibility  Criteria    
The final study procedure  eligibility criteria  will be assessed during the bronchoscopy 
procedure (Appendix 10).  The bronchoscopy procedure should occur < 60 days after 
the baseline assessment visit.  Those study participants who are found to be eligible to 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913493] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  participate in the study will be enrolled into the study and randomly assigned to 
treatment (or control) at that time.  I f randomly assigned to the study treatment arm , the 
study participant will undergo the study -directed treatment  during the same session  
unless this is contraindicated by [CONTACT_675771]; if the time remaining for safe administration of an esthesia is considered to 
be insufficient for completing the study procedure, it will be deferred to another session.     
 
To meet the study procedure eligibility criteria, the study participant must have at least 
one pre -identified target lobe  (upper or lo wer lobe) , as delineated in t he bronchoscopy 
procedure plan, which is found to have little or no CV as measured by [CONTACT_675772] (see Section 11.2).  A flow chart showing the key decision -points during  the 
bronchoscopy proce dure is provided in Appendi x 11.  Every effort will be made to have 
Pulmonx technical staff at all bronchoscopy procedures to provide support.   
8.9 Study Participant Enrollment  
A study candidate  will be enrolled into the study after meeting all screening and baseline 
eligibility criteria, providing informed consent for study participation, and meeting the 
study procedure eligibility criteria.  Enrollment of a study candidate as a study participant 
will be documented using the ap propriate Case Report Form.    
 
8.9.1  Randomization Assignment  and Study Treatment  
A study participant will be randomly assigned to treatment or control after 
determining he/she meets the study procedure eligibility criteria during the 
bronchoscopy procedure (see Section 11.2).  If the study participant does not meet 
the study procedure eligibility criteria, he/she will not be randomly assigned to 
treatment nor receive any study -related treatment.  If the study candidate is found 
to meet the study procedure eligibility criteria, then (s)he will be randomly assigned 
to study treatment  during the bronchoscopy procedure .  
 
Random assignment will be conducted using an allocation ratio of 2:1; two study 
participants will be randomized to the EBV Treatment  arm for every one 
participant randomized to the Control arm.  Random assignment will be 
conducted using a stratified permuted block design generated separately for 
each clinical site, with assignment stratified by a natomical site of the planned 
treatment (e.g. right lung or left lung).  Mixed block sizes will be used.   The goal 
of stratificatio n will be to ensure a 2:1 randomization mix within each stratum .  
8.10 Follow-Up Visits 
8.10.1  Study Schedule  
The required study schedule  for study participants is shown in Section 14.0 and 
Appendix 12.      
[IP_ADDRESS]  Study Participants Treated with EBV   
Any study participant receiving EBV treatment will be followed -up 
annually through 5 years.   
8.10.2   Visit Windows   
The study follow -up visits  required by [CONTACT_675773] .  The study follow -up visits should  be scheduled within the  range s 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913494] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  (window s) specified in the Table.  These windows have been established to all ow 
for maximum  data collect ion in a study population  known to have  a high risk of 
missing clinic visits  due to  confounding clinical circumstances .  It is 
recommended that all efforts be made to schedule follow -up visits as early as 
possible within the visit window in case the visit may need to be rescheduled.  
Utilization of these visit windows will aid in avoiding  imputation of data during  
statistica l analysis .   
Study-related testing should not be conducted if the  study participant is having an 
active COPD exacerbation at the time of a study follow -up visit. If a study 
participant has a COPD exacerbation , the study visit should  be cancelled and 
rescheduled  to be conducted at 14 days, or as early as possible after 14 days, 
following the initiation of treatment for the exacerbation. The clinical study site will 
document in the study participant’s medical record all incidents in which a 
scheduled st udy visit is cancelled and rescheduled due to occurrence of a COPD 
exacerbation.   
When the study participant informs the site of the COPD exacerbation, the 
investigator may request the study participant to come in for evaluation.  This 
evaluation may include a physical examination and review of medicat ions and 
will be classified as an interim visit.   
If the rescheduled study follow -up visit falls outside of the study follow -up visit 
window , it will be recorded as a n out of window  protocol deviation.  If t he study 
participant fails to make the rescheduled study follow -up visit  it will be captured 
as a missed visit and protocol deviation.        
Table.  Study Follow -Visits and Windows for Scheduling the Visits  
 Visit Range 
1 24-Hour‡ +/- 8 hours  
2  Daily phone call for 10 days following discharge‡ by 11:59 pm local time  
3 7 days after discharge‡ (phone call not required on this day)  + 1 business day  
4 30-day‡ +/-5 days  
5 45-day +/- 10 days  
6 3-Month  +/- 14 days  
7 6-Month  +/- 21 days  
8 9-Month  +/- 21 days  
9 1-Year  +/- 45 days  
10-13 2, 3, 4, 5 Years‡ +/- 60 days  
 ‡ EBV-treated study participants only ; *Procedure day = Day [ADDRESS_913495] attempts of study 
participants who do not return for follow -up should be documented in the study 
participant’s medical record .     
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913496] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  8.11.1  Participant W ithdrawal  
Study participants may choose to withdraw from the study at any time without 
penalty or loss of benefits to which they are otherwise entitled.  If a study 
participant provides a reason(s) for early withdrawal, the reason (s) shall b e 
documented on the appropriate Case Report Form and in the study participant’s 
medical record.  If possible, a  final medical exam , along with spi[INVESTIGATOR_1892],  shall be performed  prior to their withdrawal.       
   
 
9.0 PHARMACOLOGIC  TREATMENT S FOR STUDY PARTICIPANTS  
9.1 Optimization  of Medications  
Study participants will be carefully monitored at each study visit to confirm that 
pharmacological treatment is optimized.  Optimization of pharmacological treatment will 
also be assessed immediately prior to t he br onchoscopy procedure; if there is any 
reason to beli eve that the study participant is not receiving optimized medical therapy, 
the bronchoscopy procedure may be postponed.    
9.[ADDRESS_913497] 
variable responses to bronchodilator  treatment  or need individualized treatment  
depending on their condition . 
9.3 Corticosteroids   
Study particip ants may receive corticosteroid (s) for mitigation of  COPD exacerbations.  
The treating physician will determine medication regimen and instruct study participants 
on appropriate use.  
9.[ADDRESS_913498]-BRONCHOSCOPY PULMONARY REHABILITA TION  
The pulmon ary rehabilitation program should include the elements recommended by [CONTACT_675774][INVESTIGATOR_675672] [27] .  In general, the post-bronchoscopy program should consist of  a 
supervised  ‘in clinic’ pulmonary rehabilitation component and a ‘home -based’ 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913499] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  maintenance pulmonary rehabil itation component.  The active ‘in clinic’ pulmonary 
rehabilitation program should be initiated  for all study participants within the first [ADDRESS_913500] be cleared by [CONTACT_093].  For the active ‘in clinic’ 
component of the program, t he ATS/ERS practice guidelines recommend a minimum of 
[ADDRESS_913501] appropriate exercises.     
• Lower limb endurance training  
Lower limb endurance training should consist of walking, either done on a 
treadmill, or ambulating freely indoors or ou tdoors, for >20 minutes  in a 
session .       
• Upper limb endurance training  
Upper limb endurance training consists of a group of exercises involving 
some form and level of resistance for each hand (e.g. dumbbells or 
Therabands).      
• Lower and upper limb strength training  
Lower and upper limb strength training consists of a group of exercise 
involving some form and level of resistance (e.g. dumbbells or 
Therabands).       
 
11.0 BRONCHOSCOPY PROCEDU RE 
Every effort will be made for a Pulmonx representative to be in attendance at a study 
participant’s bronchoscopy procedure.  The bronchoscopy procedure should be recorded on 
video, CD ROM, or DVD  and a  copy maintained  in the study participant ’s files.  Alternatively, 
photographs of valve placement may be obtained.  Prior to the procedure, i dentify and 
document site pers onnel responsible for managing any pneumothorax .  During the 
bronchoscopy procedure, all study candidates  will undergo assessment of study eligibility using 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913502] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  the Chartis System .  All study candidates  found to be eligible to unde rgo the study procedure 
will be enrolled into the study and will be randomly assigned at that time . All enrolled study 
participants will be treated  as randomly assigned .  See Appendix 1 1 for an overview of the 
events occurring during bronchoscopy procedure.  
11.1 Procedure Medications  
In addition to the medications described in Pharmacologic Treatment s (Section 9 ), the 
peri-procedural  medication  regimen  shown in the Table below is recommended .   
 
Table. Summary of Procedure Medications (or equivalent)  
 
Medication  Before 
Procedure  During 
Procedure  Post-
Procedure  
Cease use of anti -coagulants [ADDRESS_913503] 3 days before , if indicated per 
physician discretion  X   
Inhaled bronchodilator 20 minutes before  X   
Initiate prophylactic a ntibiotic (e.g. Cephalosporin or 
Quinolone ) X   
Anesthetic   X  
Oral course of prophylactic antibiotics  (5-7 days)    X 
Bronchodilator therapy    X 
 
11.1.1  Medications  administered prior to the bronchoscopy  
Study candidates  will be asked to cease using anti -coagulant medications (if 
applicable) 5-[ADDRESS_913504] three days before  the procedure  if indicated per physician discretion . At the 
preference of the treating physician, prophylactic antibiotics and/or 
corticosteroids may be administered one or two days  prior to the procedure.  
Approximately [ADDRESS_913505] or second generation antibiotics such as cephalosporin or quinolone (e.g. 
Ancef, Kefzol, Cefaclor)  should be administered .       
11.1.[ADDRESS_913506] local 
protocols used for bronchoscopy. Assessment of collateral ventilation using the 
Chartis System will be performed under conscious sedation with unassisted 
breathing.  The study procedure (EBV place ment) may be performed under 
conscious sedation with unassisted breathing or under general anesthesia with 
the patient on a ventilator.    
11.1.[ADDRESS_913507] or second  generation 
cephalosporin or quinolone (e.g. Ancef, Kefzol, Cefaclor)  should be administered .  
A standard -of-care corticosteroid regimen may also be initiated at this time.  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913508] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  Beginning at 24 hours after the procedure, study participants will receive , or 
continue to receive if initiated previously, a five to seven day prophylactic course 
of oral cephalosporin , quinolone , or macrolide antibiotic s.   
11.2 Assessment of Study Procedure Eligibility  Criteria  
Study procedu re eligibility  will be determined by [CONTACT_675775]-identified target 
treatment lobe (s), as documented in the bronchoscopy plan (Section 8.8), using the 
Chartis System.  All potential target treatment lobes identified in the bronchoscopy plan 
will be assessed during the bronchoscopy session. The Chartis System will  be used as 
descri bed in the Instructions for Use.  The CV a ssessment (s) will be performed under 
conscious sed ation with unassisted breathing.  The procedure  for assessing  CV, along 
with case examples,  is provided in Appendix 14.  
11.2.1  Study Participant Meets Study Procedure Eligibility  Criteria  
If the study participant meets the study eligibility criteria, (s)he will be randomly 
assigned to study treatment or control .     
[IP_ADDRESS]   Random ization  Assignment  
A study participant will be randomly assigned to treatment using 
the method required by [CONTACT_1758] s ponsor.  Study staff will 
conduct random assignment of study participants by [CONTACT_675776] a centralized location from 
the bronchoscopy suite to learn the study participant’s random 
assignment.  Random assignment will be documented using the 
appropriate Case Report Form.   
    
11.2.[ADDRESS_913509] practice 
guidelines at the clinical site.   The study candidate will be permitted to recover 
from anesthesia by [CONTACT_675777][INVESTIGATOR_307]’s standard protocol.     
11.[ADDRESS_913510] practice 
guidelines at the clinical site and the study participant will be followed up as 
described in Section 8.10  and Appendix 12 .    
11.4 Assignment to Study Treatment Arm   
If the study participant is randomly assigned to the EBV treatment arm, (s)he 
should immediately undergo the study procedure (see Section 11. 5). However, in 
any case in which there may be insufficient time to complete the study procedure 
because the time to safely administer the anesthesia is running out, the study 
procedure may be deferred. The study participant will be followed up as 
described in Section 8.10 and Appendix 12.   
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913511] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  11.5 Execution of the Study Procedure   
The study treatment will be co nsidered to be initiated immediately upon introduction of 
the EBV delivery catheter into the bronchoscope. The study procedure may be 
performed with the study participant under conscious sedation with unassisted breathing 
or under general anesthesia on a v entilator.  For s tudy participants who are not on a 
ventilator , a bite block may be used to facilitate  access.  For general anesthesia 
procedures, a rigid bronchoscope in conjunction with a flexible bronchoscope or a 
flexible bronchoscope alone through an endotracheal tube ma y be used for valve 
placement.  The study device will be placed in accordance with the study protocol 
requirements and the Instructions for Use.   The target treatment lobe(s)  will consist of 
only one of the following:  LUL, LLL, RUL, RLL, or RUL+RML.   
11.5.[ADDRESS_913512] l from a non-valved segment to a valved segment, reducing the 
potential benefit.  Valves may be placed at the lobar, segmental, or sub -
segmental levels , in this order of preference, depending on the anatomy of the 
study participant.  Whenever possible, val ves should be placed in an earlier 
generation bronchus (e.g. if a large valve will fit in the left upper lobe bronchus, 
that should be the target instead of a valve placed in each of the segmental 
bronchi).  Potential t argets at the segmental bronchi level  are shown in 
Appendix 15.   
Success  for achieving lobar occlusion must be verified , via bronchoscopy, 
immediately following valve placement and recorded on the appropriate CRF.   If 
a valve appears to be misplaced  or misaligned , it will be removed and replaced.  
If it is not possible to place or align the valve correctly  then the valve will be 
removed and the reason for not placing the valve will be recorded on the 
appropriate CRF.   
11.[ADDRESS_913513]-Study Procedure  
____ Ensure that patient is transferred to appropriate recovery area as per local  
 hospi[INVESTIGATOR_307]’s standard protocol.  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913514] x -ray is obtained and reviewed by [CONTACT_675778] 1 hour (± 
30 minutes) of procedure for assessment of volume reduction and pneumothorax.  
   
____  Ensure that patient receives antibiotics, corticosteroids, bronchodilators, or any other 
medications as needed.  
 
____  Ensure that vital signs and pulse oximetry are recorded and assessed during the [ADDRESS_913515] x -ray is obtained and reviewed by [CONTACT_675779].  
 
____  Ensure that patient completes Daily Diary . 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913516] been given opportunity to ask/have answere d any questions.  
 
____  Ensure that you have explained to the patient that he/she will be called every  day for the 
next 10 days to follow up on how he/she is doing and whether he/she has experienced 
any adverse events.  If there is a specific time of day th at works best for the patient, 
ensure that this is documented (Time of Call) . 
 
 
11.[ADDRESS_913517] -Discharge I nstruction s are provided as 
Appendix 16 and Appendix 17 , respectively. The Treated Study Participant Bracelet 
and Transferring Instructions if Late P neumothorax should also be given to the study 
participant.    
        
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913518] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  12.0 SECONDARY  VALVE PROCEDURES  
Any s tudy participant  who receive s EBV treatment may undergo valve  removal , 
replacement, or adjustment while participating in the study.  In the case of a secondary 
valve procedure(s), the follow -up schedule will be calculated from the date of the initial  
treatment.  These procedures and the conditions in which they may be considered are 
described below.    
12.1 Valve Removal  
Study investigators  may consider removing valves due to occurrence of an adverse 
event (see Section 15 .0).  Valves may be removed according to the Manufacturer’s 
Instructions for Use.     
12.2 Valve Replacement  
Study investigators may consider replacing valves for study participants who expectorate 
a valve(s) or in cases w here the valve(s) was removed due to  an adverse event (See 
Section 14.0) which has since been  resolved.  Up through the 1 -year follow -up time 
point, valves may be replaced up to a maximum of two times.   The treating physician will 
determine the timing of a valve replacement on a per -patient basis.    Valves may be 
replaced according to the Manufacturer’s Instructions for Use.   
12.[ADDRESS_913519] with the Pulmonx EBV is thought to be 
associated with placing valves to achieve lobar occlusion.  
 
Valve adjustment may be performed only onc e for a study participant  and should be 
performed  within 75 days of the study procedure.   In any case in which  it is necessary to 
re-schedule a valve adjustment due to a study participant’s illness (e.g. COPD 
exacerbation), the valve adjustment may be cond ucted up to [ADDRESS_913520]-procedure.         
 
The investigator  may consider valve adjustment if both of the following are observed :  
 
1) The [ADDRESS_913521] changes , 
shows less than 50% v olume tric reduction in the EBV -treated lobe.  
 
2) The [ADDRESS_913522] -procedure flow and follow -up testing schedule for study participants having 
valve adjus tment is shown in Appendix 1  and Appendix 12 .  The bronchoscopy 
procedure for the valve adjustment will be conducted as described in Section 11.       
 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913523] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  13.0   CLINICAL EFFECTIVE NESS OUTCOMES  
13.1 Spi[INVESTIGATOR_675673]/ERS Task 
Force ‘Standardisation of Lung Function Testing’ [28,29].  Spi[INVESTIGATOR_675674].  For each of these conditions, 
the maneuver should be repeated until at least three good efforts are captured to ensure 
that spi[INVESTIGATOR_675675]. All three good efforts will be 
recorded.   Spi[INVESTIGATOR_675676] (NHANES III) [ 30] should be used for this study.    
13.2 Patient-Reported Health Status Measures  
The study participant should complete the health status questionnaires  themselves but 
the Clinical Coordinator or designee should be available to give advice if it is required. 
The opi[INVESTIGATOR_675677], friends or members of staff  should not influence the study 
participant’s responses . The se questionnaire s are  designed to elic it the patient’s opi[INVESTIGATOR_675678]/her health, not someone else’s opi[INVESTIGATOR_675679]. If the spouse or partner has 
accompanied the patient, then they should be asked to wait in a separate area  while the 
study participant completes the questionnaire s. Similarly, th e study participant should not 
be allowed to take the questionnaires  home.  
 
The questionnaire s should be completed in a quiet area free from distraction and , ideally,  
the study participant should be able to sit at a desk or table. The Study Coordinator or 
designee should explain to the study participant why they are completing the se 
questionnaire s, and how important it is for the researchers to understand how they feel 
about their illness and the effect it has on their daily life.  The study participant sho uld be 
asked to complete the questionnaire s as honestly as possible and it should be stressed 
that there are no right or wrong answers; the study participants should be instructed to 
provide the answer that the study participant feels best applies to them.  It should be 
explained that they must answer every  question and that study staff will be available to 
answer any questions.  
 
Once the study participant has finished completing the questionnaire s, the study 
Coordina tor or designee should review  ALL questionnaire s to confirm that  a response 
has been given to every question.  If there are missed items, the affected 
questionnaire (s) should be returned to the study participant before they leave the clinic 
so that they can complete the missed items.  
13.2.[ADDRESS_913524]. George’s Respi[INVESTIGATOR_6015] (SGRQ)  
The St. George’s Respi[INVESTIGATOR_6015] (SGRQ) is designed to measure and 
quantify disease -specific health status in patients with chronic airflow limitation.  
The SGRQ was developed in Britain and  has been use d extensively worldwide .  
It has been evaluated for reliability and validity in numerous studies of patients 
with COPD and has been validated for clinical use in the [LOCATION_002] [31].   
The SGRQ instrument consists of three discrete component scales (symptoms, 
activity, and impacts on daily life).   The first part (“Symptoms”) evaluates 
symptomatology, including frequency of cough, sputum production, wheeze, and 
breathlessness. The second  part includes questions to address two components:  
“Activity” and “Impacts”.  The “Activity” component includes questions that 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913525] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  address activities that cause breathlessness or are limited due to breathlessness.  
The “Impacts” section includes questions th at explore the effects of the patient’s 
health status on factors such as employment, being in control of health, panic, 
stigmatization, the need for medication, side effects of prescribed therapi[INVESTIGATOR_014], 
health expectations, and disturbances of daily life.   A total score is calculated 
from all three components.  The scoring range for the components and total 
score is 0 -100, with a lower score indicating relatively higher wellness and a 
higher score representing higher disability.   
13.2.2  Modified  Medical Research Cou ncil (mMRC) Dyspnea Scale  
The modified Medical Research Council Dyspnea Scale was developed  and 
validated as a simple measure that could be used to quantify the effect of 
breathlessness on daily activities [32].  It consists of five statement s designed to 
collect information about perceived breathlessness.  The statements are:  Grade 
1, “I only get breathless with strenuous exercise”; Grade 2, “ I get short of breath 
when hurrying on level or up a slight hill”; Grade 3, “I walk slower than people of 
the sam e age on the level because of breathlessness or have to stop for breath 
when walking at my own pace on the level”; Grade 4, “I stop for breath after 
walking 100 yards or after a few minutes on the level”; Grade 5, “I am too 
breathless to leave the house”.   
13.2.3  Baseline/ Transitional Dyspnea Index ( BDI/TDI) 
The BDI/TDI is used to quantify dyspnea and its validity has been reported  [33].  
The BDI will be collected at the baseline visit and the TDI should be collected at 
the 3 -month, 6 -month, 9 -month, and 1 -year follow -up visits.  The assessment 
measures three domains:  1) functional impairment, which determines the impact 
of breathlessness on the ability to carry out activities; 2) magnitude of task, which 
determines the type of task that causes breathlessness; and 3) magnitude of 
effort, which establishes the level of effort that results in breathlessness.  The 
score ranges from -3 (major d eterioration) to +3 (major improvement) for each 
domain.  The sum of all domains is the total score.  A change of at least [ADDRESS_913526] (CAT)  
The COPD Assessment Test consists of eight items , all of which are self -
assessed by [CONTACT_675780] a score ranging from 0 to 5  and it has been 
validated [34] . The eight items are designed to quantify magnitude of symptoms 
related to cough, phlegm, chest tightness, breathlessness, daily activitie s 
limitation, self -confidence, quality of sleep, and energy level.       
13.2.5  Short  Form (SF) -[ADDRESS_913527] of a disease state on an individual's general 
sense of wellbeing  [35]. It has been used extensively across many medical 
specialties to assess general health -related status  and is commonly used in 
health economic studies .   
13.2.6  EuroQol ( EQ-5D) 
The EQ -5D is a standardized instrument that is used as a measure of health 
outcome  [36].  It is applicable to a wide range of health conditions and 
treatments.  The q uestionnaire is comprised of questions that provide a 
descriptive state of health in the areas of mobility, self -care, usual activity, 
pain/discomfort and anx iety/depression. Every question contains three response 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913528] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  categories: level 1 – ‘no problems’, level 2 – ‘some problems’ and level 3 – 
‘inability or extreme problems’ .  
13.2.7  Health Care Utilization Questionnaire  
The study participant will self -report health care utilization data such as physician 
office visits, emergency room visits, hospi[INVESTIGATOR_675680], 
and use of home health care.     
13.3 Body Plethysmography Testing  
Body plethysmography will be used to determine the volume of thoracic gas (VTG ) per 
the American Association of Respi[INVESTIGATOR_1511] (AARC) Clinical Practice Guideline “Body 
Plethysmography: 2001 Revision and Update” [37].  The reported VTG should be 
averaged from a minimum of 3 -5 separate, acceptable panting maneuvers; should be 
calcul ated using values that agree within 5% of the mean (widely varying values should 
be averaged, and reported as variable); should indicate whether the thoracic volume 
was at functional residual capacity ( FRC) or at some other level; should be compared 
with o ther lung volume determinations (He dilution, N 2 washout) if such are being 
performed.    
Lung volumes including the slow vital capacity (VC) maneuver and its subdivisions 
inspi[INVESTIGATOR_14008] (IC) and expi[INVESTIGATOR_594654] (ERV) should be performed 
during the same testing session.  The ERV, IC, and VC should be measured in 
conjunction with each VTG trial before disconnecting from the measuring system.  
Tracing should be added to illustrate correct performance.  The largest volume of VC or 
forced vital capacity ( FVC) obtained should be used for calculation of derived lung 
volumes.  The mean values should be reported for IC and ERV from acceptable VTG 
maneuvers.  Total lung capacity ( TLC) = mean FRC + mean IC (mean IC should be 
close to the largest IC) an d RV = TLC – largest VC.  
Airways resistance and specific airways conductance maneuvers should be conducted 
such that the open -shutter panting maneuver shows a relatively closed loop.  The 
panting frequency for within -testing session comparisons (i.e. pre - and post -
bronchodilator t esting) and for serial testing in a given study participant should be kept 
constant to aid in interpretation.  Consensus of the group suggests a range of 60-90 
cycles per minute.   
A linked, rather than unlinked, maneuver should be performed; this means th at 
following shutter closure at FRC, an expi[INVESTIGATOR_675681], 
followed by [CONTACT_22368][INVESTIGATOR_675682].  
Body plethysmography values recorded on the CRF will be post -bronchodilator.   
Body plethysmography reference values from the ATS statement on ‘Lung 
Function Testing:  Selection of Reference Values and Interpretative  Strategies’ 
[38] should be used for this study.  
13.[ADDRESS_913529] will be conducted per the ATS document “ Standardisation of the 
Single -Breath Determination of Carbon -Monoxide Uptake in the Lung ” [39].  Acceptable 
test criteria include the use of proper quality controlled equipment, inspi[INVESTIGATOR_675683] 
85% of vital capacity in less than 4 seconds, a stable breath -hold for 8 to 12 seconds, no 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913530] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  evidence of leaks or Valsalva or Muller maneuvers, expi[INVESTIGATOR_568946] 4 seconds 
with appropriate clearance of d ead space and proper sampling/analysis of alveolar gas.   
If clinically acceptable, the study participant should not breathe supplemental oxygen for 
[ADDRESS_913531] two acceptable tests that meet the 
reproducibility requirement of being within +/ - 10% or [ADDRESS_913532] two acceptable tests that meet this reproducibility requirement should 
be reported.  
13.5 Medication Use  
Medication use is expected to fall within the guidelines e stablished for treating COPD 
[40].  Study participants will be asked to provide information regarding their use of four 
classes of medications, including bronchodilators (beta -agonists, anticholinergics, 
methylxanthines) , corticosteroids , antibiotics, and anti-inflammatories (e.g. statins, 
roflumilast) .  Addition of new medications in these classes or alterations in dose over the 
course of the study will be tracked.  Study participants will be requested to bring all 
medication containers with them to each f ollow -up visit.     
13.6 Daily Diary   
The daily diary (hard -copy form) will be given to the study candidate at the baseline visit 
and collected at  the bronchoscopy procedure visit and then electronically at  the [ADDRESS_913533] day after the bronchoscopy procedure and will be completed through  the 1 year  
follow -up visit. Every effort will be made to ensure that  study participants complete all 
diary entries, although failure to do so will not be considered a protocol deviation.      
13.6.1  Pulmonary Rehabilitation Program  Compliance  
Study participant s will be asked to self -report the number of exercises performed 
that day and the amount of time (minutes) spent doing them .       
13.6.[ADDRESS_913534] -PRO was developed to serve as a standardized outcome measure 
to evaluate COPD exacerbations [41].  Respondents  are asked to self -report 
symptoms such as cough, mucous discharge, chest discomfort, and 
breathlessness.  The questionna ire consists of 14 items, in which the patient 
grades the symptom as experienced by [CONTACT_675781] 
(e.g. ‘no t at all’, ‘rarely’, ‘occasionally’, ‘frequently’, ‘almost constantly’ ).       
13.6.[ADDRESS_913535] been deterred from their normal daily activities 
due to their emphysema symptoms . 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913536] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  13.7 Six-Minute Walk Distance (6MWD) Test  
Six-minute walk distance testing will be performed  according to the “ATS Statement” 
Guidelines for the S ix-Minute Walk Test – March 2002” [42].  The test should be 
performed indoors, along a flat, straight, enclosed corridor with a hard surface that is 
seldom traveled.  The walking course must be [ADDRESS_913537] using the Borg scale.  Required equipment, patient preparation, and 
measurements are specified in the ATS guidelines.  
13.7.1  Dyspnea Assessment  
Dyspnea and overall fatigue will be measured in all study par ticipants using the 
Borg Scale [ 43,44 ] immediately prior to and immediately after perform ing the 
6MWD test.   
13.8 Blood Work   
Blood chemistry variables collected during for the study will include  arterial blood gases 
(ABGs) , complete b lood counts (CBCs), serum (or plasma) fibrinogen, plasma cotinine 
and/or arterial carboxyhemoglobin,  and alpha -1 anti -trypsin  deficiency .  
   
13.8.1   Arterial Blood Gases (ABGs)   
Blood gases should be collected with the study participant breathing room air.  If 
the study participant is receiving supplemental oxygen at the time arterial blood 
gases are intended to be sampled, the supplemental oxygen should be 
discontinued for 10 minutes prior to sampling.  If during this 10 -minute period 
oxygen saturation falls be low 80%, supplemental oxygen should be provided and 
increased in one liter/minute increments every three minutes until the minimum 
flow necessary to achieve 90% oxygen saturation is reached.  Blood gases 
should then be sampled at this point.  Subsequent bl ood gas samples should be 
taken under the same supplemental oxygen flow rate conditions.    
13.8.2   Complete Blood Counts (CBCs)   
Complete blood counts will be collected to characterize general health status.      
13.8.[ADDRESS_913538] 
been shown to be associated with increa sed risk of COPD exacerbations [4 5]. 
13.8.4   Plasma Cotinine and/or Arterial Carboxyhemoglobin     
Plasma cotinine and/or arterial carboxyhemoglobin counts will be collected to 
monitor nicotine use.    
13.8.5   Alpha -1 Antitrypsin Protease Inhibitor Counts   
Alpha -1 antitrypsin protease inhibitor counts will be used to assess screening 
eligibility criteria .  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913539] X -ray will be collected as specified in Section 14.0 and at any other time in which it 
may be considered medically necessary following the bronchoscopy procedure  to screen 
for signs of volume reduction and pneumothorax .    
 
13.10  Physical  Exam 
A routine medical examination will be performed as specified in Section 14.0.     
13.11 High Resolution Computed Tomography   
All attempts will be made to acquire  volumetric high resolution computed tomography 
(HRCT) images using standardized methods across clinical sites  at all times of 
acquisition .  The CT  scans should  be obtained using the study CT acquisition  protocol 
(see Appendix 6).   
 
The s creening CT  study , collected for all study participants as part of the study 
screening process, will be considered the baseline CT for statistical analysis.   Study 
investigators, in conjunction with the site -based radiologist(s)  if desired , will evaluate CT 
images collected for study candidates dur ing screening using an FDA approved software 
package to determine whether study candidates meet study eligibility criteria.      
 
For study participants who receive the study treatment, p ost-bronchoscopy follow -up CT 
studies will be collected at the [ADDRESS_913540] scans to determine  whether study 
participants who receiv ed the study treatment may be candidates for valve adjustment.  
This will be conducted by 1) determining volumetric change between the screening 
HRCT scan and post -procedure [ADDRESS_913541] scans  in the treat ed lobe and 2) 
evaluat ing valve placement in the target airways .  For study participants who undergo a 
valve adjustment procedure, the [ADDRESS_913542] scan will b e assessed for volumetric 
change in the treated lobe ; valve placement  will also be evaluated .  The [ADDRESS_913543] scans may be examined to assess valve placement f or lobar occlusion and 
other radiographic features.  
13.12 BODE Index   
The BODE index is a multidimensional measure that has been reported to be predictive 
of risk of death from any cause and from respi[INVESTIGATOR_179177] [ 46,47]. It combines four 
measures frequently used in COPD studies as a composite score: body -mass index 
(BMI), obstruction (FEV 1 % predicted), dyspnea, usually c haracterized using the mMRC  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913544].  Each 
component is graded and a score of  0 to 10 is obtained as indicated in the table below. 
The BODE Index will be calculated and reported in the final study report.  
Table.  Determination of the BODE Index Score.  
 Points for BODE Index Score  
 0 1 2 3 
BMI  (kg.m-2) >21 <21  
FEV1 % predicted  >65 50-64 36-49 <35 
MMRC  0-1 2 3 4 
6MWD (m)  >350 250-349 150-249 <149 
  
 
 
14.0 SEQUENCE FOR TESTING    
14.1 Screening Assessment  – within 6 months prior to randomization  
• Informed Consent  
• Inclusion and Exclusion Criteria  
• Medical History  
• Vital Signs/Physical Exam  
• Lung Function Testing (Study Protocol Section 13.0)  
o Spi[INVESTIGATOR_038] (collected using your clinic’s normal care regime)  
o Body Plethysmography  
o Diffusing Capacity (DL co) 
• HRCT Scan (Study Protocol Section 8.5.1, Appendix 6 and core lab Protocol)  
o In order for the stu dy candidate to be found to meet the HRCT emphysema lobar 
destruction score criterion and the emphysema heterogeneity score criterion, the 
CT scan must be collected using the HRCT scan acquisition protocol   
▪ Full inspi[INVESTIGATOR_675684] (TLC)  
▪ Full expi[INVESTIGATOR_675684]  (RV) 
o Forward CT scans to core lab of all candidates meeting the HRCT scan 
screening eligibility criteria  
▪ Forward the first 5 Myrian analyses (both (in)eligible candidates) to core 
lab to confirm proficiency for using the CT scan screening software   
o NOTE:   A pre -existing CT scan that the study candidate provides to you or that is 
found during the chart screening may be “pre -screened” using the CT scan 
screening software.  
• ECG  
• 6-Minute Walk Distance (Study Protocol Section 13.7)  
• Echocardiogram  
• Blood Work (S tudy Protocol Section 13.8)  
o Arterial Blood Gases (ABGs)  
o Complete Blood Counts (CBCs)  
o Alpha -[ADDRESS_913545]  
o Plasma Cotinine  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913546] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  ▪ use Arterial Carboxyhemoglobin if candidate uses nicotine products)  
o Serum Fibrinogen  
 
If the Study Screening Eligibility Criteria are met by [CONTACT_297596], ask the Candidate to 
begin the Study Eligibility Pulmonary Rehabilitation Program (if the Study Candidate has 
already met the Pulmonary Rehabilitation Criterion you may proceed with the Baseline 
Visit) 
 
14.[ADDRESS_913547] ≤ 120 days following screening eligibility  
• Sign Participation Informed Consent (if only Screening Informed Consent was collected 
previously)  
• Pulmonary Rehabilitation Eligibility Criterion Completed  
o At least 8 sessions (4 weeks with  2 sessions per week; Study Protocol Section 
10.1)  
• Spi[INVESTIGATOR_038]  
• 6-Minute Walk Distance (Study Protocol Section 13.7)  
 
After confirmation of Baseline Eligibility:  
• Vital Signs/Physical Exam  
• Medication Use  
• Vaccinations, if necessary (Pneumococcal, Influenza)  
• Self-Reported Health Status Measures  
o SGRQ  
o SF-36  
o EQ-5D  
o BDI  
o mMRC  
o CAT  
o Health Care Utilization  
• Daily Diary  
o Send paper diary home with study candidate to complete daily for 7 days prior to 
the scheduled bronchoscopy procedure  
• Create Bronchoscopy Procedure Plan  
• Contact [CONTACT_675782]  
 
14.3 Bronchoscopy Procedure – Should occur ≤ 60 days after baseline 
assessment visit  
• Pre-Procedure Orders and Preparation  
o Female – pregnancy test, if applicable to informed consent  
o Ensure study personnel are identified for pneumothorax management  
 
Recommended:  
o Prophylactic antibiotic regimen may be initiated 2 days prior to procedure if 
desired by [CONTACT_16125]  
o Corticosteroids may be may be initiated 2 days prior to procedure if desired by 
[CONTACT_675783] #630 -0012-H              
 
Version:  June 23, [ADDRESS_913548] photos of EBV placement   
 
• Bronchoscopy  
o Anesthesia = conscious sedation with study candidate breathing spontaneously  
o Chartis System: assessment of target lobe collateral ventilation   
o After confirmation of study device eligibility criterion (finding of little or no 
collateral ventilation in tar geted treatment lobe) proceed with randomization  
 
• Study Device Placement  
o May convert study participant to general anesthesia  
o Record device lot numbers and valve placement location on worksheet  
 
14.[ADDRESS_913549] Procedure  
• Study Treatment Arm:  
o Perform chest x -ray within 1 hour  (± 30 minutes)  
o Monitor vital signs and pulse oximetry for first [ADDRESS_913550] X -rays daily x 5 days during hospi[INVESTIGATOR_4408]  
 
• Control Arm:  
o Monitor vital signs and pulse oximetry until discharge  
o Collect ABGs and serum fibrinogen before discharge  
 
14.5 Prior to Discharge  
• Study Treatment Arm  
o Perform pre -discharge chest X -ray and physical examination  
o Schedule follow -up visits, including daily contact [CONTACT_10782] [ADDRESS_913551] -Procedure Instructions  
o Adverse Event Assessme nt 
 
• Control Arm  
o Schedule follow -up visits  
o Bronchodilator inhaler, course of antibiotics, corticosteroids  
o Disburse Daily Diary  
 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913552] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  14.6 Daily Follow Up Phone Call for 10 Days after Discharge (up to 11:59 pm)  
• Study Treatment Arm  
o Symptom Checklist  
o Follow up may occur in hospi[INVESTIGATOR_675685]  
 
14.7 Day 7 after Discharge Visit (+ 1 business day)  
Study Treatment Arm Only  
• Vital Signs/Physical Exam   
• Chest X -ray 
• Symptom Checklist  
• Investigator to assess for return to regular activity and initiation of the  protocol 
required pulmonary rehabilitation program  
o Assessment should show lack of evidence  of pneumothorax, infection, or 
exacerbation, tolerance of light activities, and physical condition at least 
similar to or better than at the baseline  visit 
• Adverse Events assessment  
• Symptom Checklist may be conducted during visit  
 
14.8 Day 30 Visit (+/ - 5 days)  
Study Treatment Arm Only  
• Vital Signs/Physical Exam  
• Chest X -ray 
• Adverse Events assessment  
 
14.9 Day 45 Visit (+/- 5 days)  
• Vital Signs/Physical Exam  
• Medication Use  
• Daily Diary Collection  
• Spi[INVESTIGATOR_038]  
• Body Plethysmography  
• DLco  
• Collect mMRC Survey  
• 6-Minute Walk Distance  
• Adverse Event Assessment  
• Study Treatment Arm  
o Chest X -ray  
o HRCT Scan (may be completed in a separate visit)  
o Forward CT scan to core lab  
14.10 3 Month Visit  (+/- 14 days)  
• Vital Signs/Physical Exam  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913553] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  • Medication Use  
• Daily Diary Collection  
• Collect SGRQ Survey  
• Collect Health Care Utilization Survey  
• Collect TDI Survey  
• Collect CAT Survey  
• Study Treatment Arm  
o Only EBV treated participants who undergo valve adjustment -- may be 
completed in a separate visit  
▪ HRCT, forward CT scan to core lab  
▪  Chest X -ray 
▪ Body P lethysmography  
 
14.11 6 Month Visit (+/ - 21 days)  
• Vital Signs/Physical Exam  
• Medication Use  
• Daily Diary Collection  
• Spi[INVESTIGATOR_038]  
• Collect SGRQ Survey  
• Collect Health Care Utilization Survey  
• Collect mMRC Survey  
• Collect TDI Survey  
• Collect CAT Survey  
• 6-Minute Walk Distance  
• Adverse Event Assessment  
 
14.12 9 Month Visit (+/ - 21 days)  
• Medication Use  
• Daily Diary Collection  
• Collect TDI Survey  
• Collect CAT Survey  
• Collect Health Care Utilization Survey  
 
14.13 1 Year Visit (+/ - 45 days)  
• Vital Signs/Physical Exam  
• Medication Use  
• Daily Diary Collection  
• Spi[INVESTIGATOR_038]  
• Collect SGRQ Survey  
• Collect Health Care Utilization Survey  
• Collect SF -36 Survey  
• Collect EQ -5D Survey  
• Body Plethysmography  
• DLco 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913554] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  • Collect TDI Survey  
• Collect CAT Survey  
• Collect mMRC Survey  
• 6-Minute Walk Distance  
 
The following may be completed in a separate visit or in order as scheduling permits after all 
other testing  
• ECG  
• Blood Work (ABGs, CBCs, plasma coti nine, serum fibrinogen)  
• Adverse Event Assessment  
• Study Treatment Arm  
o HRCT Scan for EBV treated participants  
o Forward CT scan to core lab  
• Control Arm  
o After completing the [ADDRESS_913555] document the participant’s suitability for crossing 
over to study treatment ; to qualify for crossover, a control arm participant must 
have been followed up successfully through [ADDRESS_913556] be scheduled to occur within the next 60 days  
following the 1 -year visit    
o After receiving the study treatment, t he follow -up visits and testing at each visit 
will be identical to the schedule for treatment arm par ticipants   
 
14.14 Annual Visits (+/ - 60) only for Study Participants treated with EBV  
• Spi[INVESTIGATOR_038]  
• Adverse Event Assessment  
 
 
15.0  SAFETY ELEMENTS  
15.1 Adverse  Events 
Previous studies of emphysema patients who were followed longitudinally and tr eated 
using medical management [ 10,16,17 ], diagnostic or interventional bronc hoscopy 
[448,49 ], or endobronchial  valves [ 16,17 ] indicate that a moderate risk of adverse events 
may be anticipated during this study.  Adverse events will be graded by [CONTACT_675784].  
 
It is anticipated that the rates for adverse events will be higher for the study treatment 
arm than control arm during the treatment period (‘short’ , or day of the study procedure 
to 45 days) but that the rates for these occurren ces will be similar for both  study arms 
during the post -treatment period (‘long’ , or 46 days to 1 year).  
 
Adverse events that may be observed include:    
 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913557] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  ❖ Cardiovascular events such as:  
o New onset cardiac a rrhythmia   
o New diagnosis of c ongestive heart failure , which may be indicated by >1-point 
increase in NYHA functional classification score  
o Acute myocardial infarct requiring medical care  
o New diagnosis t ransient ischemia attack ( TIA) or stroke  
o New diagnosis d eep vein thrombosis  
o Pulmonary embolism , which may be indicated by [CONTACT_675785] V/Q 
evidence of segmental or larger perfusion defects   
 
❖ COPD and Emphysema events such as:   
o COPD exacerb ation  requiring treatment with antibiotics and/or oral steroids  
▪ AECOPD requiring emergency room visit or hospi[INVESTIGATOR_059]  
o Respi[INVESTIGATOR_675686] -intubation at any time during follow -up and/or 
invasive mechanical ventilation >[ADDRESS_913558] scan and clinical characteristics of active infection (fever, leukocytosis, 
hypotension)   
 
❖ Pulmonary / Thoracic events such as:  
o Hemop tysis requiring new evaluation or intervention  
o Pneumothorax  indicated by [CONTACT_675786]/or X -ray 
▪ Pneumothorax requiring intervention  
o Empyema requiring new evaluation or intervention  
o Non-cardiac chest pain  driving the study participant to seek medical care  
o Pleural e ffusion  noted radiologically  
o Lung mass / cancer noted radiologically  
o Fractured rib  noted radiologically  
o Laryngospas m driving the study participant to seek medical care  
o Dysphonia  driving the study participant to seek medical care  
o Hypoxemia  requirin g increased or new oxygen use   
o Adverse tracheobronchial observations  such as bronchial granulation tissue, 
bronchial ulceration, bronchial trauma  
 
❖ Other events such as:  
o Death, any cause  
o Septicemia as evidenced by [CONTACT_675787] (with at least two separate blood cultures positive for the 
same pathogen(s), requiring systemic antimicrobial therapy)   
o Non-pulmonary infection requiring medical care  
o Fever > 99. 5 ⁰C for > 24 hours  
 
❖ Endobronchial Valve events such as:   
o Valve expectoration , as reported by [CONTACT_87755]  
o Valve migration , as indicated by [CONTACT_284747]/or radiological evidence that a valve 
has left the target airway  
o Pneumonia distal to implanted val ves, indicated by [CONTACT_675788] X -ray or CT 
scan and clinical characteristics of active infection (fever, leukocytosis, 
hypotension)  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913559] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  15.2 Serious Adverse Events   
An adverse event is considered serious if it meets the definition of a s erious adverse 
event (SAE) as defined in Section 21.2.  Serious adverse events may occur at any time 
during the study and will be reported as serious regardless of when they occur, provided 
they meet the definition of a serious adverse event.  
15.3 Management of Selected Anticipated Adverse Events  
15.3.1  Pneumothorax    
Pneumothorax is an expected and anticipated event in patients undergoing a 
lung volume reduction procedure.   With lung volume reduction surgery (LVRS), 
pneumothorax occurs in all (100%) cases  and all patients leave the operating 
room with a chest tube(s) to manage air leaks.  After EBV treatment, it is 
anticipated that the collapsed lung in the target lobe or expanding lung in 
adjacent lobe(s) may develop an air leak (s).  With lung volume redu ction 
procedures, achieving a higher success rate may be associated with having a 
higher risk of pneumothorax.   
 
In the VENT study, pneumothorax was seen in 15%-20% of EBV-treated  study 
participants who were thought to have little or no lobar CV (i.e. had HRCT 
suggestive of complete fissure)  along with HRCT evidence of lobar occlusion 
with valve treatment.  Therefore , it is anticipated in this study that approximately 
one in five of EBV -treated study participants may experience a post -procedure 
pneumothora x.   
 
Study participants who received the study treatment will be provided with a 
Medical Alert Card, Treated Study Participant Bracelet, Transferring Instructions 
if Late Pneumothorax, and Post -Procedure Instructions prior to hospi[INVESTIGATOR_7954].  Study pa rticipants who received the study treatment will be contact[CONTACT_675789] [ADDRESS_913560] tube should be transferred to the 
treating hospi[INVESTIGATOR_675687].  
 
15.3.2  Pneumonia  
Pneumonia -like symptoms, including low -grade fever, increased sputum, and 
radiographic abnormalities, are  anticipated consequence s of bronchoscopy.  In 
this study, pneumonia will be defined as:  1) fever ( > 99 ⁰F) persisting for >48 
hours and 2) white blood count >15,000 cells/ mcL.  Any study participant having 
clinical and radiological signs of pneumonia or pneumonia -like symptoms will be 
medically treated.        
[IP_ADDRESS]  Pneumonia Distal to Valve (s)  
Any study participant observed to have consolidation on X -ray or 
CT scan and clinical characteristics of active infection (fever, 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913561] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  leukocytosis, and hypotension) will be considered to have 
pneumonia distal to valve(s) .       
15.3.3  COPD Exacerbation  
Any study participant reporting or admitted to the hospi[INVESTIGATOR_675688] a treatment plan will 
be formulated .  An exacerbation will be defined as a worsening of the study 
participant’s  sympt oms from his or her usual stable state that is beyond normal 
day-to-day variations, and is acute in onset , and requires modification of the 
study participant’s medication regimen .  Commonly reported symptoms are 
worsening breathlessness, cough, increased sputum production , and change in 
sputum color.     
15.3.4  Hemoptysis   
Any study participant experiencing hemoptysis will be immediately evaluated and 
a treatment plan will be formulated.  Generally, only minimal hemopt ysis after the 
procedure is observed.  Larger  amounts of bleeding may require imaging or 
endoscopy as dictated clinically at the discretion of the study investigator. 
Massive hemoptysis is defined as > 200 ml blood loss in less than 24 hours.       
15.3.5  Respi[INVESTIGATOR_675689] -intubation will 
undergo immediate clinical evaluation and management as dictated by [CONTACT_675790].       
15.4 Events Anticipated to Precipi[INVESTIGATOR_675690] U.S. VENT study, 31 (14.5%) patients underwent valve removal after the 
procedure. Therefore, it is anticipated that valve removal attributed to the following 
conditions may occur.       
15.4.1  Valve Migration   
In any case in which a valve migration , as defined in Section 15,  is observed, 
removal o f the valve is required.    
15.4.2  Pneumonia and Pneumonia Distal to Valve(s)  
If the pneumonia does not resolve normally with medical therapy  then valve 
removal may be consider ed. 
15.4.3  Respi[INVESTIGATOR_675691].         
15.4.4  Hemoptysis  
In cases where hemoptysis is observed, valve removal may be considered.   
15.4.5  Granulation   
In cases where granulation is observed, valve removal may be con sidered.   
15.4.6  Continuing COPD exacerbations  
In cases where a study participant has recurrent COPD exacerbations, valve 
removal  may be considered.     
15.4.7  Increased Dyspnea  
In cases where severely increased dyspnea is observed, valv e removal may be 
considered.     
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913562] that the v alves be removed  for any reason .  
 
16.0   RISK - BENEFIT EVALAUATION  
16.1 Potential Benefits  
Potential benefits include improvement in the study participant’s lung function  and other 
improvements that may be associated with improved lung function.    
16.2 Potential Risks  
The primary risks associated with use of the Pulmonx EBV, as proposed in t his study 
protocol (see Adverse Events section ), are similar to other bronchoscopic and  surgical 
procedures used to treat emphysema.   
16.3 Risk Minimization  
Risk mitigation measures include the following:  
a) The use of standard medical grade materials that have been thoroughly 
characterized and tested to assure biocompatibility,  
b) Extensive pr e-clinical evaluation including in vitro  bench testing and animal study,  
c) Prior human clinical trial experience including four hundred ninety two (492) 
patients followed for one year.  
d) The well -established, standard nature of the bronchoscopic procedure and 
technique (i.e., used in placement of bronchial stents),  
e) The ability to abort the procedure at any time.  The physician may elect to 
discontinue the use of the Pulmonx Endobronchial Valve at any time in favor of 
alternative medical or surg ical procedures, and   
f) Reversibility, as the Pulmonx Endobronchial Valves may be removed.  
 
17.[ADDRESS_913563] (IRB) Approval  
The Investigator will obtain IRB approval prior to asking participants to sign the I nformed 
Consent Form and complete any study -specific procedures.  The IRB approval must be 
maintained for the duration of the study.  If IRB approval is withdrawn, the Investigator 
must immediately discontinue any study related activities that will not adv ersely affect the 
health and welfare of the study participant. The investigator must notify the study 
Sponsor of such withdrawal in writing within 5 working days.  
17.2 Confidentiality  
All information and data concerning participants or their participation in this trial will be 
considered confidential, and handled in compliance with the Declaration of Helsinki, ICH 
guidelines  (to the extent that they are consistent with U.S. federal regulations) , CFR 
section 21 , and HIPAA requirements . Only authorized personnel , the study Sponsor or 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913564] that biomedical research involving human subjects 
should:  
• Conform to generally accepted scientific principles.  
• Be conducted only under the supervision and direction of scientifically or 
medically qualified persons.  
• Be preceded by [CONTACT_675791].  
• Be more concerned with the interest of the participant than those of science and 
society.  
• Respect the privacy of the participant.  
• Preserve the accuracy of the results in publication.  
• Inform each potential participant of the aims, methods, anticipated benefits and 
potential hazards of the study , the discomfort it may enta il, and alternatives to 
study participation . 
• Never interfere with the physician -patient relationship.  
17.[ADDRESS_913565] udy.  Participant selection criteria will be closely followed and the demographics 
and the condition of each participant will be documented prior to treatment.  Additionally, 
a standardized arm -specific treatment protocol will be followed for each pa rticip ant and it  
will be clearly documented.  Finally, both the investigat ive site staff  and the study 
participant s will be instructed to complete the data forms in a consistent manner.  Any 
significant deviations from the procedures described in this protocol w ill be documented.  
17.5 Early Termination of the Clinical Investigation  
If the investigation is terminated prematurely  or suspended, the Sponsor will promptly 
inform the Clinical Investigators/investigation sites of the termination or suspension and 
the reason( s) for this. The Independent Ethics Committee (IEC) will also be informed 
promptly and provided with the reason(s) for the termination or suspension by [CONTACT_675792]/investigation  sites.  
 
18.0 CLINICAL SITE TRAINI NG 
18.1 Clinical Study Staff Training  
The site Principal Investigator [INVESTIGATOR_675692].  The Study Sponsor  will train 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913566] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  the Principal Investigator [INVESTIGATOR_675693], face -to-face 
meetings, and site visits.   
18.2 Procedure and Training Videos  
All site Investigators participating in the study will attend  a presentation  designed to 
convey the technical aspects of the study device and procedure.   
18.3 Physician Hands -on Training:  Endobronchial Valve  
All site Investigators will be trained on an anatomical bronchial model that simulates the 
clinical experience of using the EBV.  After instruction from a qualified Pulmonx trainer  
and passing the training pr ogram evaluation , the physician will demonstrate successful 
placements as well as successful removals of valves using the bronchial model.  
 
18.3.[ADDRESS_913567] be demonstrated in 
different anatomical locations to achieve lobar occlusion .  A successful 
placement has been achieved when the trainer verifies appropriate placement.  
• At least two large valves shall be successfully placed.  One (1) in the right 
upper and one (1) in the left upper bronchus.  
• At least two small valves shall be successfully placed.  One (1) in the right 
api[INVESTIGATOR_675694] (1) in the left api[INVESTIGATOR_675695].   
18.3.[ADDRESS_913568] been retrieved from the bronchial model.  
18.4 Physician Hands -on Training:  Chartis Assessment System  
All site Investigators will be trained on the Chartis Assessment System using an 
anatomical br onchial model that simulates the clinical experience of using the Chartis 
System.  After instruction from a qualified Pulmonx trainer, the physician will 
demonstrate successful catheter placements to simulate isolation of the discrete lung 
lobes .   
 
The Investigator will also be trained to determine CV status for a series of sample 
assessments to demonstrate accurate interpretation.  
18.5 Study Coordinator Training  
The Study Coordinator (s) with primary responsibility for managing the study at each site 
will be provided with comprehensive training on the study device, study procedure, post -
procedure study participant management, study protocol, and duties and responsibilities 
of the Study Coordinator.  They will be provided with detailed information on impor tant 
logistical and administrative tasks with regards to reporting requirements, CRF 
management, and product tracking.  Each site coordinator will receive a study binder 
containing, at a minimum, the study protocol, case report forms (CRFs), sample 
informe d consent document, and study contact [CONTACT_3031].  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913569] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  18.6 Protocol Training  
Prior to enrollment of study participants, the site Principal Investigator(s) , Sub -
Investigators,  and the Study Coordinator(s) will meet with Pulmonx personnel to discuss 
the protocol an d to ensure that all study eligibility criteria and study protocol details are 
well understood.  Staff will be trained to encourage all study participants to continue full 
adherence to the study protocol activities and follow -up schedule.  A training recor d will 
be maintained for each site Investigator and Study Coordinator and shall be used to 
document completion of successful training.   
18.7 Assistant Physicians, Scrub Nurses, and Technicians  
The site Principal Investigator (or designee) will be responsible for providing oversi ght of 
all allied health personnel who will be assisting with execution of study -related activities  
in order to ensure compliance with clinical trial requirements .   
18.[ADDRESS_913570] (DSMB)  
A data safety monitoring board (DSMB) will be utilized to review data to evaluate safe ty of 
study p articipants during their part icipation in the study  and to review  the interim data 
analysis .  The DSMB will consist of a statistician, a pulmonologist, and a thoracic surgeon 
with LVRS experience who have no scientific, financial, or other conflict of interest related 
to the investigation. Members will not have a ny direct affiliation with the s tudy Sponsor or 
the Investigational Sites that would create a conflict of interest impacting their ability to  
serve objectively on the DSMB.  
The DSMB will be responsible for making recommendations to the Operations Committee 
regarding the primary endpoint at the interim a nalysis and monitoring for any potential 
problems  at any time during the study . DSMB responsi bilities, membership, meeting 
frequency and procedures will be documented in a committee charter but the DSMB may 
call a meeting at any time if there is reason to suspect that safety is an issue.  The DSMB 
will be provided access to all study safety data i ncluding all adverse e vent reports. 
Interaction on the part of DSMB members with clinicians, nurses, technicians and other 
protocol participants will be strongly discouraged in order to avoid any potential bias. The 
DSMB will function in accordance with applicable regulatory guidelines.  
 
The DSMB will be expected to review all adverse events and other safety outcomes for 
the duration of the study.  Meetings are anticipated to be conducted on a quarterly basis.  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913571] 
safety or issues relating to data monitoring or quality control will be submitted in writing 
to Pulmonx for consideration.   
19.2  Clinical Events Committee  
The Clinical Events Committee  (CEC) will consist of  board-certified physicians who may 
be specialists in pulmonology, t horacic surgery, interventional pulmonology, or thoracic 
radiology  who are  not otherwise participating in the study (Note: The CE C members will be 
not be DSMB participant s). The CE C will regularly  review and a djudicate  all serious and/or 
potentially device -related Adverse Events  through at least the [ADDRESS_913572] been randomly assigned to study treatment or control , regardless of whether or not 
they undergo the assigned treatment.  
 
Statistical analyses will also be performed on a Completed Cases (CC) basis and Per -
Protocol (PP) basis. The CC population is defined as all randomized and eligible patients 
who received study -directed treatment and had 1 year  of follow -up. The PP population is 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913573] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  defined as all randomized study partic ipants who meet study eligibility criteria, who were 
treated as randomly assigned, and had follow -up for the endpoints .  
 
If applicable, statistical a nalyses will also be conducted after sorting patients by [CONTACT_675793].  
20.2 Safety Analysis Population  
Both t he ITT  analysis population and ‘As Treated’ ( AT) analysis population will be used to 
assess the safety  data.  For the AT analysis, study participants will be analyzed based on 
the treatment they actually received.            
20.3 Primary Effectiveness Endpoint  
Achievement of the primary effectiveness endpoint will be determined by  [CONTACT_675794] 
>15% improved forced expi[INVESTIGATOR_31737] (FEV 1), collected post -
bronchodilator,  as compared to the Control arm at [ADDRESS_913574] obstruction.  It is a well -accepted parameter 
for both staging of COPD and assessment of lung function improvement after treatment.   
Increased expi[INVESTIGATOR_84423], manifested as a decreased FEV 1, is one of the 
hallmarks of emphysema.  The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) reports that FEV [ADDRESS_913575] for measuring airflow limitation in COPD  
(44).  In addition, FEV [ADDRESS_913576] -bronchodilator FEV 1 (45-47).  Decline of FEV 1 is associated with 
adve rse health consequences such as increased COPD exacerbations and reduced 
quality of life  (48).     
20.3.1  Sample Size Rationale  
The results of two prospective studies were used to inform the sample size 
estimation.  The Endobronchial Valve for Emphysema Palliation Trial (“VENT 
Pi[INVESTIGATOR_243897]”, IDE#G020230, [STUDY_ID_REMOVED]) was a multi -center, prospective, 
randomized, controlled study conducted at sites in both the [LOCATION_002] and 
Europe to assess the safety and effectiveness of using the Zephyr EBV device fo r 
palliating symptoms associated with severe heterogeneous emphysema.  Four 
hundred ninety two (492) participants were enrolled into the study and randomized 
to Zephyr EBV Treatment o r medical management (control) [ 16,17 ].  The Chartis 
Pulmonary Assessment  System study is a recently completed prospective post -
market study that was conducted in [LOCATION_013], The Netherlands, and Sweden.  The 
primary objective of the study was to quantify the accuracy of the Chartis System 
when used to identify targeted treatment lobes as having or not having inter -lobar 
CV in patients with emphysema who were to be treated using endobronchial valves 
(26).  The results of both the VENT Study and the Chartis System study showed 
that treatment effect with the endobronchial valve is correlated with lack of inter -
lobar CV [16,17,2 5].   
Patients in the VENT Study and in the Chartis Study who were considered to have 
little or no  inter-lobar CV contributed the information used for the sample size 
estimate .  Patients who have little or no lobar CV in the targeted treatment lobe are 
expected to be good responders to endobronchial valve treatment.  For the sample 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913577] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  size estimate, a ‘responder’ was considered to be a study participant who had 
>15% improved FEV 1 after EBV treatment.   
Based on the results of these studies, the responder rate in the EBV Study 
Treatment Group is expected to be approximately 35% at 1 year .  The responder 
rate for the control group is not expected to exceed 10% at 1 year .   Assuming a 
two-sided 0.05 alpha level, study power of 90%, and 2:[ADDRESS_913578] for superiority .   
The study sample size will be increased to 183 in order to allow for 20% lost to 
follow -up and incomplete data.  Each study site will be allowed to enroll a 
maximum of 2 5 study participants.  
20.4 Safety Endpoint  
Safety will be determined  by [CONTACT_675795] 1) the shorter -term treatment period, defined as the d ay of the 
study procedure until 45 days  after the study procedure (‘short’) and 2) the longer -term 
post-treatment period, defined as 46 days after the study procedure until the 1 year  
follow -up visit  (‘long’) .   
20.5 Secondary Effectiveness Measures  
The followi ng will be assessed for the EBV treatment arm:   
1) Treatment Lobe Volume Reduction (TLVR) for the EBV Treatment Arm  
a. TLVR, measured as the ‘ absolute  change from baseline’ for treated lobe 
volume as seen via HRCT (high resolution computed tomography), will be 
evaluated at 45 days  and 1 year .  
b. TLVR, measured as the ‘ percentage  change from baseline’ for treated lo be 
volume as seen via HRCT  will be evaluated at 45 days  and 1 year .   
 
The study participants in the EBV treatment arm will be compared to the control arm at 1 
year to assess:  
 
2) St. George’s Respi[INVESTIGATOR_6015]  
a. Difference between study arms in ‘absolute change from baseline’ for SGRQ 
score at 1 year.   
 
3) FEV [ADDRESS_913579] will be evaluated by [CONTACT_675796] ‘ absolute  change from baseline’ for FEV [ADDRESS_913580] will be evaluated by [CONTACT_675797] s tudy arms for ‘ percentage  change from baseline’ for FEV 1 at 45 
days, 6 months, and 1 year.  
 
 
4) 6-Minute Walk Distance  
a. Difference between study arms in ‘absolute change from baseline’ for 6 -
minute walk distance at one year.   
b. Difference between study arms i n ‘percentage change from baseline’ for 6 -
minute walk distance at one year.   
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913581] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  20.6 Additional Measures  
Mean changes and/or changes measured using responder analyses for:   
 
• Spi[INVESTIGATOR_675696] 1, forced vital capacity (FVC  and, the ratio of FEV 1/FVC  
• Body plethysmography including residual volume (RV) , inspi[INVESTIGATOR_14008] (IC) , functional 
residual capacity (FRC), total lung capacity ( TLC), and the ratio s of RV/TLC  and IC/TLC   
• SGRQ global and domain (i.e. ‘symptoms’, ‘activity’ and ‘impacts on daily life’ s cores   
• Modified Medical Research Council (mMRC) Dyspnea Scale Score  
• BODE Index  
• Transitional Dyspnea Index (TDI) from Baseline Dyspnea Index (BDI)  
• COPD Assessment Test (CAT)  
• SF-36 Health Survey score  
• EQ-5D Health Survey score  
• Health Care Utilization Questionnaire  
• 6 minute walk distance  
• Borg scale dyspnea scores  before and after 6MWD test  
• Change in use of ‘ maintenance’ medications, including bronchodilators, 
corticosteroids, antibiotics, and anti -inflammatories  
• Daily diary (EXACT -PRO, p ulmonary rehab ilitation compliance , health status 
changes )  
• Carbon Monoxide Diffusing Capacity (DL CO) 
• Lung radiographic features  
• Blood chemistry measures  
20.7 Interim Analysis   
An interim analysis designed to evaluate effectiveness for continuing  crossover of control 
arm study participants after the 1 year follow -up visit to EBV treatment will be performed 
when 74 (50% of the required minimum of 147) study participants have completed the 1 
year follow -up. If crossover of control arm study participa nts is found to be justified by [CONTACT_675798] a control arm study participant  after ( s)/he has reached 
the [ADDRESS_913582] of FEV 1 scores and adverse events.  
20.9 Time Points for Data Analysis   
20.9.1  Length of Follow -up for PMA Study Data Analysis   
Safety and effectiveness will be evaluated at the Interim Analysis and at 1 year .    
20.9.2   Length of Follow -up for Durability Data Analysis   
Long -term data will be collected annually  through  5 years .  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913583] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  20.10 Statistical Analysis Plan  
The details for the Statistical Analysis Plan are provided in Appendix 19. 
 
21.0    REGULATORY AND REPOR TING REQUIREMENTS   
21.1 Adverse Events and Reporting  
An adverse event (AE) is an untoward medical occurrence in a patient or clinical 
investigation participant receiving a procedure using a medical device and that does not 
necessarily have a causal relationship with the treatment . An adverse event can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medical device, 
whether or not related to the medical device.  Generally, a cond ition is an adverse event 
if it is undesirable and was not present before the participant underwent the procedure or 
is more severe than before the participant underwent the procedure, and/or is more 
frequent than before the participant underwent the proce dure.  
Adverse event information will be collected over the entire duration of the study. 
Collection of adverse event data will commence upon random assignment of a study 
participant.  The following information will be recorded on the appropriate case repor t 
form:  
 
• Event diagnosis or syndrome  
• Date of onset  
• Duration  
• Severity (mild, moderate, or severe)  
• Relationship to the device (not related, possibly related, probably related, related, 
or unknown)  
• Relationship to the procedure (not related, possibly related,  probably related, 
related, or unknown)  
• Action taken, and  
• Outcome (not resolved, resolved with sequelae, or resolved).  
 
If the diagnosis or syndrome is not known, the unfavorable or unintended sign or symptom 
experienced by [CONTACT_675799].  Adverse events will be 
determined by [CONTACT_675800].  Adverse events will be 
monitored and treated as appropriate until the event has subsided or, in case of 
permanent impairment, until the event stabilizes and the overall clinical outcome has been 
ascertained.  Adverse events will be followed until resolution or until the end of the study. 
In addition, all IRB and FDA reporting requirements will be followed.   
21.2 Serious Adverse Events and Reporting  
A serious adverse event (SAE) is any untoward medical occurrence that:  
• Results in death,  
• Is life-threatening,  
• Requires inpatient  hospi[INVESTIGATOR_6929], or  
• Results in persistent or significant disability/incapacity, or congenital 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913584] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  anomaly/birth defect.  
All serious adverse events should  be reported immediately (within 24 hours of 
knowledge of t he event) to the study sponsor .  All IRB and FDA reporting requirements 
will be followed.  
21.3 Unanticipated Adverse Device Effects (UADE) and Reporting  
Unanticipated adverse device effects (UADE) are defined as:  Any serious adverse 
effect on health or safety or any life -threatening problem or death caused by, or 
associated with the study device, if that effect, problem, or death was not previously 
identified in nature, severity, or degree of incidence in the investigational plan, 
Investigator’s Brochure, or packa ge insert, or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects.  All 
unanticipated adverse device effects must be reported immediately (within 24 hours of 
knowledge of the event) to  the study Sponsor.  The Investigator must submit to the 
sponsor and to the reviewing IRB a written report as soon as possible, but in no event 
later than [ADDRESS_913585] learns of the event.  
A sponsor who conducts an eva luation of a UADE under CFR 812. 46(b) shall report the 
results of such evaluation to FDA and to all reviewing IRBs and participating 
investigators within [ADDRESS_913586] by [CONTACT_3488]/ EC, FDA, or study sponsor, 
provide accurate, complete, and current information, or a summary report, about any 
aspect of the investigation.  
 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913587] reports obtained from the 
individual clinical sites, a master tracking system will be utilized.  Deficiencies identified 
by [CONTACT_675801].  In addition, regularly scheduled teleconferences between the 
Study Coordi nator(s) for each site and the s ponsor may occur.   
 
All clinical sites will be monitored  periodically by [CONTACT_456]’s personnel, or s ponso r’s 
designee, for protocol adherence, accuracy of CRF completion, and compliance to 
applicable regulations.  Ongoing and/or serious non-compliance with respect to these 
standards will be evaluated and appropriate corrective/preventive actions required will  
be determined .  If corrective /preventive  actions are not subsequently undertaken, the 
clinical sites will be asked withdraw from the study.   
22.[ADDRESS_913588] 
teleconference calls between the s ponsor monito r, data management, and / or each 
clinical s ite, as necessary, to r esolve any problems concerning the protocol and  / or data 
collection.  Every effort will be made to ensure compliance with the protocol.  In addition, 
sponsor repr esentative(s) will maintain personal contact [CONTACT_675802], mail, email and on -site visits.  If problems cannot be 
resolved immediately, an appropriate expert (s) will be consulted.     
22.4 Recruitment Tracking  
A weekly recruitment status report generated by [CONTACT_675803].  For any well -
balanced trial, a normal distribution in recruitment is expected; however, outliers w ill be 
investigated for trial compliance.   
22.5 Data Processing and Quality Control  
Data gathered during the course of the study will be reported on the study CRFs via a 
secure web -based database.  The sponsor  will evaluate all CRFs upon receipt .  Missing, 
incomplete, or inconsistent data will be requested form the Investigator and corrections 
will be made.  All efforts will be made to avoid loss of data.  All changes will be 
appropriately documented.  Passwords will be issued to appropriate personnel to ensure 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913589] be accurately recorded in the C ase Report 
Forms . Sourc e data verification (a comparison of data in the CRF with the subject’s 
medical records and other records at the investigation site) with access to records will 
also be performed. The monitor or other s ponsor personnel will be available between 
visits if t he Investigator or other staff at the site need s information and/or advice.   
Authoriz ed representatives of  the study sponsor, and FDA,  may visit the site to perform 
audits  / inspections , including source data verification.  
22.[ADDRESS_913590] to follow -up.   
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913591] of medications 
dispensed or devices used, clinic charts or hospi[INVESTIGATOR_1097]. Data will be transcribed 
onto participant case report forms (CRFs) or recorded on eCRFs (electronic CRFs)  in a 
database supplied by [CONTACT_941] s ponsor.  
23.4 Study Monitoring  
Monitoring of the study will  be conducted by [CONTACT_941] s ponsor or its designee following 
21CFR 50, 54, 56, and 812 and the guidelines established by [CONTACT_675804]  (to the extent that they are consistent with U.S. federal regulations) . A site 
initiation meeting will be held and periodic site visits will be performed. The monitor will 
maintain oral and written communications with the Investigators and study personnel . 
Case report forms will be reviewed with source records and compliance with the protocol 
will be documented.  
23.[ADDRESS_913592] -protected electronic database created by 
[CONTACT_675805]. Study participants will be identified only 
by [CONTACT_675806].  
23.6 Registration of the Clinical Trial  
The clinical trial will be registered and maintained on the publicly available clinical trials 
website ( www.clinicaltrials.gov ) by [CONTACT_1758] s ponsor within [ADDRESS_913593] be documented in a written and 
numbered CIP amendment with a justification for the amendment . Changes to the 
investigational plan  will only be effected following IRB and FDA approval as applicable . 
23.8 Device Accountability  
All of the valves  and valve de livery catheters used in the study will be maintained in a 
secure location at the investigational site  until used or returned to the s ponsor.  Study 
devices will only be used under the Investigator’s supervision in study participants. The 
Investigator will  not supply the study device to any person not authorized under this 
protocol to receive it. The Investigator shall maintain accurate device accounting records 
including quantity and date of receipt, person in receipt, lot number, use or disposition, 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913594] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  participant identification associated with device, date of expi[INVESTIGATOR_1516] (if applicable) and 
quantity and date of any devices returned to the Sponsor.  
23.[ADDRESS_913595] the 
scientific soundness of the study or the rights, safety, or welfare of participants, FDA and 
IRB approval is required.  Every effort should be  made to comply with the requirements 
of the protocol.   Deviations will be recorded with an explanation for the  change. The 
study Sponsor  is responsible for analyz ing the deviations and assessing their 
significance.  Corrective action will be implemented to avoid repeat deviations.   
 
24.0 INVESTIGATOR RESPONS IBILITIES  
The Investigator is responsible for ensuring that this investigation is conducted according 
to all signed agreements, the study protocol, and the  applicable  code of Federal 
Regulations.  This section describes these responsibilities at his/her site.   
24.[ADDRESS_913596] read and acknowledge his/her understa nding of the study protocol 
and ensure adequate training of staff for executi ng the study has occurred.  Specifically, 
he/she must:  Sign the Protocol Signature [CONTACT_3490], Clinical Trial Agreement, Non -
Disclosure Agreement and Financial Disclosure and provide a copy of each to the 
Pulmonx Clinical Research Department  or designee .   
• Provide current copi[INVESTIGATOR_675697]’s, Sub -Investigator’s, and Coordinator’s 
Curriculum Vitae (CV) to the Pulmonx Clinical Research Department.  
• Provide current copi[INVESTIGATOR_675697]’s, and Sub -Investigator’s Medical License as 
required throug hout the course of the study.  
• Provide documentation of GCP training for all study staff.  
• Complete training using the Pulmonx Chartis Assessment System prior to treating 
enrolled subjects.  
• Complete training using the Pulmonx Endobronchial Valve System pr ior to treating 
enrolled subjects.  
• Delegate appropriate and qualified staff as indicated on the Site Delegation of Authority 
Log.  
• Complete all required study procedures and documentation at all visits.  
24.[ADDRESS_913597] (IRB) Approval  
The Invest igator must submit the study protocol to his/her IRB and obtain their written 
approval before being allowed to participate in the study.  Specific responsibilities 
include:   
• Submit proposed protocol amendments and informed consent revisions to the IRB/IEC  
and await approval.  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913598] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  • Inform sponsor and IRB of any unanticipated  device -related events (UADEs) within 24 
hours of knowledge.  
• Submit all required reports to IRB/IEC and sponsor within specified timeframes.  
24.[ADDRESS_913599] include approval of an Informed Consent Form specific to 
the study.  The I nvestigator or his/her designee must administer these  approved 
Informed Consent text to each prospective study candidate and obtain the study 
candidate’s signature [CONTACT_675881], prior to conducting any study -specific tests and 
enrollment into the study , respectively .  The study sponsor  will provide S ample Informed 
Consent text for the Informed Consent forms  to the Investigator .  This text may be 
modified to suit the requirements of the individual site.  A copy of the informed consent 
form that has been approved by [CONTACT_675807] s ponsor.  
Specifically, the Investigator must:   
• Explain all study proc edures to the study candi dates and obtain written informed 
consent.   
• Ensure HIPAA Authorization is obtained from each study participant and on file.  
24.[ADDRESS_913600] facilities and records .  Specific examples of records 
maintenance include:   
24.5.[ADDRESS_913601] s of each study p articipant’s case history, including study -required Case 
Report Forms, evidence of informed consent, all relevant observations of 
adverse device effects, the condition of each study p articipant upon entering and 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913602] with the 
Investigator.   
Type of Report  Prepared by [CONTACT_675808]: Time Constraints of  
Notification  
Unanticipated Adverse Effect  Sponsor  As soon as possible but no 
later than 10 working days  
after knowledge of the event . 
Withdrawal of IRB Approval  Sponsor  Within 5 working days.  
Progress Report  Sponsor / IRB  Submitted at least annually.  
Protocol Deviations  to protect the 
life or physical well -being of the 
subject in an emergency  Sponsor  / IRB  Within 5 working days.  
Informed Consent Not Obtained  
prior to device use  Sponsor / IRB  Within 5 working days.  
Final Summary Report  Sponsor / IRB  Within 3  months  of study 
completion/termination . 
  
25.0  SPONSOR RESPONSIBILI TIES  
25.1 Clinical Site Selection and Training     
• Submit the IDE application to FDA and obtain approval from FDA to initiate the study.  
• Ensure that IRB approval and continuing review are obtained.  
• Select the clinical Investigators and study sites, and other consultants who participate in 
the study.  
• Ensure that the Investigator is an appropriately qualified practitioner legally entitled to 
practice.  
• Ensure that the Investigator is trained a nd experienced in the field of application of the 
device under consideration.  
• Ensure that the Investigator has sufficient background and meets the requirements for 
conducting a clinical investigation.  
• Ensure that the appropriate information and training ar e provided to the Investigator in 
the use of the device to be used in the study in accordance with the clinical investigation 
plan.  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913603] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  • Obtain from each participating Investigator a signed agreement which includes:  1) 
Investigator’s CV, statement of the inves tigator’s relevant experience and/or information 
regarding other research activities, including instances where the research activity was 
terminated.  
• Provide financial support to each study site and the core laboratories per individual 
contracts with each site.   
• Provide the study device to participating study sites, in quantities sufficient to support 
study activities, per agreements executed with the study sites.   
• Provide training to Principal Investigator(s) and Study Coordinator(s).   
25.2 Good Clinical Practice  
• Ensure that the study is conducted according to ICH Good Clinical Practice Guidelines 
(to the extent that they are consistent with U.S. federal regulations), and all applicable 
regulatory standards per federal regulations for clinical study sites , core laboratories, 
and other participants, and perform regular site monitoring to assure compliance with 
them.   
• Perform site monitoring of clinical data at clinical study sites.  
• Provide the Investigator with sufficient clinical study material and help t he Investigator to 
carry out the clinical investigation in compliance with the approved protocol.  
• Evaluate  (together with the Investigator) all serious adverse events (SAE) and 
unanticipated adverse device effects (UADE) without delay and take all necessar y steps 
to protect the study participant. The appropriate authorities will be notified of all SAEs  
and UADEs in accordance with the legal requirements.  
• The Sponsor will inform the Investigator(s) when the prescribed period for retaining 
clinical study doc uments has elapsed.  
25.3 Clinical Site Management     
The sponsor reserves the right to:  
• Demand the exclusion of a study participant from the clinical investigation in  the case of 
ineligibility . 
• Exclude /Terminate  Investigator(s) from the clinical investigation because of severe 
protocol deviations or because of fraud and misconduct.  
• Terminate the study investigation prematurely. If this should become necessary, the 
Sponsor and the Investigator will conclude the pr oceedings after consideration and 
consultation, taking into account the protection of the study participants’ interests.   
25.4 Study Sponsor Monitoring on Site  
 The s tudy Sponsor per sonnel or their designee will perform study site monitoring.  Each 
site will be monitored according to 21 CFR 812 and Pulmonx Inc. (or designee’s) internal 
monitoring SOPs.  This will be done to ensure that the study is conducted in ful l 
compliance with all applicable regulations, and with the study protocol.  A pre -
investigation meeting will occur with each potential study site in order to orient the 
prospective Investigator and staff to the clinical trial protocol, applicable regulations and 
requirements, and expectations of the study , including the nu mbers and time frame for 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913604] the study properly.   
 No study site may receive shipment of the study device components until Pulmonx 
receives the following documents:   
1. Written IRB approval for conduct  of the study  
2. Review  of the site’s approved written study -specific informed consent document.  
3. Executed Clinical Trial Agreement  
25.5 Sponsor Records     
25.5.1  Correspondence  
Records of all correspondence with Investigator s, IRB, Core Laboratories , 
Clinical Research Or ganizations (CRO), study monitor s, or FDA, including 
required reports, will be maintained.  
25.5.2  Study Devices  
Records of study device shipments and disposition shall be maintained.  Records 
of shipments shall include the name [CONTACT_675882], type and 
quantity of devices shipped.  Records of disposition shall describe the batch 
numbers of any de vices returned to the Sponsor, repaired, or disposed of in 
other ways by [CONTACT_675809], and the reasons for and 
method of disposal .   
25.5.3  Research Agreements and Financial Disclosure  
The sponsor shall maintain s igned copi[INVESTIGATOR_675698], including the financial disclosure informati on. 
25.5.4  Study Participant Records  
The sponsor shall maintain r ecords concerning adve rse device effe cts.   
25.6 Sponsor Reports  
25.6.1  Unanticipated Adverse Device Effects  
The s ponsor shall report the result of such evaluations to FDA and to all 
reviewing IRB’s and participating Investigator s within [ADDRESS_913605].   
25.6.2  Withdrawal of IRB Approval  
The s ponsor shall notify FDA and all reviewing IRB’s and participating 
Investigators of any withdrawal of approval of an investigation or a part of an 
investigation by a reviewing IRB within 5 working day s after receipt of the 
withdrawal of approval.   
25.6.3  Withdrawal of FDA Approval  
The s ponsor shall notify all reviewing IRB’s and participating Investigators of any 
withdrawal of approval of an investigation or a part of an investigation by [CONTACT_675810] 5 working days after receipt of the withdrawal of approval.   
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913606] 
The s ponsor shall maintain and update as necessary a current of the names and 
addressed of all Investigator s participating the investigation.   
25.8 Progress Reports  
The s ponsor shall submit annual progress reports to all reviewing IR B’s an d FDA.   
25.9 Recall and Device Disposition  
The s ponsor shall notify FDA and all reviewing IRB’s of any request that an Investigator 
return, report, or otherwise dispose of any study devices.  
25.10 Final Reports  
The s ponsor shall submit to FDA and all reviewing IRB’s a final report upon completion 
or termination of the study.   
 
 
26.[ADDRESS_913607] – The six -minute walk distance test is a cardiopulmonary function test that measures 
a patient’s  exercise capacity by [CONTACT_675811].  
AE – An Adverse Event is any pulmonary complication whether considered major or minor and 
whether or not associated directly with the Pulmonx Endobronchial Valve procedure. Anticip ated 
AE’s are listed as endpoints, but unanticipated events are documented as well.  
Atelectasis – Lung collapse.  
Body Plethysmography – a box -like device in which the patient sits that measures pressure and 
volume changes in the lung to determine functional residual capacity and other lung volumes.  
COPD – Chronic obstructive pulmonary disease is a condition in which the lungs are limited by 
[CONTACT_675812][INVESTIGATOR_007].  
CRF – Case report forms are used to collect data for this study.  
CV – Collateral ventilation; inter -lobar communication of air  
HRCT Scan – a high -resolution computed tomography scan used to generate a cross -sectional 
image of the lungs and other thoracic organs and tissues.  
Diffusing Capacity – Measures the rate of carbon monoxide gas transfer across the alveolar -
capi[INVESTIGATOR_17276] -gas membrane (DLCO).  
DLCO – a measure of diffusing capacity (see above)  
Dyspnea – Shortness of breath.  
EBV – Pulmonx Endobronchial Valve  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913608] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  ECG – Electrocardiogram; a recording of the heart’s electrical activity.  
EBV – Pulmonx Endobronchial Valve (EBV) Procedure – a bronchoscopic method of delivering 
and deploying a valve to prevent inspi[INVESTIGATOR_675699] a targeted lung segment while allowing for 
expi[INVESTIGATOR_400459].  
ERV – Expi[INVESTIGATOR_594654] – the maximal amount of gas that can be exhaled from the 
resting end -expi[INVESTIGATOR_675700].  
FEV 1 – Forced expi[INVESTIGATOR_675701] a maximal inspi[INVESTIGATOR_1516].  
FRC – Functional residual capacity:  the volume in the lungs at the end -expi[INVESTIGATOR_248649].  
FVC – Forced vital capacity is the total volume forcefully exhaled after a maximal inspi[INVESTIGATOR_1516].  
Heterogeneous – A term used to describ e non -uniform distribution of diseased, emphysematous 
areas in the lung.  
Homogeneous – A term used to describe uniform distribution of diseased, emphysematous areas 
in the lung.  
IC – Inspi[INVESTIGATOR_675702].  
LVRS – acronym for lung volume reduction surgery.  
mmHg – Millimeters of mercury is a unit of measure for pressure.  
NETT – acronym for National Emphysema Treatment Trial  
PaCO2 – Partial pressure of carbon dioxi de in arterial blood.  
PaO2 – Partial pressure of oxygen in arterial blood.  
RV – Residual volume:  the volume of air remaining in the lungs after a maximal exhalation.  
SAT – Blood saturation is the percentage of hemoglobin sites occupi[INVESTIGATOR_675703] .  
SGRQ – St. George’s Respi[INVESTIGATOR_6015]: a standardized quality of life measurement used 
to assess patients with obstructive pulmonary diseases.  
Spi[INVESTIGATOR_038] – a method of measuring lung volumes and flows.  
TLC – Total lung capacity is the total volu me of gas that is held within the lungs at maximal 
inspi[INVESTIGATOR_1516].  
VC – Vital capacity:  the volume equal to TLC – RV. 
VTG – Volume of thoracic gas: the absolute volume of gas in the thorax at any point in time and 
any level of alveolar pressure.  
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913609] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  V/Q Scan – Ventilation/perfusion scan is used to assess regional lung function. Note: Xenon gas 
will be used at some centers to identify areas of poor ventilation in the lung.   
 
27.[ADDRESS_913610] 1999;116;[ADDRESS_913611] SI, Reilly JJ Jr, Sciurba FC, Thomashow 
BM, Wise RA .  Physician and patient perceptions in COPD:  the COPD Resource Network 
Needs Assessment Survey. Am J Med  2005;118(12):1415.  
 
3.  Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC.  Chronic obstructive pulmonary 
disease surveillance —[LOCATION_002], 1971 -2000. MMWR Surveill Summ  2002;51(6):1 -16.   
 
4.  Sciurba FC, Rogers RM, Keenan RJ, et al.  Improvement in pulmonary function and elastic 
recoil after lung -reduction surgery for diffuse emphysema.  N Engl J Med  1996;334:1095 -9. 
 
5.  Martinez FJ. Montes de Oca M, Whyte RI, et al.  Lung -volume reduction improves d yspnea, 
dynamic hyperinflation, and respi[INVESTIGATOR_13945].  Am J Respir Crit Care Med  
1997;155:1984 -90. 
 
6.  Sabanathan A, Sabanathan S, Shah R., Richardson J.  Lung v olume reduction surgery for 
emphysema.  J Cardiovasc Surg  1998;39:[ADDRESS_913612] of lung-volume -reduction surgery in patients with 
severe emphysema.  N Engl J Med  2000;343:[ADDRESS_913613] 1999;116,1608 -1615.  
 
9.  Criner GJ, Cordova FC, Furukawa S, Kuzma AM, Travaline JM, Levenson V, O’Brien GM.    
Prospective randomized trial comparing bilateral lung volume reduction surgery t o pulmonary 
rehabilitation in severe chronic obstructive pulmonary disease.  Am J Respir Crit Care Med  
1999;160(6):2018 -27.   
 
10.  Fishman A, Martinez F, Naunheim K, Pi[INVESTIGATOR_640965] S, Wise R, Ries A, Weinmann, Wood DE; 
National Emphysema Treatment Trial Resea rch Group.  A randomized trial comparing lung -
volume -reduction surgery with medical therapy for severe emphysema. N Engl J Med  
2003;348(21):2059 -73.   
 
11.  Gelb AF, McKenna RJ, Jr., Brenner M, Epstein JD, Zamel N. Lung function 5 yr after lung 
volume reduction surgery for emphysema. Am J Respir Crit Care Med  2001;163:[ADDRESS_913614] ion 
improves dyspnea, dynamic hyperinflation, and respi[INVESTIGATOR_13945]. Am J Respir Crit 
Care Med  1997;155:1984 -93. 
 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913615] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  13.  Benzo R, Farrell MH, chang  CC, Martinez JF, Kaplan R, Reilly J, Criner G, Wise R, Make 
B, Luketich J, Fishman AP, Sciurba FC; N ETT Research Group.  Integrating health status and 
survival data:  the palliative effect of lung volume reduction surgery.  Am J Respir Crit Care Med  
2009; 180(3):239 -46.   
 
14.  Naunheim KS, Wood DE, Krasna MJ, DeCamp MM Jr, Ginsburg ME, McKenna RJ Jr, 
Criner GJ, Hoffman EA, Sternberg AL, Deschamps C.  National Emphysema Treatment Trial 
Research Group.  Predictors of operative mortality and cardiopulmonary morbidity in the 
National Emphysema Treatment Trial. J Thorac Cardiovasc Surg 2006;131(1):43 -53.   
 
15.  Naunheim KS.  Lung -volume reduction surgery: a vanishing operation? J Thorac 
Cardiovasc Surg  2007;133(6):[ADDRESS_913616] A, Herth F, Strange C, Criner G, Marquette C, Kovitz K, Chiacchierini R, 
Goldin J, McLennan G.  A randomized study of endobronchical valves for advanced 
emphysema.  N Engl J Med  2010;363:[ADDRESS_913617] A, and the International VENT Study Group.  Efficacy 
predictors of lung volume reduction with Zephyr valves in a European cohort.  Eur Resp ir J, 
2012;Jan 26[ epub ahead of print] .   
 
18.  Hayhurst MD, MacNee W, Flenley DC, Wright D, McLean A, Lamb D, Wightman AJ, Best J.  
Diagnosis of pulmonary emphysema by [CONTACT_14781].  Lancet  1984;2:320 -2. 
 
19.  Fessler HE.  Collateral ventilation, the bane of bronchoscopic volume reduction.  Am J 
Respir Crit Care Med 2005;171:423 -24.   
 
20.  Cetti EJ, Moore AJ, Geddes DM.  Understanging collateral ventilation is probably central to 
planning new bronchoscopic t echniques for treating emphysema.  Thorax  2006;61:371 -3. 
 
21. Van Allen CM, Lindskog GE, Richter DW.  Gaseous interchange between adjacent lung 
lobules.  The Yale journal of biology and medicine  1930;2:297.  
 
22.  Culiner MM.  Bronchial cysts and collateral  ventilation.  Dis Chest  1964;45:[ADDRESS_913618]  1969;48(3):[ADDRESS_913619] A, Herth FJF.  Predicting atelectasis by 
[CONTACT_675813]: A feasibility 
study.  Respi[INVESTIGATOR_1516] 2010; 80(5):[ADDRESS_913620] selection for endobronchial lung volume reduction (ELVR) in 
subjects with heterogeneous emphysema.  Accepted for publication; Eur Respir J  April 2012.         
 
26.  Global Initiative for Chronic Obstructive Lung Disease (GOLD):  Global strategy for the 
diagnosis, management, and prevention of chronic obstructive pulmonary disease (Updated 
2010).   
   
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913621] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  27.  Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, 
Engelen M, Fahy B, Garvey C, Roger Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais 
F, Morgan M, O’Donnell D, Prefault C, Reardon J, [COMPANY_002]ster C, Schols A, Singh S, Troosters T, 
on behalf of the ATS/ERS Pulmonary R ehabilitation Writing Committee.  American Thoracic 
Society/European Respi[INVESTIGATOR_675704] t on Pulmonary Rehabilitation.  Am J Respir 
Crit Care Med 2006;173:1390 -1413.   
 
28.  Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, 
van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntryre N, McKay R, Navajas 
D, Pedersen OF, Pellegrino R, Viegi G, Wanger J.  General considerations for lun g function 
testing.  Eur Respir J  2005;26:153 -61.   
 
29.  Miller, MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, 
vander Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, 
Pedersen OF, Pellegr ino R, Viegi G, Wanger J. Standardisation of spi[INVESTIGATOR_038].  Eur Respir J  
2005;26:319 -38.  
 
30.  Hankinson JL, Odencrantz JR, Fedan KB.  Spi[INVESTIGATOR_375576] a Sample of 
the General U.S. Population.  Am J Respir Crit Care Med  1999; 159:[ADDRESS_913622]. George’s Respi[INVESTIGATOR_6015].  Clin 
Ther 2000;22(9):1121 -45. 
 
32.  Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW , Wedzicha JA. Usefulness of the 
Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with 
chronic obstructive pulmonary disease.  Thorax 1999;54;581 -6.   
 
33.  Witek TJ Jr and Mahler DA.  Minimal important difference of the transition dyspnea index in 
a multinational clinical trial.  Eur Respir J  2003;21:[ADDRESS_913623]. Eur Respir J  2009 ;34: 648 –654.   
 
35.  Ware JE Jr, Sherbourne CD.  The MOS 36 -item short -form health survey (SF -36).  
Conceptual framework and item selection . Med Care  1992; 30:473-483. 
 
36.  The EuroQol Group. EuroQol -a new facility for the measure ment of health -related quality of 
life. Health Policy  1990; 16:199 -208. 
 
37.  Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo 
R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R , Johnson D, 
MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G.  Standardisation of the 
measurement of lung volumes.  Eur Respir J  2005;26:511 -22.   
 
38.  ATS Statement:  Lung Function Testing:  Selection of Reference Values and Interpretative 
Strategies , Official Statement of the American Thoracic Society, Approved March 1991 .  Am 
Rev Respir Dis  1991; 144:1202 -1218.  
 
39.  MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos 
R, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller 
Pulmonx LIBERATE Study  
Clinical Investigational Plan #630 -0012-H              
 
Version:  June 23, [ADDRESS_913624] not be disclosed to persons not directly involved with the study.  Duplication 
and distribution of this document require prior written a pproval from Pulmonx  MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J.  Standardisation of the single -breath 
determination of carbon monoxide uptake in the lung.  Eur Respir J  2005;26:[ADDRESS_913625] Physicians, the American 
Thoracic Society, and the European Respi[INVESTIGATOR_3764].  Diagnosis and managem ent of stable 
chronic obstructive pulmonary disease:  a clinical practice guideline update from the American 
College of Physicians, the American College of Chest Physicians, the American Thoracic 
Society, and the European Respi[INVESTIGATOR_3764].  Ann Intern M ed 2011;155(3):179 -191. 
 
41.  Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT -PRO Study 
Group.  Standardizing measurement of chronic obstructive pulmonary disease exacerbations.  
Reliability and validity of a patient -reported diary.  Am J Respir Crit Care Med  2011;183(3):323 -
9.   
 
42. ATS Statement: Guidelines for the Six -Minute Walk Test, Official Statement of the American 
Thoracic Society, Approved March 2002. Am J Crit Care Med  2002; 166:111 -117. 
 
43.  Silverman M, Barry J, Hellerstei n H, et al. Variability of the perceived sense of effort in 
breathing during exercise in patients with chronic obstructive pulmonary disease. Am Rev 
Respir Dis  1988;137 (1):206 -9. 
 
44.  Dyspnea: Mechanisms, Assessment, and Management: A Consensus Statement, Official 
Statement of the American Thoracic Society, Adopted July 1998. Am J Crit Care Med  1999; 
159:[ADDRESS_913626]  2008;133:350 -
57.  
   
46. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pi[INVESTIGATOR_619414] V, 
Cabral HJ.  The body -mass index, airflow obstruction,  dyspnea, and exercise capcity index in 
chronic obstructive pulmonary disease.  N Engl J Med  2004;350:1005 -12.   
  
47.  Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, DeCamp MM, Benditt 
J, Sciurba F, Make B, Mohsenifar Z, Diaz P, Hoffman E, Wise R, for the NETT Research Group.  
Predictors of mortality in patients with emphysema and severe airflow obstruc tion.  Am J Respir 
Crit Care Med  2006;173:1326 -34.   
 
48.  Faguang J, Deguang M, Dongling C, Enqing F, Yonghong X, Tonggang L.  Severe 
complications of bronchoscopy.  Respi[INVESTIGATOR_1516] 2008;76:[ADDRESS_913627] stents for emphysema (EASE trial): randomized, sham -controlled, 
multicentre trial.  Lancet 2011;378:997 -1005 .   
 
LIBERATE Study 
Clinical Investigational Plan #630-0012-H Appendix 1.  Study Participant Flow     
 
Version:  June 23, 2017              CONFIDENTIAL                Page 1 of 1 
    
 D  
 
 Initial Eligibility Screen 
Found Eligible for Study Procedure:   Enrolled,  Randomized,  Treated as AssignedBronchoscopy  with  Study Procedure  Eligibility Screen (CVAssessment)  
Control  EBV Treatment  
45 Day Visit (+/‐ 10 days) Chest X‐ray, CT scan Baseline Eligibility Screen & Baseline Assessments
Year 2, Year 3, Year 4, Year 5 (+/‐ 60 days) 
Spi[INVESTIGATOR_038],  Adverse Events  3 Month Visit (+/‐ 14 days) 
Clinical Measures
6 Month Visit (+/‐ 21 days) 
Clinical Measures
1 Year Visit (+/‐ 45 days) 
Clinical MeasuresPost‐Procedure  [ADDRESS_913628] X‐ray (within 1hour ± 30 min)& Daily Chest X‐rayuntil dischar ge
Daily Follow‐Up Telephone  Contact [INVESTIGATOR_8178] 10 Days (to 11:59 pm) 
EBV Treatment,  
if allowed  Control Arm  EBV Treated Arm 
Study Exit Valve Adjustment?  
(see Section12. 3)Yes No
Valve Adjustment  Procedure   
(within 75 days of study procedure  unless COPD 
exacerbation  occurs, then  within 90 days) 
Daily Follow‐Up Telephone  Contact 
[INVESTIGATOR_8178] [ADDRESS_913629]‐Procedure  [ADDRESS_913630] X‐ray (within 1 hour ± 30 min) & Daily 
Chest X‐ray until discharge  
9 Month Visit (+/‐ 21 days) 
Health Status Changes  Only45 Day Visit (+/‐ 10 days) 
 
1 Year Visit (+/‐ 45 days) 
CT, Clinical Measures<120 Days 
<60 Days 
30 Day Visit (+/‐ 5 days) Chest X‐ray  Day 7 after Discharge Visit  (+1 business day) Chest X‐ray 
Day 7 after Discharge  Visit (+1 business  day)
Chest X‐ray 
LIBERATE Study  
Clinical Investigational Plan #630- 0012-H 
Appendix 2.  Study Participant Screening and Enrollment Flowchart 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 1 of 1 
    
 
 Initial Eligibility Screening  
Signed Screening or Study Participation Informed Consent   
Physical Examination & Medical History  
CT Assessment by [CONTACT_675814] (EC G) 
Lung Function Testing ( Spi[INVESTIGATOR_038] , Body Plethysmography , DL CO) 
6-minute walk distance (6MWD)  
Blood Work  (ABGs, CBCs, alpha -1 antitrypsin, plasma cotinine , serum fibrinogen ) 
 
 
Meets Screening Eligibility Criteria   
No  Yes 
Patient is not eligible for study.  Note 
reason onto screening log  Baseline Eligibility Screening  
Pulmonary Rehabilitation Eligibility  Criterion  Completed  
Spi[INVESTIGATOR_247190], 6MWD  
No  Yes 
Patient is not eligible for study.   Note 
reason onto screening log  Collect Other Baseline Measures  
Self-Reported Health Status Measures (HR QOL) 
Medication Use, Vaccinations if needed  
 Create  Bronchoscopy Procedure Plan  
Bronchoscopy Procedure  
Meets Study Procedure Eligibility Criteria?  Meets Baseline  Eligibility Criteria   
Signed Study Informed Consent  (if not done at screening) 
No  Yes 
Enrolled, Randomized, Treated as Assigned  
 
 Patient is not eligible for study.  Note 
reason  onto screening log  Enter Study Candidate onto Screening Log   
LIBERATE Study  
Clinical Investigational Plan #630- 0012-H 
Appendix 3.   Example  Informed Consent Form:  Study Screening   
 
Version: June 23, 2017               CONFIDENTIAL                Page 1 of 4 
  
 
Investigator Name: ________________  Site ID#___________________ Institution: _______________________  Participant ID: ______________ 
________________________________ ________________________________  Telephone: _________________ 
 
 
Dear Patient:  
 
You are being invited to be screened for a clinical study involving research .  This Informed Consent Letter 
describes the study and the screening tests that must be done to fin d out if you would be a candidate for the study.  
If you choose to be screened for the study you must read this form carefully . You are urged to discuss any 
questions you have with your physician and / or the hospi[INVESTIGATOR_307]’s research staff.   
 
 
Purpose of the Research Study 
Since you are being asked to consider undergoing screen ing to find out if you may be a candidate for  this study, 
you have probably suffered an impaired lifestyle as a result of emphysema.  Emphysema is a serious disease that 
afflicts more than four million people worldwide.  It is one form of Chronic Obstructive Pulmonary Disease, or 
COPD.  Emphysema  causes the lungs to lose the ability to move air in and out normally an d to efficiently absorb 
oxygen, making breathing more difficult.   
 
The purpose of this research is to study a medical device that is designed to be placed by a  doctor in a diseased 
section of the lungs .  This device is called the Pulmonx Endobronchial Valve (EBV).  The EBV is a one-way 
valve that blocks off the diseased lung section  to inhaled air but lets the trapped air already inside the area escape.   
With placement of the EBV, the diseased part of the lung collapses; this allows the healthier parts of the lung to 
expand.  The aim of the EBV treatmen t is to help someone with emphysema breathe more easily  by [CONTACT_675815].  This research study is designed to investigate the safety and 
effectiveness of th e Pulmonx EBV for treating emphysema symptoms.  The EBV is  considered experimental.  
This means that it has not yet been approved by [CONTACT_941] U.S. FDA (Food and Drug Administration) for commercial 
use in the [LOCATION_002].  
  
 
Number of Patients in the Study  
Approximately two hundred (200) patients will be enrolled into this study. In order to qualify for enrollment into 
this study, you must undergo a bronchoscopy procedure.  During the bronchoscopy procedure, your doctor will measure some of the airways in your lungs using a device that measures airflow to find out if you meet the study 
criteria for having the EBV treatment.  There is a chance that after measuring some of airways in your lungs you 
will not be eligible to take part in this study.   
 
During the bronchoscopy procedure, one hundred and eighty- three (183) patients will be found to qualify for the 
study.  The [ADDRESS_913631] EBV, they will be expected to continue coming to the research clinic once a year through 5 years.   
LIBERATE Study  
Clinical Investigational Plan #630- 0012-H 
Appendix 3.   Example  Informed Consent Form:  Study Screening   
 
Version: June 23, [ADDRESS_913632] (High Resolution Computed Tomography) of Chest 
You will be asked to  lie down on your back on an x- ray table that will slide into a large, tunnel -shaped 
machine.  You must not move during the test  and will be asked to  relax and breathe normally. The technician 
will also ask you to do some breathing maneuvers such as take a deep breath in or out.
    
 
Echocardiogram 
An echocardiogram will be done to assess your heart’s function.  An echocardiogram is a test that uses sound 
waves to create a moving pi[INVESTIGATOR_675705]. The pi[INVESTIGATOR_675706] a plain  x-ray image and 
involves no radiation exposure.  
 Electrocardiography (EC G) 
During this test, small electrodes will be attached to your skin in several places and measurements will be taken of your heart rhythm and blood flow in and out of your heart.    
Lung Function Tests  
Spi[INVESTIGATOR_038] : During the test, you will be asked to breathe in and out of a mouthpi[INVESTIGATOR_675707] a machine 
measures the amount of air you are breathing into and out of your lungs.  These maneuvers may be somewhat 
difficult and you may become tired during the test but you will be a llowed to rest periodically.   
 
Plethysmography : This test is used to determine how much air you can hold in your lungs.  You will sit in a 
small box, comparable to the size of a telephone booth, to undergo breathing tests similar to those described 
above. There is a chance that y ou may experience claustrophobia in addition to some fatigue.  
 
Diffusing Capacity :  This test is used to determine the overall ability of your lungs to transfer gas into and out 
of your blood.   
 
Six Minute Walk Test  
You will be asked to walk back and forth between a start and end point as many times as possible within [ADDRESS_913633] you will be asked questions 
about how breathless you feel you are.  
 
Blood Gas (P aO2 and PaCO2) and Blood Chemistry Analysis 
A blood sample will be taken to measure the amount of oxygen and carbon dioxide in the sample. This blood sample will need to be taken from an artery (as opposed to a vein, which is done for the more routine blood 
tests), and therefore may be more painful than other blood tests that you may have had previously.  Standard compounds and the number of blood cells will also be measured.  You must have stopped smoking for at least 
[ADDRESS_913634] stopped.  It is 
important that you do not smoke during the study.  In addition, the blood sample will be tested for alpha-1 
antitrypsin deficiency and a marker for systemic inflammation (serum fibrinogen).     
 
Pulmonary Rehabilitation Program 
In order to participate in this study, you will have:   
• Successfully completed a supervised pulmonary rehabilitation program within the past 6 months, 
or 
• Be regularly performing maintenance respi[INVESTIGATOR_675708] 6 months ago.   
LIBERATE Study  
Clinical Investigational Plan #630- 0012-H 
Appendix 3.   Example  Informed Consent Form:  Study Screening   
 
Version: June 23, [ADDRESS_913635] to you.  Your doctor 
may also make changes to your emphysema medi cations at this time .   
 
Financial Responsibility  
The costs of any routine medical care administered during the study will be the responsibility of you and/or your health insurer. For such routine costs, you will be responsible for any co-payments or deductibles required under 
your insurance. You are not, however, expected to pay for  any medical care that is specifically required by [CONTACT_675816].  
 
 
Questions  
If you have any questions about the screening for this study you should ask your doctor or one of his or her staff 
members.  
 
  
LIBERATE Study  
Clinical Investigational Plan #630- 0012-H 
Appendix 3.   Example  Informed Consent Form:  Study Screening   
 
Version: June 23, [ADDRESS_913636] titled: Lung Function Improvement after Bronchoscopic Lung Volume 
Reduction with Pulmo nx Endobronchial Valves used to Treat Emphysema . 
 
If I agree to be screened for  the research study and if my questions are answered, I should sign this form.  I f I 
wish to refuse to be screened for the study, I may do so without any loss of medical care or benefits.   Once I have 
consented, I still have the right to withdraw from being screened at any time.  To withdraw, all I have to do is 
simply tell Dr. ________________________ or complete the Revocation of Consent at the bottom of this form. 
 
I will be given a copy of this form to keep and to refer to as needed. 
 
Printed Name [CONTACT_2385] (or legal representative):         
 
Signature:       [CONTACT_1782]:      
  I declare that I have been present when the research study was explained to the above participant and I believe that the participant has an application and understanding of the explanation given.  
Witness:       Date:      
 
 
 
REVOCATION OF CONSENT  
I hereby [CONTACT_675817].  Withdrawal 
WILL NOT jeopardize any treatment or my relationship with _________________ Hospi[INVESTIGATOR_307]. 
 
Printed Name [CONTACT_2385] (or legal representative):        
 
Signature:       [CONTACT_1782]:      
 
LIBERATE Study  
Clinical Investigational Plan #630- 0012-H 
Appendix 4. Screening Log 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 1 of 3 
 #  Screen ID  Met All Screening Eligibility Criteria  If no, list number for criterion not 
met 
1   Yes   No  
2   Yes   No  
3   Yes   No  
4   Yes   No  
5   Yes   No  
6   Yes   No  
7   Yes   No  
8   Yes   No  
9   Yes   No  
10   Yes   No  
11   Yes   No  
12   Yes   No  
13   Yes   No  
14   Yes   No  
15   Yes   No  
16   Yes   No  
17   Yes   No  
18   Yes   No  
19   Yes   No  
20   Yes   No  
21   Yes   No  
22   Yes   No  
23   Yes   No  
24   Yes   No  
25   Yes   No  
26   Yes   No  
27   Yes   No  
28   Yes   No  
29   Yes   No  
30   Yes   No  
 
LIBERATE Study  
Clinical Investigational Plan #630- 0012-H 
Appendix 4. Screening Log 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 2 of 3 
 #  Screen ID  Met All Baseline  Eligibility Criteria  If no, list number for criterion not 
met 
1   Yes   No  
2   Yes   No  
3   Yes   No  
4   Yes   No  
5   Yes   No  
6   Yes   No  
7   Yes   No  
8   Yes   No  
9   Yes   No  
10   Yes   No  
11   Yes   No  
12   Yes   No  
13   Yes   No  
14   Yes   No  
15   Yes   No  
16   Yes   No  
17   Yes   No  
18   Yes   No  
19   Yes   No  
20   Yes   No  
21   Yes   No  
22   Yes   No  
23   Yes   No  
24   Yes   No  
25   Yes   No  
26   Yes   No  
27   Yes   No  
28   Yes   No  
29   Yes   No  
30   Yes   No  
 
 
LIBERATE Study  
Clinical Investigational Plan #630- 0012-H 
Appendix 4. Screening Log 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 3 of 3 
 #  Screen ID  Met All Study Procedure  Eligibility Criteria  If no, list number for criterion not 
met 
1   Yes   No  
2   Yes   No  
3   Yes   No  
4   Yes   No  
5   Yes   No  
6   Yes   No  
7   Yes   No  
8   Yes   No  
9   Yes   No  
10   Yes   No  
11   Yes   No  
12   Yes   No  
13   Yes   No  
14   Yes   No  
15   Yes   No  
16   Yes   No  
17   Yes   No  
18   Yes   No  
19   Yes   No  
20   Yes   No  
21   Yes   No  
22   Yes   No  
23   Yes   No  
24   Yes   No  
25   Yes   No  
26   Yes   No  
27   Yes   No  
28   Yes   No  
29   Yes   No  
30   Yes   No  
 
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 5. Screening Eligibility Criteria  
Version:  June 23, 2017  CONFIDENTIAL  Page 1 of 1 Screening Inclusion Criteria  
1 Signed  Screening or Study Procedure Informed Consent using a form that was reviewed and approved by [CONTACT_1201]  
2 Age 40  to 75 years  
3 BMI less than 35 kg/m2 
4 Stable with  less than  20 mg prednisone (or equivalent) qd  
5 Nonsmoking for 4 months prior to screening interview 
Screening Exclusion Criteria  
6 Currently enrolled in another clinical trial studying an experimental treatment 
7 Previously enrolled in this study for which protocol required follow up is not complete  
8 Clinically significant ( greater than 4 Tablespoons per day) sputum production  
[ADDRESS_913637] year at screening 
11 Unplanned weight loss >10% usual weight <90 days prior to enrollment 
12 History of exercise -related syncope  
13 Myocardial Infarction or congestive heart failure within 6 months of screening 
14 Prior lung transplant, LVRS, bullectomy or lobectomy  
15 Clinically significant bronchiectasis  
16 Unabl e to safely discontinue  anti-coagulants or platelet activity inhibitors for 7 days  
17 Uncontrolled  pulmonary hypertension (systolic pulmonary arterial pressure > 45 mm Hg) or evidence or history of 
CorPulmonale  as determined by [CONTACT_675818]  (completed within the last  3 months prior to screening visit)  
[ADDRESS_913638] software shows:  
a Parenchymal destruction score of greater than 75% in all three right lobes or both left lobes 
b Emphysema heterogeneity score less than 15% (Not Applicable for Crossover subjects as of Revision H of 
protocol)  
c Large bullae encompassing greater than  30% of either lung  
d Insufficient landmarks to evaluate the CT study using the software as it is intended  
20 Left ventricular ejection fraction (LVEF) less than 45% as determined by [CONTACT_675818] (completed within the last 3 
months prior to screening visit)  
21 Resting bradycardia  (<50 beats/min), frequent multifocal PVCs, complex ventricular arrhythmia, sustained SVT  
[ADDRESS_913639]-bronchodilator FEV 1 less than  15% or greater than  45% of predicted value at screening  
24 TLC less than  100% predicted (determined by [CONTACT_568995]) at screening  
25 RV less than  175% predicted (determined by [CONTACT_568995]) at screening  
26 DLCO less than  20% predicted value at screening  
27 6-minute walk distance less than  100 meters or  greater than  450 meters at screening  
28 PaCO 2 greater than  50mm Hg (Denver greater than  55 mm Hg) on room air at screening  
29 PaO 2 less than  45 mm Hg (Denver less than  30 mm Hg) on room air at screening  
30 Elevated white cell count (> 10,000 cells/mcL) at screening  
31 Presence of alpha-1 anti-trypsin deficiency as determined by [CONTACT_675819] 
32 Plasma cotinine level greater than  13.7 ng/ml (or arterial carboxyhemoglobin > 2.5% if using nicotine products) at screening  
33 Any disease or condition that interferes with completion of initial or follow -up assessments  
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913640] Scan Acquisition Protocol  
Version:  June 23, [ADDRESS_913641] acquired using Scan Acquisition Protocol  
Upon determining that the study candidate meets all screening and baseline eligibility criteria, 
site personnel will:  
a)Complete the bronchoscopy plan
b)Transmit screening HRCT scan data to the core reading laboratory
45-day and 1 -year follow -ups* for Study Treatment Arm ONLY : 
a)Acquire HRCT and transmit scan data to core reading lab
b)Determine lobar volume change from baseline
c)Evaluate EBV placement
d)Apprise clinical site and sponsor of findings within [ADDRESS_913642] to the core reading lab
*Also [ADDRESS_913643] software to 
determine screening eligibility  of the study candidate.  The study candidate is INELIGIBLE IF 
(s)he has : 
a)Parenchymal destruction score > 75% in all three right lobes or both left lobes;
b)Emphysema heterogeneity score <15%  (see Note for cross over subjects)
c)Large bullae encompassing >30% of either lung
d)Insufficient landmarks to evaluate  the CT study using the software as it is intended
Site personnel will develop the bronchoscopy plan to: 
a)Pre-identify target treatment lobes for assessing collateral ventilation
b)Plan the EBV placement strategy (only to be performed during thebronchoscopy if candidate meets study procedure eligibility and is randomlyassigned to study treatment)
NOTE:   HRCT scan s should be submitted to the core reading lab as soon as possible 
after their acquisition For the first 5 candidates per site with conclusive (in)eligibility: export the 
CT analysis to CD and send to core reading laboratory for review  
CROSSOVER NOTE:  Per Revision H of this protocol, the requirement of a heterogeneity score of 15% 
between lobes is not applicable for any remaining crossover subjects. The most diseased target can 
be treated regardless of heterogeneity, provided that the target lobe is collateral ventilation negative 
(CV-). 
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913644] Scan Acquisition Protocol  
 
Version:  June 23, [ADDRESS_913645] Scans 
The scanning procedure described below will require approximately 15 minutes of 
the scanner time. Minimal respi[INVESTIGATOR_675709].  In unusual cases, this may require more time.  However, in many cases the procedure will be completed in 10 
minutes or less.  
Preparation of the Patient  (3 minutes)  
Patient s weighing more than 300 pounds (150 Kg) will not be scanned due to 
technical difficulties.  The technologist will ask women if they might be pregnant and will not scan them if they answer affirmatively.  The patient  will lie in the supi[INVESTIGATOR_675710] . 
Breath- Holding Instruction (3 minutes).  
The technologist will instruct the patient  on the importance of breath- holding and 
immobility during scanning.  An interpreter will assist in the instruction of patient s 
not fluent in English. Technologists will be trained to coach patients to attain reproducible maximum inspi[INVESTIGATOR_99807]-h old. To ensure that the breath- hold 
maneuver is performed as close to pulmonary function laboratory standards. The CT programmed auto -voice is never  used; instead patient s are coached prior to 
scanning as follows:  
For the TLC series:  
“Take your biggest breath in until you feel your lungs are completely full, in 
the same way you do in the lung function laboratory, and hold the breath.”  
For the RV series:  
 
For the RV Scan (Sequence #2), the patient should be coached with 
emphasis on instruction to blow all their air out.  The participant should be 
told “ to take another big breath in to fill up their lungs and then to blow all 
the air out as hard and fast as possible without moving their body and then to squeeze all their air out until they feel that their lungs are completely 
empty and then they should signal that they are empty and hold their breath”.   This can be done by [CONTACT_675820].  At this stage, the technologist should remind the subjects to hold their breath for the entire scan and start the 
scan.  
Only after the technologist is satisfied that the patient  understands the importance 
of breath- holding should s/he proceed.  
  
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913646] Scan Acquisition Protocol  
 
Version:  June 23, 2017                         CONFIDENTIAL               Page 3 of 6 
 Checki ng the Scout Image (1 minute).  
The technologist will instruct the patient  to take a deep breath in, and then to hold 
his/her breath (at end- inspi[INVESTIGATOR_1516]) while acquiring anterior -posterior (A/P) and 
lateral scout image, beginning 10 mm above the sternal notch and ending 10 mm 
below the posterior costophrenic angle.  This will provide an A/P and lateral view of the chest on the image monitor at the operator console.  From this, the technologist will check patient centering and choose the position for the full chest scan. The table will be automatically moved to the start position.   The technologist 
will check patient  and phantom positioning in the scout image.  
Imaging (6 minutes).   
Total imaging time will be approximately 6- 19 seconds (depending on scanner 
generation and configuration). The technologist will instruct the patient  to relax on 
the table while s/he reconstructs the images and assesses the adequacy of positioning, and lack of respi[INVESTIGATOR_64947].  
Remember to keep consistent the selected FOV and table height for a patient 
at all study points.   
The imaging procedure invol ves the following mandatory sequence for all 
study patients:  
Supi[INVESTIGATOR_050], Full Chest at TLC  
In this sequence, thoracic CT will be performed with the patient in the supi[INVESTIGATOR_675711]. Image data will be acquired during 
suspended end inspi[INVESTIGATOR_1516] (TLC ). Images are non- gated and no intravenous 
contrast will be used.   Technical guidelines for thoracic CT image data 
acquisition will include:  
(a) TLC Scout: This series is to be acquired for planning the full chest CT and is to 
be acquired at TLC.  
(b) TLC Full Chest: Volumetric spi[INVESTIGATOR_675712].  
1. Breathing Instructions : Patient  will be instructed to, “ take a deep breath in 
until you feel your lungs are completely full, in the same way you do in the 
lung function laboratory. ” 
2. Scanner Acquisition:  See Table 1.  Sample provided for each site; a 
protocol specific for chart will be provided.    
3. Anatomic Coverage:  Entire thorax (full chest).  Typi[INVESTIGATOR_897] a ≤[ADDRESS_913647] scanners.  
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913648] Scan Acquisition Protocol  
 
Version:  June 23, 2017                         CONFIDENTIAL               Page 4 of 6 
 4. Dose Consideration: For the above scan the estimated dose is 2-3msv 
compared with conventional CT Chest of 5- [ADDRESS_913649] will be performed with the patient in the supi[INVESTIGATOR_675713].  Image data will be acquired at residual volume (RV).  Images are non- gated and no intravenous contrast 
will be used.  Technical guidelines for thoracic CT image data acquisition will 
include:  
(a) RV scout  – this series is to be acquired for planning the full chest CT and is 
to be acquired at RV.  
(b) RV Full Chest : Volumetric spi[INVESTIGATOR_675714] 1 – except at residual 
volume: 10 mm collimation, pi[INVESTIGATOR_23025] ≤ 1.5 reconstructed contiguously (i.e., every 
10 mm) using a standard reconstruction algorithm.   
1. Breathing Instructions:   The participant should be told “ to take another big 
breath in to fill up their lungs and then to blow all the air out as hard and fast as possible without moving their body and then to squeeze all their air out until they feel that their lungs are completely empty and then they 
should signal that they are empty and hold their breath” .  This can be done 
by [CONTACT_675821].  At this stage, the technologist should remind the subjects to hold their breath for the entire scan and start the san.  
2. Sample Acquisition (This will be tailored for each site based on available 
CT technology):  Siemens Sensation 16 scanner, 120 kVp, 80 “effective” 
mAs, 0.5 sec rotation time, 16 x 0.75 mm collimation, 18 mm/rotation table feed (pi[INVESTIGATOR_23025] 1.5); This will be specified for your site.  
3. Anatomic coverage:   Entire thorax (full chest).  Typi[INVESTIGATOR_897] a ≤[ADDRESS_913650] scanners.  
4. Sample reconstructions   
i. Contiguous thick section – 10 mm thickness, 10 mm spacing, B30F 
reconstruction filter, Display Field of View of 35 cm (Typi[INVESTIGATOR_897] 35 images)  
ii. Overlapped thin section – 1.5mm thickness, 1 mm spacing, B50f 
reconstruction filter and DFOV = 35 cm (Typi[INVESTIGATOR_897] 350 images).  
 
 
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913651] Scan Acquisition Protocol  
 
Version:  June 23, 2017                         CONFIDENTIAL               Page 5 of 6 
 Table 1.   
Shaded fie lds are user input fields on the scanner console.  Other values are either calculated or 
derived from user inputs.  
Techniques for Siemens Sensation 16  
16-slice/0.5 sec   Helical – Full Chest at TLC  
REQUIRED  
[IP_ADDRESS] kV 120 
[IP_ADDRESS] Gantry Rotation Time  0.5 sec 
[IP_ADDRESS] mAs1 (Regular patient -
Large patient values)  80 – 100 
[IP_ADDRESS] Collimation (mm)   0.75 mm collimation  
[IP_ADDRESS] Table incrementation 
(mm/rotation) – I 18 mm 
[IP_ADDRESS] Detector Collimation (mm) 
– T 0.75 mm 
[IP_ADDRESS] Number of active channels 
– N 16 
[IP_ADDRESS] Detector Configuration – N 
x T 16 x 0.75 mm  
[IP_ADDRESS] Pi[INVESTIGATOR_23025] ([mm/rotation] /beam 
collimation) – I/NT 1.5 
[IP_ADDRESS] Table Speed 
(mm/sec)  36 mm/sec  
[IP_ADDRESS] Scan Time (40 cm 
thorax) 12 sec 
[IP_ADDRESS] REQUIRED 
Reconstructed Thin Slice Width  1.5 mm 
[IP_ADDRESS] REQUIRED Thin 
Slice Reconstruction Interval  0.8 mm 
[IP_ADDRESS] REQUIRED Thick 
Slice Reconstruction Interval 5.0mm 
[IP_ADDRESS] REQUIRED Thin 
and Thick Slice Reconstruction 
Algorithm  B45f 
[IP_ADDRESS] REQUIRED # 
Images/Data set (40 cm) thin/thick  500/60  
1 – Siemens Scanners use the term “effective mAs”  which is really [(mA*time)/Pi[INVESTIGATOR_23025]].  Sites should enter the value in the 
mAs row at their scanner.  
Definitions  
T = Z axis collimation, or  width of one data channel.  In multi -detector CT scanners, several 
detector elements maybe grouped together to form one data channel.  
N = # data channels, or the  actual number of data channel s used during an acquisition.  
I = Increment, or the  table increment per rotation  of the x-ray tube in a helical scan . 
Table 2.   
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913652] Scan Acquisition Protocol  
 
Version:  June 23, 2017                         CONFIDENTIAL               Page 6 of 6 
 Shaded fields  are user input fields on the scanner console.  Other values are either calculated or 
derived from user inputs.  
Techniques for Siemens Sensation 16  
16-slice/0.5 sec   Helical – Full Chest at RV  
REQUIRED  
[IP_ADDRESS] kV 120 
[IP_ADDRESS] Gantry Rotation Time  0.5 sec 
[IP_ADDRESS] mAs1 (Regular patient -
Large patient values)  80 – 100 
[IP_ADDRESS] Collimation (mm)   0.75 mm collimation  
[IP_ADDRESS] Table incrementation  
(mm/rotation) – I 18 mm 
[IP_ADDRESS] Detector Collimation (mm) 
– T 0.75 mm 
[IP_ADDRESS] Number of active channels 
– N 16 
[IP_ADDRESS] Detector Configuration – N 
x T 16 x 0.75 mm  
[IP_ADDRESS] Pi[INVESTIGATOR_23025] ([mm/rotation] /beam 
collimation) – I/NT 1.5 
[IP_ADDRESS] Table Speed 
(mm/sec)  36 mm/sec  
[IP_ADDRESS] Scan Time (40 cm 
thorax) 12 sec 
[IP_ADDRESS] REQUIRED 
Reconstructed Thin Slice Width  1.5 mm 
[IP_ADDRESS] REQUIRED Thin 
Slice Reconstruction Interval  0.8 mm 
[IP_ADDRESS] REQUIRED Thick 
Slice Reconstruction Interval  5.0mm 
[IP_ADDRESS] REQUIRED Thin 
and Thick Slice Reconstruction 
Algorithm  B45f 
[IP_ADDRESS] REQUIRED # 
Images/Data set (40 cm) thin/thick  500/60  
1 – Siemens Scanners use the term “effective mAs”  which is really [(mA*time)/Pi[INVESTIGATOR_23025]].  Sites should enter the value in the 
mAs row at their scanner.  
Definitions  
T = Z axis collimation, or  width of one data channel.  In multi -detector CT scanners, several 
detector elements maybe grouped together to form one data channel.  
N = # data channels, or the  actual number of data channels used during an acquisition.  
I = Increment, or the  table increm ent per rotation  of the x-ray tube in a helical scan . 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 7 .  Baseline Eligibility Criteria  
Version:  June 23, 2017                         CONFIDENTIAL               Page 1 of 1 
  
Study Candidate Selection – Baseline Eligibility Criteria  
Baseline Inclusion Criteria  
1 Completed a supervised pulmonary rehabilitation program less than equal to 6 months prior to the baseline exam or 
is regularly performing maintenance respi[INVESTIGATOR_675715] 6 
months prior  
2 Baseline evaluation occurred ≤ 120 days after screening exam  
3 Signed written informed consent to participate in study using a form that was reviewed and approved by [CONTACT_1201]  
4 Continued nonsmoking between initial screening and baseline exams  
5 Willing and able to complete protocol required study follow -up assessments and procedures  
6 FEV 1 between 15% and 45% of predicted value at baseline exam  
[ADDRESS_913653]-rehabilitation 6-minu te walk distance between 100 meters  and 500 meters at baseline exam  
8 Current Pneumococcus vaccination  
9 Current Influenza vaccination  
Baseline Exclusion Criteria  
10 Myocardial infarction or diagnosis of congestive heart failure between screening and baseline exams  
11 Fever or other clinical evidence of active infection  at baseline exam  
12 Two or more COPD exacerbation epi[INVESTIGATOR_675716]  
13 Two or more pneumonia epi[INVESTIGATOR_675717] #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 1 of 17 
  
 Investigator Name: ________________  Site ID#___________________ Institution: _______________________  Participant ID: ______________ ________________________________ ________________________________  Telephone: _________________ 
 
Dear Patient:  
 
You are being invited to par ticipate in a clinical study involving research.  This Informed Consent Letter 
describes the study and your role as a participant .  If you choose to consider taking part in the study you 
must read this form carefully . You are urged to discuss any questions you have about the study with 
your physician and/or the hospi[INVESTIGATOR_307]’s research staff.   
 Persons who participate in a research study are entitled to ce rtain rights.  These rights include, but are 
not limited to, your right to:  
 
• Be informed of the nature and purpose of the medical experiment ( ie. study); 
• Be given an explanation of the procedures to be followed in the study, and information about the 
drugs or devices to be used ; 
• Be given a description of any discomforts and risks that are reasonable to expect;  
• Be given an explanation of any benefits that are reasonable to  expect; 
• Be given information about other appropriate treatments that might be given to you and information about their risks and benefits; 
• Be informed of the med ical treatment s, if any, that are available to you if complications should arise 
after the investigational (ie. study) procedure;  
• Be given an opportunity to ask questions concerning the study or the procedures involved in the study; 
• Be informed that you may withdraw your consent to participate in the study at any time;  
• Be given a copy of the consent form you signed;  
• Be given the opportunity to decide for yourself whether or not you should consent to take part in the study. 
 
 
Purpose of the Study  
Since you are being asked to participate in this study, you have probably suffered an impaired lifestyle as a result of emphysema.  Emphysem a is a serious disease afflicting more than four million people 
worldwide.  It is one form of Chronic Obstructive Pulmonary Disease, or COPD.  Emphysema causes the lungs to lose the ability to move air in and out normally and to efficiently absorb oxygen. Eventually, breathing becomes more difficult as damaged parts of the lungs trap air. As the disease advances, the 
damaged, inelastic areas of the lung progressively expand within the chest cavity, leaving one constantly feeling out of  breath. 
 Lung volume reduction surgery (LVRS) has been shown to offer relief to patients  suffering from 
emphysema.  With LVRS, some of the diseased portions of the lungs are removed .  This allows the 
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 2 of 17 
 remaining lung tissue to function better.  O ther surgical procedures like plication (folding) and stapling 
of lung tissue, which are done  without surgically removing parts of the lung, have been seen to have 
results similar to LVRS .  These results suggest that  removal of damaged lung tissue is not necessary  and 
that a process that gets rid of the trapped air in the damaged regions of the lungs should work in the 
same way.   
 
The purpose of this research is to study a medical device that is designed to produce lung volume reduction.  This device is called the Pulmonx En dobronchial Valve (EBV).  The EBV is a one- way 
valve that blocks off the diseased lung section to inhaled air but lets the trapped air already inside the area escape.  With placement of the EBV, the diseased part of the lung collapses; this allows the 
healthier parts of the lung to expand.  The EBV is considered experimental.  This means that it has not 
yet been approved by [CONTACT_941] U.S. FDA (Food and Drug Administration) for commercial use in the [LOCATION_002]. 
 The EBV can be placed by a doctor in a diseased section of the lungs using bronchoscopy.  
Bronchoscopy is a way to access your lungs using a small tube with a camera on the end.  With 
bronchoscopy, your physician can reach the airways in your lung by [CONTACT_675822].  Use of bronchoscopy for performing lung volume reduction may have fewer risks than surgery and have reduced recovery time.  This study is designed to investigate the safety and effectiveness of the Pulmonx EBV for treating your emphysema symptoms as compared to a standard medical therapy program alone.   
 
 
Number of Patients in the Study  
Approximately two hundred (200) patients will be enrolled into this study. In order to qualify for enrollment into this study, you must undergo a bronchoscopy procedure.  During the bronchoscopy 
procedure, your doctor will measure some of the airways in your lungs using a device that measures 
airflow to find out if you meet the study criteria for having the EBV treatment.  There is a chance that 
after measuring some of airw ays in your lungs you will not be eligible to take part in this study.   
 During the bronchoscopy procedure, one hundred and eighty- three (183) patients will be found to 
qualify for the study.  The [ADDRESS_913654] pain, palpi[INVESTIGATOR_814], 
nausea, severe difficulty breathing or wheezing, during any of the following testing, please tell your 
healthcare professional immediately.  
 
Blood Gas (PaO2 and PaCO2) and Blood Chemistry Analysis 
A blood sample will be taken to measure the amount of oxygen and carbon dioxide in the sample.  
This blood sample will need to be taken from an artery (as opposed to a vein).  An arterial blood 
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, [ADDRESS_913655].  
 
Echocardiogram 
An echocardiogram will be done to assess your heart’s function.  An echocardiogram is a test that 
uses sound waves to create a moving pi[INVESTIGATOR_675705]. The pi[INVESTIGATOR_517180] m uch more detailed than a 
plain x-ray image and involves no radiation exposure. 
 
Fluoroscopy  
Fluoroscopy is used to make a moving pi[INVESTIGATOR_675718].  In rare instances, fluoroscopy may be 
used by [CONTACT_675823]/her to see your lung structures and anatomy using 
the bronchoscope alone.   
 
Electrocardiography (ECG)  
During this test, small electrodes will be attached to your skin in several places and measurements 
will be taken of your heart rhythm and blood flow in and out of your heart.    
Lung Function Tests  
Spi[INVESTIGATOR_038] : During the test, you will be asked to breathe in and out of a mouthpi[INVESTIGATOR_675707] a machine 
measures the amount of air you are breathing  into and out of your lungs.  These breathing maneuvers 
may be somewhat difficult and you may be come tired  during the test but you will be allowed to rest 
periodically.    
 
Plethysmography: This test is used to determine how much air you can hold in your lungs.  You will 
sit in a small box, comparable to the size of a telephone booth, to undergo breathing tests similar to those described above. There is a chance that y ou may experience claustrophobia in addition to 
fatigue.  
 
Diffusing Capacity:  This test is used to measure the ability o f your lungs to transfer carbon  
monoxide.  You will be asked to breathe a mixture of helium, oxygen, nitrogen and carbon 
monoxide and hold your breath for [ADDRESS_913656] (High Resolution Computed Tomography) of Chest  
You will be asked to lie down on your back on an x-ray table that will slide into a large, tunnel-
shaped machine.  You must not move during the test and will be asked to relax and breathe normally. The technician will also ask you to do some breathing maneuvers such as take a deep breath in or out.    
Pregnancy Test  
If you are a woman of child-bearing pot ential, a urine or blood pregnancy test may be performed.  
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, [ADDRESS_913657] you will be asked questions about how breathless  you feel you are.  
 
Questionnaires  
During the study, you will be asked to complete a few simple questionnaires. These questionnaires 
will ask you about your daily activ ities and your opi[INVESTIGATOR_675719]. You will also be asked about frequency of visits to health care providers, such as your regular 
physician, emergent care facilities, and the hospi[INVESTIGATOR_307].  
 
Pulmonary Rehabilitation Pr ogram—to be Eligible for the Study  
In order to participate in this study, you will have:   
• Successfully completed a supervised pulmonary rehabilitation program within the past 6 
months, or 
• Be regularly performing maintenance respi[INVESTIGATOR_675720] [ADDRESS_913658] to you.   
   
Daily Diary  
At the baseline visit y ou will be given a paper based diary to answer some questions about your health 
and your pulmonary rehabilitation exercises.  You will be asked to complete the diary  immediately 
before going to bed every night and it is expected to take you approximately 15 minutes each time.  The 
information that is recorded in the diary will be collected when you return for the bronchoscopy procedure.   
• Pulmonary rehabilitation program 
o You will be asked about how long you spent doing pulmonary rehabilitation exercises that day and how many exercises you did. 
• EXACT-PRO Questionnaire 
o You will be asked 14 questions about your COPD symptoms. 
• Health status changes  
o You will be asked if you’ve had any change to your medications, any emphysema symptoms, and whether or not your activities or lifestyle has changed from normal due to your emphysema symptoms.   
 Description of the Study Treatment Groups  
 
Control Group 
All participants in this study will receive optimal medical therapy .  Optimal medical therapy  consists of 
smoking cessation support, selected medications, pulmonary rehabilitation therapy, and oxygen 
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 5 of 17 
 supplementation as medically necessary .  After their 1 -year follow -up visit, control group participants 
may be eligible to receive the EBV treatment if they continue to meet study criteria.  If they receive 
EBV treatment, these participants will be followed up according to the same visit schedule as the initial 
EBV treatment group.      
EBV Treatment Group  
In addition to optimal medical therapy, the EBV treatment group will undergo bronchoscopic lung volume reduction using the Pulmonx EBV.   
 
 Description of the Bronchoscopy  Procedure  
During the bronchoscopy procedure, your physician will measure some of the airways in your lungs 
using a device called the Chartis ® Pulmonary Assessment  System.  This system is designed to measure 
air pressure and flow in lung airways.  The air pressure and flow  measurements that are collected using 
the Chartis System will help the physician decide if you are eligible to potentially have the EBV 
treatment. Your physician will plan t he areas that will be measured before the day of the bronchoscopy 
procedure using the results of your CT scan.      
 
If you are found to have air pressure and flow measurements that  show you are NOT eligible to receive 
the EBV treatmen t, your physician and his or her team will stop the bronchoscopy procedure and you 
will not receive any further treatment during the bronchoscopy procedure.  
 
If you are found to have air pressure and flow measurements that show you are eligible  to receive  the 
EBV treatment, you will be randomly assigned to either the EBV treatment group or the control group.  
If you are randomly assigned to the EBV treatment group, you will have the EBV treatment.  If you are 
randomly assigned to the control group, you wil l not receive any further treatment during the 
bronchoscopy procedure.        
 Personnel from the study sponsor (Pulmonx) will attend your bronchoscopy procedure.  The doctor’s view of the procedure (the inside of your lung) may also be videotaped or photographed.    
 
 Description of the Study Procedure  
 
The EBV Procedure 
A bronchoscope (a tube with a camera at the tip, connected to a monitor) will be guided down an access 
tube all the way to the point where the EBV will be placed.  Once your physician can clearly see the area where the EBV will be placed, he or she will guide a catheter (flexible tube), with the EBV attached,  to 
the targeted treatment area.  Once the catheter  is in the proper position, he or she wil l implant the EBV 
in the lung. This may be done several times depending upon how many EBV are to be placed in your lungs.    If there is a problem with the EBV at any time during or after the procedure that makes it difficult or 
inappropriate to continue with the study, your physician may remove the EBV.  In some cases, if the EBV is removed, it can be replaced.  In rare cases, the EBV may not have been placed in the original 
procedure as it wa s intended to  be (to completely stop the airflow from the damaged part of the lung).  
This may initiate a discussion between you and your physician about having another procedure to adjust the placement of the EBV.    
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 6 of 17 
  
 After the Bronchoscopy Procedure 
After the procedure, you will be taken to a recovery area of the hospi[INVESTIGATOR_307].  If you are in the control group 
(did not receive the EBV) or were found to not be eligible for the study, you will be allowed to go home a few hours after the bronchoscopy procedure.  If you had EBV placed (are in the study treatment group), you will be required to remain in the hospi[INVESTIGATOR_34092] [ADDRESS_913659] x-ray to confirm you are not experiencing any 
complications .  Your study physician may keep you in the hospi[INVESTIGATOR_675721]/she feels your health 
needs further monitoring.   
 If you received the EBV, a chest x -ray will be taken at [ADDRESS_913660] to 
give to any physician that may need to treat you informing him/her of the pneumothorax risk.  Additionally , you will be given post-discharge instructions by [CONTACT_675824] .  
 
After Discharge (For the EBV Treatment Group)  
 
You will return to your study physicia n’s office [ADDRESS_913661] x -ray will be taken of your lungs at this time.  At this visit, the study doctor will 
assess you to determine if you may resume your regular activities and start the pulmonary rehabilitation program.    After you are discharged from the hospi[INVESTIGATOR_307], you will be contact[CONTACT_675825] 10 days to answer questions about your health status.    
After Discharge (For the EBV Treatment and Control G roups) 
 
Pulmonary Rehabilitation after the Bronchoscopy Procedure 
Within [ADDRESS_913662] completed the supervised pulmonary rehabilitation program you will be expected to do a home-based maintenance program  which will be described to you by [CONTACT_675826] #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, [ADDRESS_913663] day after the bronchoscopy procedure until your 1 year follow-up visit, you will be 
expected to complete an electronic diary to answer some questions about your health and your 
pulmonary rehabilitation exercises.  You will be asked to complete the d iary immediately before going 
to bed every night and it is expected to take you approximately 15 minutes each time.  The information 
that is recorded in the electronic diary will be collected at each of your study visits (up to your 1 year follow-up).  The study staff will remind you to bring your electronic diary to your visits.   
• Pulmonary rehabilitation program 
o You will be asked about how long you spent doing pulmonary rehabilitation exercises that day and how many exercises you did. 
• EXACT-PRO Questionnaire 
o You will be asked 14 questions about your COPD symptoms. 
• Health status changes  
o You will be asked if you’ve had any change to your medications, any emphysema symptoms, and whether or not your activities or lifestyle has changed from normal due to your emphysema symptoms.   
 
Length of the Study and Patient Evaluations  
The results of the study will be evaluated after all of the study participants have made the [ADDRESS_913664] over 
10 
days* 30 
days 45 
days 3 
months 6 
months 9 
months 1 
year Annual 
visits  
(2-5 
years) Early 
Termination 
Visit  
Physical Exam  X^  X^ X X X  X  X 
Medications & Events 
Review    X X X X X   
X-ray X^  X^ X^       
Blood Work         X   
Lung function     X  X  X X X 
[ADDRESS_913665] scan‡    X^ ‡   X^   
           
Daily Diary  Complete the daily diary every day before going to bed at night starting on the first day after the 
bronchoscopy procedure until the 1 year follow -up visit.  Bring the diary to every follow -up visit. 
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 8 of 17 
 *You will be contact[CONTACT_675827][INVESTIGATOR_307].   
‡Study participants who undergo the study treatment will have a CT scan at [ADDRESS_913666] 
a study procedure (valve) adjustment, a CT scan will be collected at 3 months too.   
†It is expected that study participants will complete the daily diary at home every day before bedtime starting right after 
discharge from the hospi[INVESTIGATOR_675722] 1 year follow -up (approximately 365 days) .   
^EBV treated study participants only.   
   
 
Random Assignment to the Control Group  
If you are randomly assigned to the control group you potentially have the opportunity to receive the study treatment after you complete the [ADDRESS_913667] treatment for emphysema patients.  The EBV was previously tested in the [LOCATION_002] with a large study that included four hundred ninety-two (492) patients from 
both the [LOCATION_002] and Europe.  The results of this large (VENT) study are discussed below. 
The Endobronchial Valve for Emphysema Palliation Trial (VENT study) was a multi -center, prospective, 
randomized, controlled study conducted in the [LOCATION_002] and Europe to evaluate safety and 
effectiveness of endobronchial valve treatment (along with optimal medical management) compared to optimal medical management alone (control gro up).  In the U.S. study, the endobronchial valve treatment 
was found to improve forced expi[INVESTIGATOR_31737] (FEV
1) by [CONTACT_675828] 6.8% and 
the [ADDRESS_913668] results by [CONTACT_675828] 5.8%.  These results were significantly better than the results seen with medical management alone.   The European patients had similar results.   
After the VENT study was finished, the data was further analyzed.  We found that patients who showed signs that the airflow in some parts of the ir lungs could be blocked off, had the best results with the EBV 
and procedure.  For the study you are considering taking part in, we are planning to select patients who show these same signs BEFORE they have the study treatment.  This will be done using t he Chartis System 
during the bronchoscopy procedure.  At the end of the study, we will then compare the results of the EBV treatment to the control treatment.   
 In the VENT study, some adverse events were seen. The type of major adverse events and the percentage of patients who had them are shown below:   
 Table 2.  Adverse events that were seen through 90 days in the EBV Treatment Group in VENT Study  
 
Event % of 
Patients  
COPD exacerbation (without hospi[INVESTIGATOR_059])  7.9% 
   COPD exacerbation (with hospi[INVESTIGATOR_059])  1.4% 
Hemoptysis (coughing up any amount of blood)   5.6% 
   Massive Hemoptysis (coughing up a large amount of blood)  0.5% 
Valve expectoration, aspi[INVESTIGATOR_1516], migration (valve moved from the place it was put by 
[CONTACT_099]) 4.7% 
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 9 of 17 
  
Event % of 
Patients  
Pneumoni a  2.3% 
   Pneumonia (distal, or behind, the valve)  0.9% 
Formation of bronchial granulation (scab -like) tissue with valve  2.3% 
Pulmonary infection (infection in the lung)  1.9% 
Respi[INVESTIGATOR_1399] (poor lung function --too much carbon dioxide or too little oxygen in 
your blood--where you need to have assistance with breathing using a mechanical 
ventilator)  1.4% 
Pneumothorax (air leak in the lung)  that required treatment for more than 7 days  1.4% 
Pneumothorax (air leak in the lung) that expanded, or  got larger  1.4% 
Pneumothorax (air leak in the lung) that was stable, or stayed the same size  1.4% 
Hypoxemia (decreased oxygen in the blood)  1.4% 
Hypercapnia (excess carbon dioxide in the blood)  0.9% 
Death 0.9% 
Noncardiac chest pain  0.5% 
Bronchial (airway) trauma  0.5% 
 
 
Removal of the EBV in the VENT Study  
In some instances, patients enrolled in the valve treatment study group who experienced an adverse event required that the valves be removed.  In the U.S. VENT study, 31 (14.5%) patients had valve(s) removed after the procedure. The reasons for removal included:  valve migration, pneumonia, bleeding (hemoptysis), granulation, increased dyspnea (breathlessness), continuing COPD exacerbations, and 
patient request.      
 
Alternative Treatments  for Emphysema  
Oxygen, drug therapy, nutrition and lifestyle changes are the standard therapi[INVESTIGATOR_675723].   An additional alternative treatment may be Lung Volume Reduction Surgery (LVRS).    
Summary of Benefits and Risks of Participation in the LIBERATE  Study 
As the EBV is still an investigational device in the [LOCATION_002] , the actual benefits and risks are 
unknown at this time.  The investigators may learn from this study whether the EBV treatment and 
procedure is safe and effective.  There may or may not be direct benefit from your participation in this study.   
Potential Benefits  
Potential benefits you may experience as a participant in the study include having improved lung 
function and other improvements that may be associated with improved lung function, such as improved quality of life.  If it is  determined that control group participants still meet study eligibility criteria and it 
seems clinically appropriate for them after their 1 -year follow-up visit, the study sponsor will pay for 
these participants to undergo the EBV and bronchoscopy procedure .      
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, [ADDRESS_913669] 
frequently, a treatment using a small tube to drain out the air is required.  In rare cases, a pneumothorax 
may require a surgical intervention .  In addition, there is a chance that it can  be a serious and life-
threatening complication.    Potential Risks (Adverse Events )  
Acute bronchitis (inflammation or infection of the airways)  
Acute bronchospasm (spasm of the airway ; may result in wheezing or increased shortness of breath)  
Acute respi[INVESTIGATOR_1505] (sudden, severe injury to lungs) 
Airway blockage due to implant migration  
Airway perforation (hole in the airway wall)  
Airway stenosis (narrowing)  
Anxiety 
Aphonia (difficulty talking)  
Aspi[INVESTIGATOR_1516] (inhalation of vomit)  
Bowel function impairment  
Bronchial (airway) trauma or ulceration  
Chest pain  
COPD exacerbation (acute worsening of COPD symptoms)  
Death 
Depression  
Deep Vein Thromboembolism (DVT, blood clot)  
Dysphonia (hoarse or rough sounding voice)  
Empyema (presence of pus)  
Fever 
Formation of bronchial granulation (scab-like) tissue  near the valve(s)  
Fractured Rib  
Headache  
Heart arrhythmias (irregular heartbeats)  
Heart Attack  
Heart fail ure (heart function is impaired;  could result in increased breathlessness or fluid retention)  
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 11 of 17 
 Hemoptysis (coughing up blood)  
Hemothorax (accumulation of blood between the lungs and the chest wall  
Iatrogenic injuries (injury caused by [CONTACT_675829])  
Impaired lung function  
Increased cough  
Increased dyspnea (shortness of breath)  
Increased hypercapnea (excess carbon dioxide  in the blood)  
Increased hypoxemia (decreased oxygen in the blood)  
Infection  
Laryngospasm (throat spasm)  
Lethargy and disorientation  
Lung cancer or lung mass  
Nausea 
Pleural effusion (collection of fluid around the lungs)  
Pleuritis (inflammation of  chest lining)  
Pneumonia  
Pneumothorax (air leak in the lung)  
Pulmonary shunting (uneven blood flow through the lung)  
Pulmonary embolism (a blood clot in the lung which can lead to chest pain and shortness of breath)  
Respi[INVESTIGATOR_1399] (poor lung function; could require you to have  assistance with breathing using a 
mechanical ventilator)  
Septicemia ( severe infection)  
Stroke or Transient Ischemic Attack (sudden temporary loss of neurological function)  
Valve expectoration, aspi[INVESTIGATOR_1516], or migration  (valve moves from the place it was put by [CONTACT_271519])  
Vomiting  
Wheeze or whistling of valve  
 
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, [ADDRESS_913670] s makes 
you feel abnormal.   Vein or arter y blood tests.  The risks of drawing blood include temporary pain and discomfort and/or 
tenderness form the needle stick, redness, or bruising at the site, bleeding, fainting, and lightheadedness.  While rare, there is a possibility of infection or a local  blood clot with any procedure in which the skin is 
pi[INVESTIGATOR_675724] a needle.   Radiation.  This study involves a radi ation exposure from the CT scans and chest x -rays that is typi[INVESTIGATOR_675725].  There is a small chance that the study doctor may choose 
to use fluoroscopy during the bronchoscopy procedure to be able to see the EBV better than he/she can using the bronchoscope and this may expose you to some additional minimal radiation. The amount of radiation exposure received in this study is below the levels that are thought to r esult in a significant risk 
of harmful effects.  If  you are especially concerned with radiation exposure, you should discuss this with 
your study doctor.    Antibiotics.  Antibiotics will be prov ided to you around the time of the procedure and afterwards to 
minimize possible side effects.  All pharmaceutical drugs have side effects.  Antibiotics may also have side effects, including diarrhea, allergic reactions, and overgrowth of dangerous bacteri a such as C. 
difficile which can result in a serious infection.  However, antibiotics are used routinely to treat COPD 
exacerbations.   
 
Anesthesia.  The side effects of moderate procedural sedation or general anesthesia medications an d 
other medications r equired to perform bronchoscopy include, but are not limited to, allergic reaction, 
drowsiness, slurred speech, tremor, fatigue, low blood pressure, slowing of the heart rate, anxiety, confusion, dizziness, temporary loss of consciousness, and respi[INVESTIGATOR_2341].  Trained medical professionals with extensive experience and expertise will administer the medications and will be responsible for your care during the course of the procedure.    Echocardiogram.  If you have a transesophageal echo cardiogram (TEE, as opposed to a transthoracic 
echocardiogram or TTE ), some risks are associated with the medicine given to help you relax. For 
example, you may have a bad reaction to the medicine, problems breathing, and nausea (feeling sick to your stomach).  Your throat also might be sore for a few hours after the test. Rarely, the tube used during TEE causes minor throat injuries.  
Voluntary Participation and Study Withdrawal  
Decisions regarding whether or not you should participate in this study are entirely volu ntary.  If you 
decide not to participate, you will not lose any benefits to which you are entitled, nor will you be denied 
access to other available treatments for emphysema.  You will receive the standard treatment and care 
normally provided by [CONTACT_675830]. 
 Information obtained in the operating room after anesthesia is given to you will affect whether or not 
you are eligible to receive treatment during the bronchoscopy procedure.  This will happen, for instance, if it is determined that the air pressur e and flow measured in the airways in your lungs make you 
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, [ADDRESS_913671] you from possible injury arising from ex cessive blood drawing, 
excess x-rays, and interactions with other research devices or drugs, or similar hazards.  
 
Pregnancy and Contraception (Birth Control)  
Pregnant women may not participate in this research study as the risk of the procedure on an embryo or 
unborn fetus is unknown.  Women of childbearing potential must actively utilize appropriate means of 
birth control to avoid becoming pregnant throughout the course of the study.  
 
Confidentiality  
Information derived from this study and from your medical record may be reviewed and photocopi[INVESTIGATOR_491603] (FDA) and/or state and federal regulatory agencies and by [CONTACT_352038], Pulmonx Inc., with protection of confidentiality so far as permitted by [CONTACT_1289].  
Information resulting from this study and from your medical record may be used for research purposes 
and may be published; however, you will not be identified by [CONTACT_491609].    
 
Financial Responsibility  
The costs of any routine medical care admini stered during the study will be the responsibility of you 
and/or your health insurer. For such routine costs, you will be responsible for any co-payments or deductibles required under your insurance. You are not, however, expected to absorb the cost of any medical care specifically required by [CONTACT_50568]. The study Sponsor (Pulmonx) will pay 
for tests and procedures performed solely for the purpose of this study.    
Research Related Injury  
In the event that you believe participation in this research study has led to injury, contact [CONTACT_675831]. You should understand that neither _____________________ (hospi[INVESTIGATOR_307]) nor the Federal Government has any programs to provide compensation for persons participating in research projects who may experience injury. However, necessary facilities, emergency treatment and professional services will be available to you. You should not expect anyone to pay you for pain, worry, lost income, or non- medical care costs that occur from taking part in this research study. 
No funds have been set aside by _________________ (hospi[INVESTIGATOR_307]) to pay you in case of injury, nor will the study Sponsor provide direct compensation to patients in the event of an injury.   
Study Information at www.clinicaltrials.gov
 
A description of this clinical trial will be available on the http:www.clinicaltrials.gov, as required by 
U.S. Law.  This web site will not include information that can identify you.  At m ost, the web site will 
include a summary of the results.  You can search this web site at any time.   
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 14 of 17 
  
Add Financial Compensation Section as Applicable  
This section is site specific – include financial compensation information as needed.  
 
Questions  
If you have any questions about the study, its procedures, risks or benefits, your alternatives or your rights, or if you experience a potentially research related injury you should contact [CONTACT_4904]. If you 
cannot reach your doctor, contact [CONTACT_675832].  
Physician Contact [CONTACT_7171] (24 hour):  
 
Name:   ______________________ 
 
Phone Number:______________________ Alternate Contact [CONTACT_7171] (24 hour):  
 
Name:   ______________________ 
 
Phone Number:______________________ 
  
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 15 of 17 
 Authorization to Use and Disclose Health Information  
I agree to permit ____________________ (physician) and his/her staff (“Researchers”) to use and disclose 
health information that identifies me for the purposes described below.  I also agree to permit 
________________________ (hospi[INVESTIGATOR_307]), my doctors, and my other health care providers to disclos e health 
information in my medical records to the Researchers for the purposes described below.    
1. The health information that may be used and disclosed includes all information collected during the research described in this document and health informatio n in my medical records that is 
relevant to the research described.  
2. The researchers and Pulmonx may use and share my health information to conduct research; 
disclose my health information to Pulmonx to confirm the research results; disclose my health 
information as required by [CONTACT_675833], effectiveness and the conduct of the research; and remove from my health information my name [CONTACT_675883]. 
3. Once information that could be used to identify me has been removed, the information that remains is no longer subject to this authorization and may be used and disclosed by [CONTACT_675834]. 
4. Once my health information has been disclosed to a third party, federal privacy laws may no longer 
protect it from further disclosure.  However, the researchers and Pulmonx agree to protect my 
health information by [CONTACT_675835].  Also, no publication about the research will reveal my identity without my specific written permission.  These limitations continue even if I revoke this Authorization.   
5. Please not e that you do not have to sign this authorization, but if you do not, you may not be 
allowed to participate in this research study.  You may change your mind and revoke this 
authorization at any time.  However, if you revoke this authorization, you may no longer be 
allowed to participate in this research study.  Also, even if you revoke this authorization, the 
information already obtained may remain part of the research.  To revoke this authorization, you must write to: 
 
 
 
 While the research is in progress, you will not be allowed to see your health information that is created or collected in the course of the research.  After the research is finished, however, you may see this information as described in (hospi[INVESTIGATOR_307]) Notice of Information practices.      
6. This authorization does not have an expi[INVESTIGATOR_320]. 
  
  
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, [ADDRESS_913672] titled: Lung Function Improvement after Bronchoscopic Lung Volume Reduction 
with Pulmonx Endobronchial Valves used in Emphysema . 
1) The nature, purpose, and contemplated effects of the project, so far as it affects me, have been fully 
explained to my satisfaction  by [CONTACT_53775] w orker.  My consent is informed and given voluntarily.  
2) The details of the procedure proposed have also been explained to me. 
3) It has been explained to me that the purpose of this research project is to improve the quality of 
medical care, and that my involvement may not be of any benefit to me. 
4) I have been given the opportunity to have a member of my family or a friend present while the project is explained to me.  
5) I am informed that no information regarding my medical history will be divulged, other than that described in the consent form, and that my identity will be kept confidential in all published results of the study. 
6) I have been informed that my involvement in the project will not affect my relationship with my 
medical advisors in their managemen t of my health.  I have also been told that I am free to withdraw 
from the project at any stage without prejudice for future treatment at this hospi[INVESTIGATOR_307], and if I so choose, I can ask for any information collected up to that point to be withheld from use in the research. 
7) I declare that all of my questions have been answered to my satisfaction.  
 
If I agree to participate in the research study and if my questions are answered, I should sign this form.  
If I wish to refuse  to participate in the study , I may do so without any loss of medical care or benefits.  
Once I have consented, I still have the right to withdraw at any time.  To withdraw, all I have to do is 
complete the Revocation of Consent portion of the form below and provide to or simply tell Dr. ________________________.  I will be given a copy of this form to keep and to refer to as needed.  
Printed Name [CONTACT_2385] (or legal representative):         
 
Signature:       [CONTACT_1782]:      
 I declare that I have been present when the research study was explain ed to the above participant and I 
believe that the participant has an application and understanding of the explanation given.  
Witness:       Date:      
  
LIBERATE Study  
Clinical In vestigational Plan #630 -0012-H 
Appendix 8 .  Example Informed Consent:  Study Participation  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 17 of 17 
  
 
 
REVOCATION OF CONSENT  
I hereby [CONTACT_675836].  
Withdrawal WILL NOT jeopardize any treatment or my relationship with _________________ 
Hospi[INVESTIGATOR_307]. 
 
Printed Name [CONTACT_2385] (or legal representative):        
 
Signature:       [CONTACT_1782]:      
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 9.  Bronchoscopy Procedure Planning:  Radiologic Identification of Target Treatment 
Lobe(s) 
Version:  June 23, 2017                           CONFIDENTIAL                Page 1 of 1 
  
 
Instructions:   Follow the procedure shown in the chart  below to identify appropriate 
target lobes for study treatment .  Targeted lobes will be assessed for collateral 
ventilation during the bronchoscopy procedure using the Chartis System to determine whether the study participant meets the study procedure eligibility criteria.   
 
 KEY 
DS = emphysema destruction score  
HS = emphysema heterogeneity score  
RUL = right upper lobe  
RML = right middle lobe  
RLL = right lower lobe  
LUL = left upper lobe  
LLL = left lower lobe  
 Determine 
Emphysema Score of 
each Lobe using the    
-910 HU threshold
Left Lung
Target Lobe = LUL or LLL . All target 
lobes >50% emphysema score
Left Lung 
HeterogeneityRight Lung
Target Lobe = RUL or (RUL + RML ) or 
RLL. All target lobes >50% emphysema 
score
Right Lung 
Heterogeneity 
RUL – RML ≥ 15%
AND
RUL – RLL ≥ 15%
RUL =  TargetRLL – RML ≥ 15%
AND
RLL – RUL ≥ 15%
RLL =  TargetLUL – LLL ≥ 15%
LUL =  Target LLL =  TargetLLL – LUL ≥ 15%RUL – RLL ≥ 15% 
AND 
RML – RLL ≥ 15%
(RUL + RML ) =  
TargetIs RML 
>50%?
(RUL + RML ) =  
Secondary 
TargetIs RML 
>50%?
Note:  Per Revision H of this protocol, the requirement of a 
heterogeneity score of 15% between lobes is not applicable 
for any remaining crossover subjects. The most diseased target can be treated regardless of heterogeneity, provided 
that the target lobe is collateral ventilation negative (CV -). 
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 10 .  Study Procedure Eligibility Criteria 
Version: June 23, 2017               CONFIDENTIAL                Page 1 of 1 
  
 
Study Candidate Selection – Study Procedure Eligibility Criteria  
Study Procedure Inclusion Criteria  
1 Procedure occurs < 60 days following baseline exam  
2 Continues to meet all screening and baseline eligibility criteria  
3 Little or no collateral ventilation (CV-) as dete rmined using the Chartis System  
Study Procedure Exclusion Criteria  
3 Evidence of c ollateral ventilation  (CV+)  as dete rmined using the Chartis System  
4 Collateral ventilation could not be dete rmined using the Chartis System    
5 Collateral ventilation assessment was not cond ucted using the Chartis System  
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 11 .  Bronchoscopy Procedure Flow  
 
Version:  June 23, [ADDRESS_913673] -procedure care  and 
protocol -specified study follow -up visits  Treatment  Any of the pre-identified 
target lobe(s) identified as  
CV- All of the  pre-identified 
target lobe(s) identified as  
CV+ CV assessment not 
conducted or CV could not 
be determined  
Not Eligible for Study  
Enrolled; Random Assignment  OR OR 
Perform EBV (Study) 
Treatment  OR Identify and document site personnel 
responsible for management of potential 
pneumothorax  
LIBERATE Study Clinical Investigation Plan #630-0012-H
Appendix 12.  Required Schedule for Tests and Procedures at Screening and Baseline
TESTING Screen Eligibility Pre-Baseline Baseline Eligibility & 
Assessmen t
IMAGING
   Chest X-ray   High Resolution CT Scan X
LUNG FUNCTION TESTIN
G
   Spi[INVESTIGATOR_675726] X
   Diffusing Capacity X
EXERCISE TOLERANCE   Six-Minute Walk Test XX
BASIC MEDICAL   Medical History X
   Vital Signs / Physical Exam XX
   ECG X
   Echocardiogram X
   Review of Medications XX
BLOOD WORK   Arterial Blood Gases (ABGs) X
   Complete Blood Counts (CBCs) X
   Alpha-1 Antitrypsin X
   Plasma Cotinine or Arterial Carboxyhemoglobin X
   Serum Fibrinogen X
MEDICAL MANAGEMENT   Pulmonary Rehabilitation X
   Pneumococcal Vaccine X
   Influenza Vaccine X
HEALTH SURVEYS   SGRQ X
   MMRC X
   BDI/TDI X
   CAT X
   SF-36 X
   EQ-5D X
   Health Care Utilization X
DAILY DIARY*
   PR Program Compliance X
   Exact-PRO X
   Health Status Change X
*paper diary 
Version: June 23, 2017 Confidential Page 1 of 4 
LIBERATE Study Clinical Investigation Plan #630-0012-H
Appendix 12.  Required Schedule for Follow Up Tests and Procedures CONTROL Subjects
TESTING Day 0 - Bronchoscopy 45 Days 3 Months 6 Months 9 Months 1 Year ET/EWD
LUNG FUNCTION TESTING
   Spi[INVESTIGATOR_675727] X X
   Body Plethysmography XX
   Diffusing Capacity XX
EXERCISE TOLERANCE
   Six-Minute Walk Test XX X
BASIC MEDICAL   Vital Signs / Physical Exam XX X X X X
   Review of Medications X X X XXX
   Electrocardiography X
   Pulse Oximetry X
BLOOD WORK   Arterial Blood Gases (ABGs) XX
   Complete Blood Counts (CBCs) X
   Plasma Cotinine or Arterial Carboxyhemoglobin X
   Serum Fibrinogen XX
MEDICAL MANAGEMENT   Pulmonary Rehabilitation* X
HEALTH SURVEYS   SGRQ XX X
   MMRC XX X
   BDI/TDI XXX X
   CAT XXX X
   SF-36 X
   EQ-5D X
   Health Care Utilization XXX X
DAILY DIARY**   PR Program Compliance XX X X X
   Exact-PRO XX X X X
   Health Status Change XX X X X
SAFETY   Adverse Events X X X X XXX
*starts within 30 days after bronchoscopy procedure; **daily diary recording to begin Day 1 after Bronchoscopy through 1 year f ollow up visit
Version: June 23, 2017 Confidential Page 2 of 4
LIBERATE Study Clinical Investigation Plan #630-0012-H
Appendix 12.  Required Schedule for Follow Up Tests and Procedures TREATED Subjects
TESTING Day 0 - 
Index ProcedureDay 1 Day 2 Day 3 Day 4 Day 5 (or 
day of discharge)Daily Phone 
Call (for 10 days after discharge)*Day 7 
After Discharge30 Days45   Days3 Months6 Months9 Months1    Year2 Years3 Years4 Years5 YearsET/EWD
IMAGING
   Chest X-ray X * XXXX X X X X
   Electrocardiography X
   High Resolution CT Scan XX
LUNG FUNCTION TESTING   Spi[INVESTIGATOR_675728] X X X X X
   Body Plethysmography XX
   Diffusing Capacity XX
EXERCISE TOLERANCE   Six-Minute Walk Test XXX
BASIC MEDICAL   Pulse Oximetry (first 24 hours after procedure) X
   Vital Signs / Physical Exam XX X X X X X X X
   Symptom Checklist XX
   Review of Medications XX X X X X X
BLOOD WORK   Arterial Blood Gases (ABGs) X X
   Complete Blood Counts (CBCs) X
   Plasma Cotinine or Arterial Carboxyhemoglobin X
   Serum Fibrinogen X X
MEDICAL MANAGEMENT   Pulmonary Rehabilitation** X
HEALTH SURVEYS   SGRQ XX X
   MMRC XXX
   BDI/TDI XXX X
   CAT XXX X
   SF-36 X
   EQ-5D X
   Health Care Utilization XXX X
DAILY DIARY***   PR Compliance XX X XX
   Exact-PRO XXXX X X X XX X X X X
   Health Status Change XXXX X X X XX X X X X
SAFETY   Adverse Events X XXXX X X X XX X X X XX X XX X
*chest x-ray within one hour ( ± 30 minutes)
**must receive PI [INVESTIGATOR_675729]-bronschoscopy pulmonary rehabilitation program; Pulmonary r ehabilitation must be initiated within the first 30 days following the bronchoscopy procedure
***daily diary recording to begin Day 1 after Index Procedure through 1 year follow up visit
Version:  June 23, 2017 Confidential Page 3 of 4
LIBERATE Study Clinical Investigation Plan #630-0012-H
Appendix 12.  Required Schedule for Follow Up Tests and Procedures ADJUSTMENT
TESTING Adjustment Procedure VisitDay 1 Day 2 Day 3 Day 4 Day 5 (or 
day of discharge)Daily Phone Call (for 10 days after discharge)Day 7 After Discharge3 Months**
IMAGING
   Chest X-ray X * X XXX X X X
   High Resolution CT Scan X
LUNG FUNCTION TESTIN
G
   Body Plethysmography X
BASIC MEDICAL   Pulse Oximetry  (first 24 hours after procedure) X
   Vital Signs/Physical Exam XX X
   Symptom Checklist XX
BLOOD WORK   Arterial Blood Gases (ABGs) X
   Serum Fibrinogen X
SAFETY   Adverse Events X XXX X X X
*Chest X-ray within one hour ( ± 30 minutes)**Study participants who undergo a valve adjustment procedure will resume the study mandated follow-up schedule aft er the 7-
Day Post-Discharge Visit following the the valve adjustment procedure, with the next planned clinic visit occuring at the [ADDRESS_913674] 
scan, X-ray, and body plethysmography.
Version:  June 23, 2017 Confidential Page 4 of 4
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 13 .  Pulmonary Rehabilitation Program  MOP 
Version:  June 23, [ADDRESS_913675]-Bronchoscopy  
Pulmonary Rehabilitation  
Manual of Operations  
   
 
   
 
  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 13 .  Pulmonary Rehabilitation Program  MOP 
Version:  June 23, 2017  CONFIDENTIAL  Page 2 of 8 
    
  
1.0 Background  
 
It is not the intent of the LIBERATE study sponsor to constrain study participants from 
taking part in a multidisciplinary PR program consisting of elements other than those delineated herein but rather to allow a uniform set of recommendations relative to a PR 
exercise program. The LIBERATE study PR program itself includes both an in- clinic 
element and a home- based maintenance element.   
  2.0 Administrative Responsibilities 
 
Investigative Study Center Representative   
Each investigative study  site will ha ve a designated study representative(s) who is 
responsible for coordinating the care of study participants with the Pulmonary Rehab ilitation  (PR) centers.  For most study centers, this responsibility will reside with the 
study coordinator; however, the responsibility may be delegated to other qualified personnel at the study site. 
 
Pulmonary Rehabilitation Center Representative 
Each Pulmonary Rehabilitation center will have a designated representative(s) 
responsible for communicating with the investigative study center representative.   The 
designated PR representative will be responsible for ongoing coordination and communication with the designated Investigative Study Site Representative.   
 
 
  
3.[ADDRESS_913676] adequate staff. Staff members should include at a minimum:  
• A Licensed Physician and/or Registered Nurse  
• A Physical Therapi[INVESTIGATOR_541], Exercise Physiologist and/or Respi[INVESTIGATOR_287965].  
 
Equipment  
The PR facility should have the following equipment in good working condition and readily 
available:  
 
 Supplemental Oxygen Source  
 Pulse Oximeter  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 13 .  Pulmonary Rehabilitation Program  MOP 
Version:  June 23, 2017  CONFIDENTIAL  Page 3 of 8 
    
  Heart Rate Monitor  
 Treadmill  
 Arm Ergometer  
 Free Weights, Therabands or other suitable forms of variable resistance.  
 
Training 
Training  of each PR facility  should consist of providing the facility with a copy of the  
LIBERATE Study protocol, including this Manual of Operations.   
 
Documentation Pulmonary Rehabilitation Facility Information Form  
This form is to be completed for each study participant and maintained in the study 
participant’s binder.  A copy of the form is attached to this manual as Appendix 13a.  
 
 
4.0 Pulmonary Rehabilitation Agreement  
 
It is anticipated that a  Services  Agreement will be executed between the investigative 
study site and the PR facility or the PR facility and the study sponsor.    
 
 5.0 Supervised In-Clinic Program  
 The study participant’s initial visit to the PR facility should include the following elements:  
 
 A review of the Pulmonary Rehabilitation Patient Information sheet and any other 
educational materials relevant to PR education.  
 
 An assessment of the study participant’s need to take part  in a smoking cessation 
program. If determined necessary, the PR facility is expected to aid and encourage the study participant’s attendance  in such a program.  
  An initial assessment of the study participant’s physical condition including, at a minimum , the evaluation of:  
 
 Any physical limitations that may affect the selection of exercises to be performed.  
 Baselin e characterization of strength and exercise tolerance.  
 Requirements for supplemental oxygen.  
 Establishment of specific PR exercise program and training for proper execution of each exercise maneuver.  
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 13 .  Pulmonary Rehabilitation Program  MOP 
Version:  June 23, [ADDRESS_913677], oxygen saturation will be monitored during 
exercise.  
 
Upper Limb Endurance Training  
Upper limb endurance training consists of a group of exercises involving some form and level of resistance for each hand (e.g. dumbbells or Therabands).  Appropriate exercises 
will be selected by [CONTACT_38802][INVESTIGATOR_541]. The exercises should remain constant during the course of the program and should include a minimum of eight (8) individual exercises. A list of some examples of these exercises is provided below.  
 
Upper Limb Endurance Training Suggestions  
 
1. Punching bag 
2. Overhead scissors  
3. Pump the tire 
4. Windshield wipers  
5. Crawl stroke  
6. Backstroke 
7. Breaststroke  
8. Climb the mountain  
9. Arm jog  
10. Disco criss -cross 
 
The group of exercises should be performed as a set, one right after the other, with each 
exercise performed for the same length of  time. The goal of this training is to gradual ly 
and continually increase tolerance to both duration of the exercise and resistance level 
over the course of the program.  The following general progression should apply:  
 
a. Select a resistance that can be tolerated while performing a complete set of 
exercises with a time of 20 seconds  for each separate exercise.  
b. As the patient gets stronger, gradually increase the time for each exercise to a maximum of 90 seconds.  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 13 .  Pulmonary Rehabilitation Program  MOP 
Version:  June 23, 2017  CONFIDENTIAL  Page 5 of 8 
    
 c. When a time of 90 seconds for each exercise is achieved, increase the level of 
resistance and restart with a  time of 20 seconds  for each exercise. 
 
Note: If the study participant is unable to perform unsupported arm exercises, an arm 
crank ergometer may be substituted at the therapi[INVESTIGATOR_541]’s discretion.  
 
Lower and Upper Limb Strength Training  
Lower and upper limb strength training consists of a group of exercises involving some 
form and level of resistance (e.g. dumbbells or Therabands).   Appropriate exercises will 
be selected by [CONTACT_38802][INVESTIGATOR_541]. The exercises should remain constant during the course of the program and should include a minimum of eight (8) individual exercises. A list of suggested exercises is provided below.  
 
Lower and Upper Limb Strength Training Suggestions  
 
1. Chest butterfly (chest)  
2. Sit to stand from chair (legs)  
3. Side forward arm raise (shoulders)  
4. Seated knee extension (quadriceps)  
5. Sideward arm raise (shoulders)  
6. Seated march (hip flexors & abdominals)  
7. Shoulder shrugging (shoulders)  
8. Standing hamstring curl (hamstrings)  
9. T-tube pull -down (shoulders & back)  
10. Standing toe raise (calves)  
 
The group of exercises should be performed as a set with an appropriate amount of rest time between exercises. The goal of this training is to gradually and continually increase the patients’ tolerance to both the number of repetitions and resistance level over the course of the program.   The following general progression should apply for each exercise:  
 
a. Select a resistance that can be tolerated for [ADDRESS_913678] after every session and is to be maintained 
at the PR facility. A copy of the log should be provided to the investigative study site representative on a weekly basis to enable monitoring of the study participant’s progress and compliance with the PR program. A copy of the log is attached to this manual as Appendix 13b.   
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 13 .  Pulmonary Rehabilitation Program  MOP 
Version:  June 23, [ADDRESS_913679] of the following 
general components:  
Lower Limb Endurance Training:  
Walking for 20- 30 minutes substituted for treadmill  
 
Upper Limb Endurance Training:  
As recommended by [CONTACT_675837][INVESTIGATOR_541], intended to be similar to in- clinic program.  
 Lower and Upper Limb Strength Training:  
As recommended by [CONTACT_675837][INVESTIGATOR_541], intended to be similar to in- clinic program.  
 
 
7.[ADDRESS_913680] clearly demonstrated that those who comply with a regimen 
of pulmonary rehabilitation (PR) exercises and who remain physically active are in better overall health and function more effectively that their sedentary counterparts. The purpose of the Patient Information sheet is to provide study participants with the theory behind why this is the case, which may aid in their understanding of the importance of complying with the PR program for this study.   
 The Patient Information Sheet (see the following section) has been provided to use as  an 
educational tool to be reviewed with each patient.   
 
  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 13 .  Pulmonary Rehabilitation Program  MOP 
Version:  June 23, [ADDRESS_913681] cycle of physical de- conditioning. This cycle has been described in several 
publications and is referred to as the “dyspnea cycle” or “downward spi[INVESTIGATOR_23585]”.  An illustration of this cycle is shown below
1. 
 
 
 The cycle starts as a result of respi[INVESTIGATOR_88739] (reduced pulmonary function) brought on by [CONTACT_325011]. As this impairment progresses you may have begun to experience discomfort and breathing difficulty, or dyspnea, during physical activity or exertion. In order to avoid this discomfort you may understandably start to refrain from or limit this activity. As for everyone, even highly trained athletes, a withdrawal from exertion (exercise) can lead to general physical de- conditioning.  
 
                                                 
1 Figure taken from “The Chronic Bronchitis and Emphysema Handbook”, Haas F, Hass SS, John Wiley & 
Sons, Inc., 2000.  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 13 .  Pulmonary Rehabilitation Program  MOP 
Version:  June 23, 2017  CONFIDENTIAL  Page 8 of 8 
    
 Physical de -conditioning affects all of the systems in your body including the 
cardiovascular system and the musculoskeletal system.  As you know, the health and 
strength of these systems are crucial to maintaining a lifestyle that is as active as possible.  
 Physical de -conditioning by [CONTACT_5071] (in the absence of a disease such as emphysema) is 
enough to contribute to discomfort during exercise for anyone.  This problem of discomfort is likely to be increased in patients suffering from emphysema.  The result of this discomfort during activity may cause you to further limit your physical exertion. This is the beginning of the “dyspnea cycle” or “downward spi[INVESTIGATOR_23585]”.  
 It is possible that some amount of your dyspnea is due to physical de- conditioning which 
is compounded by [CONTACT_675838]. Although pulmonary rehabilitation has not been demonstrated to improve pulmonary function, it has been demonstrated to 
improve exercise tolerance
2. The reason for this is likely associated with some degree of 
“re-conditioning” of the bodies systems.  It is reasonable to expect that improved exercise 
tolerance will result in your ability to perform daily tasks with less discomfort.  
 Conditioning as a result of exercise is a physiologically complex matter. It includes factors that are both easily comprehended and visually identifiable, such as improved muscle tone, as well as factors that are much more difficult to appreciate, such as improvements in blood flow due to a stronger heart muscle or improvements in the ability of the lungs to transfer oxygen to the blood and the ability of the recipi[INVESTIGATOR_675730].  Although some of these things may happen on a cellular level and may not be evident to you as a patient, they are significant in their role in promoting the health and strength of your body.  
 
The goal of your pulmonary rehabilitation program is to interrupt this “dyspnea cycle” in 
an effort to ensure that your physical limitations are as minimal as possible.  For this reason it is important for all patients to be committed to their Pulmonary Rehabilitation program.  
                                                 
2Pulmonary Rehabilitation: Joint AACP/AACVPR Evidence-Based Guidelines.  Chest 1997;112:1363- 96 
           
Clinical Investigational Plan #630 -0012 -H 
Appendix 13a.  PR Facility Information Form  Confidential Page 1 of 2 
June 23, 2017  
 
Pulmonary Rehabilitation Facility Information  Form  
 
This form is to be completed by a representative from the Pulmonary Rehabilitation Facility to be 
involved in the LIBERATE Study.  
Referring LIBERATE   Study Site:   _______________________________________________________  
PR Facility Name:    ________________________________ _______________________   
Address:    ________________________________ _______________________   
  ________________________________ _______________________   
Telephone:   ________________________________ _______________________   
Facsimile:   ________________________________ _______________________   
Email:   ________________________________ _______________________   
Director of PR Program:   ________________________________ _______________________   
 
Pulmonary Rehabilitation Personnel : 
Designated Study Representative (s):    ________________________________ _____________________   
 _____________________________________________________  
Address:    ________________________________ _____________________   
(If different than  above)   ________________________________ _____________________   
Telephone:   ________________________________ _____________________   
Facsimile:   ________________________________ _____________________   
Email:   ________________________________ _____________________   
Licensed Physician(s):   ________________________________ _____________________   
Licensed Nurse(s):   ________________________________ _____________________   
Physical Therapi[INVESTIGATOR_541](s):   ________________________________ _____________________   
Exercise Physiologist(s):   ________________________________ _____________________   
Other (specify):   ________________________________ _____________________   
Other (specify):   ________________________________ _____________________   
  
           
Clinical Investigational Plan #630 -0012 -H 
Appendix 13a.  PR Facility Information Form  Confidential Page 2 of 2 
June 23, 2017  
Pulmonary Rehabilitation Facility Information  Form  
 
Facility Equipment : 
a. Number of treadmills?   ___________  
b. Number of cycle ergometers?   ____________________________  
c. Number of arm  ergometers?     ____________________________  
d. Are there free weights, Therabands,  or other suitable forms of variable resistance equipment ?   ____  
Sources of supplemental oxygen for exercise training?  
 _____________________________________________________________________________________  
 _____________________________________________________________________________________  
Pulse Oximeter available?  ................................ ................................ ................................ .....  Yes   No 
Heart Monitors available?  ................................ ................................ ................................ ....  Yes   No 
Designated and secure storage area for LIBERATE Study documentation?  .........................   Yes   No 
 
 
 
Signature:  
I hereby [CONTACT_675839]:  
 
Signature:   ___________________________________   Date:   __________________________  
 
Name (please print):   ___________________________________  
 
Name [CONTACT_675884]  (please print):   _ _____  ________________________  
______________________________________________________________________________  
 
              
In-clinic  Pulmonary Rehabilitation Log  – POST -Bronchoscopy  PR 
 
Clinical Investigational Plan #630-[ADDRESS_913682] -bronchoscopy PR In -Clinic Log                                        Confidential                                      Page 1 of 2 
June 23, 2017  
 
Patient ID:  __________________  Facility Name:  ____________________________________________  
 
Referring L IBERATE  Study Site:  ____________________________________  
 
All LIBERATE study participants should participate in a supervised pulmonary rehabilitation program that is 
initiated within [ADDRESS_913683] 
of an active ‘in clinic’ pulmonary rehabilitation component and a ‘home-based’ maintenance pulmonary  
rehabilitation component.  The active ‘in clinic’ pulmonary rehabilitation program should be initiated for all study participants within the first 30 days following the bronchoscopy procedure. For the active ‘in clinic’ 
component of the program, the ATS/E RS practice guidelines recommend a minimum of [ADDRESS_913684] 3 home -based sessions per week.   
 
 
AT THE END OF EACH WEEK OF THE ACTIVE ‘IN CLINIC’ PROGRAM, A COPY OF THE COM PLETED LOG 
SHOULD BE SENT TO THE INVESTIGATIVE  SITE, WHICH WILL BE MAINTAINED IN THE STUDY PARTICIP ANT’S 
STUDY BINDER.   
  
 Session 1  Session 2  Session 3  
Date     
Duration of Entire Session (minutes)     
Therapi[INVESTIGATOR_675731] 4  Session 5  Session 6  
Date     
Duration of Entire Session (minutes)     
Therapi[INVESTIGATOR_675731] 7  Session 8  Session 9  
Date     
Duration of Entire Session (minutes)     
Therapi[INVESTIGATOR_675732]-clinic  Pulmonary Rehabilitation Log  – POST -Bronchoscopy  PR 
 
Clinical Investigational Plan #630-[ADDRESS_913685] -bronchoscopy PR In -Clinic Log                                        Confidential                                      Page 2 of 2 
June 23, 2017  
 
 
 Session 10  Session 11  Session 12  
Date     
Duration of Entire Session (minutes)     
Therapi[INVESTIGATOR_675731] 13  Session 14  Session 15  
Date     
Duration of Entire Session (minutes)     
Therapi[INVESTIGATOR_675731] 1 6 Session 17  Session 18  
Date     
Duration of Entire Session (minutes)     
Therapi[INVESTIGATOR_675731] 1 9 Session 20  ------------------------  
Date     
Duration of Entire Session (minutes)     
Therapi[INVESTIGATOR_675733] A COPY OF THE HOME -BASED PROGRAM SUGGESTED TO THE STUDY PARTICIPANT TO 
THIS FORM AT THE COMPLETION OF SESSION 20  
LIBERATE Study  
Clinical Investigational  Plan #630 -0012-H 
Appendix 14 .  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 1 of 8 
  
Collateral ventilation (CV) status of the target ed treatment lobe will be assessed  by [CONTACT_675840] :   
1.  Place the Chartis catheter balloon.  The balloon should be placed to occlude all segments of the 
target treatment lobe.  
2.  The tip of the catheter should be placed in a manner that allows airflow from all segments of the 
target treatment lobe to reach the catheter tip.  
3.  Complete sealing of the target lobe  by [CONTACT_675841] (including the [ADDRESS_913686]-assessment 
periods).  
4.  NOTE:   
a. If difficulties are encountered with occluding the target lobe , measurement of the 
adjacent lobe /lobes may be used as a proxy measure  of the collateral ventilation status 
of the target lobe . 
1.  Example:  If the patient’s anatomy does not allow placement of the balloon in 
the LLL, the collateral ventilation of the LUL can be assessed and u sed in the 
treatment decision since the lobes share a common interlobar fissure and hence 
their collateral ventilation status.  
5.  After completing the assessment of the target treatment lobe, r emove the Chartis catheter.  
  
LIBERATE Study  
Clinical Investigational  Plan #630 -0012-H 
Appendix 14 .  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 2 of 8 
 An example output for an accept able  Chartis  System assessment is shown in Figure 1  below.   
While assessing CV status of a targeted treatment lobe, there are s everal i mportant items  to note 
during the assessment, including :   
1) The patient should demonstrate consistent tidal breathing prior to start of assessment .  This 
indicates that the patient has been adequat ely sedat ed.  Ensuring  adequate sedation will aid in 
achieving complete sealing of the targeted segment with the Chartis catheter balloon. 
2) Duration of the assessment should be 2 minutes or longer.   
3) Throughout the assessment, c onsistent deeper negative pressure should be observed.  This 
indicates that proper catheter balloon positioning and sealing has been achieved. 
4) At the end of the assessment, the t otal volume of air exhal ed by [CONTACT_675842] 50 ml.   
5) During the post-assessment period, e nsure that tidal breathing pattern has return ed.  The 
balloon seal should be maintained until the review screen appears.  
6) During the assessment, if the patient coughs, the catheter tip clogs, or loss of the balloon seal is 
noted, the duration of the assessment  should be extended.  If any of these issues are significant , 
the assessment should be abandoned  and a new one should be re -initiated. 
7) During the assessment, if there is an instantaneous loss or drop in flow within the first [ADDRESS_913687] -assessment  Assessment longer than 2 minutes  
Exhaled volume greater than 50mL  Figure 1  
LIBERATE Study  
Clinical Investigational  Plan #630 -0012-H 
Appendix 14 .  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 3 of 8 
 Assessment of a Lobe that has Little or No Collateral Ventilation  (CV- Lobe)  
1.  When high resistance to collateral ventilation or high collateral resistance is noted, the Chartis 
assessment indicates that the target treatment lobe has little or no  collateral ventilation (is CV 
negative or CV -). 
2.  An  example of a CV - assessment is shown in Figure  2 below.   
3.  The key features of a CV- assessment include:   
a. The peaks of the flow indicator waveforms  (orange ) show a steady downward trend . 
b. The Collateral Resistance index ( Rndx) and / or Collateral Resistance realtime (Rrt) 
profile lines climb in a stepwise and steady fas hion . 
c. Potential artifacts to avoid include:   
i. Instantaneous climbing of the Rndx and Rrt lines  should not be considered a CV - 
assessment.  This observation could be an artifact of an underlying issue such as 
clogging of the catheter tip.   
ii. An instantaneous drop in flow seen within the first [ADDRESS_913688] trend 
of flow 
Climb in Rndx  Climb in Rrt Figure 2  
LIBERATE Study  
Clinical Investigational  Plan #630 -0012-H 
Appendix 14 .  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 4 of 8 
 Assessment of a Lobe that has Collateral Ventilation (CV+ Lobe)  
1.  When low resistance to collateral ventilation or low collateral resistance is noted, the Chartis 
assessment indicates that the target treatment lobe has high collateral ventilation (CV positive or 
CV+).   
2.  An example of a CV+ assessment is shown in Figure 3 below.   
3.  The key features of a CV+ assessment include:   
a. The peaks of the flow indicator waveforms (orange) remain flat and do not show a 
downward trend.  
b. The Collateral Resistance index (Rndx) and / or Collateral Resistance realtime (Rrt) 
profile lines have little or no  change and do not steadily increase.  
 
  
 
   
Flow remains flat.   
No downward trend.  
No climb in  
Rndx or Rrt  Figure 3  
LIBERATE Study  
Clinical Investigational  Plan #630 -0012-H 
Appendix 14 .  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
 
Version:  June 23, [ADDRESS_913689] the outcome of the collateral ventilation assessment 
include clogged catheter tip, instantaneous drop in flow, loss of balloon seal, and patient coughing.  It should be noted that these anomalies can occur together or independently during the course of an 
assessment.   
 
Assessment of a Lobe that has mucous clogging  
An example of a case with c logging at the catheter tip is shown in Figure 4.   
 
  
Clog  
Clog causes instantaneous climbing of 
the Rndx and Rrt lines and should not 
be considered a CV - Figure 4 
 
 
 
  
 
  
  
 
  
   
LIBERATE Study  
Clinical Investigational  Plan #630 -0012-H 
Appendix 14 .  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 6 of 8 
 Assessment of a Patient with instantaneous drop in flow  
An example of a case with an instantaneous drop in flow is shown in Figure 5.   
 
 
 
   
Figure 5  
Instantaneous drop in flow.  
Instant drop in flow causes instantaneous 
climbing of the Rndx and Rrt lines and 
should not be considered a CV - 
LIBERATE Study  
Clinical Investigational  Plan #630 -0012-H 
Appendix 14 .  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
 
Version:  June 23, [ADDRESS_913690] its seal.  Figure 6 
LIBERATE Study  
Clinical Investigational  Plan #630 -0012-H 
Appendix 14 .  Procedure for Assessing Target Treatment Lobe CV using the Chartis System  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 8 of 8 
 Inadequate Balloon Seal and Coughing  
An example of a case having inadequate balloon seal at the beginning of the assessment and a cough  at 
the end of the assessment is shown in Figure 7 .   
 
 
    
Cough  
Inadequate balloon seal 
at beginning of 
assessment.  Figure 7 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 15 .  Segmental Bronchial Targets for Lobar Occlusion  
 
Version:  June 23, 2017               CONFIDENTIAL                Page 1 of 1 
  
The information shown in the table below may be used as a guide for EBV placement in 
bronchial targets to achieve lobar occlusion.   
 
 Bronchial Segment Number  Bronchi  
Right Upper Lobe B1 
B2 
B3 Api[INVESTIGATOR_675734]  B4 
B5 Lateral  
Medial  
Right Lower Lobe B6 
B7 
B8 
B9 
B10 Superior, lower lobe  
Medial basal  
Anterior basal  
Lateral basal  
Posterior basal  
Left Upper Lobe  B1+2  
B3 
B4 
B5 Api[INVESTIGATOR_675735]  B6 
B7+8  
B9 
B10 Superior, lower lobe  
Anteromedial basal  
Lateral basal  
Posterior basal  
 
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913691]  
 
Version:  June 23, [ADDRESS_913692] consult one of the contacts on the reverse side, unless 
the situation requires immediate emergent care.   If symptoms of 
pneumothorax are evident (chest pain, nausea, shortness of 
breath), please treat me as appropriate for pneumothorax .  If 
pneumothorax persists, please transfer me to the hospi[INVESTIGATOR_675736] . 
 
  
(FRONT)  
   
 
 
(BACK) 
 Medical Alert – Contact [CONTACT_675843]:  NAME [CONTACT_675885]  
[ADDRESS_913693] number:  (xxx) xxx - xxxx 
 
Physician: NAME [CONTACT_675886]: (xxx) xxx - xxxx 
 
Hospi[INVESTIGATOR_120442]:       
Address:        
       
Phone: (xxx) xxx - xxxx 
 
Treated Lung:  ________ (Lobe:  LUL, LLL, RUL, RLL)  
 
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913694]-EBV Pro cedure Discharge Instructions for the Study Treatment Arm  
 
Version: June 23, [ADDRESS_913695]-EBV Procedure Discharge Instructions for the Study Treatment Arm  
 
Key Points  
 
• Please contact [CONTACT_675844] , severe chest pain and/or tightness , nausea and/or dizziness , 
or any other symptoms or changes in your health that you are worrisome to you 
 
• Please wear your study bracelet  and put your Medical Alert Card in your wallet in 
case of an emergency  
 
• Do not drive yourself home from the hospi[INVESTIGATOR_675737] 7 days after your 
procedure 
 
• Plan on having someone stay with you for the first few days and nights after you 
are discharged  
 
• Only engage in light physical activities for at least 7 days after you are 
discharged and don’t start pulmonary rehabilitation until the study doctor meets 
with you at your 7-day post -discharge visit  
  Discharge Day Schedule  
Prior to your discharge, your study doctor will complete a physical examination and a 
chest x -ray to determine how you are doing and whether it is safe for you to leave the 
hospi[INVESTIGATOR_307].  If the study doctor decides that it is safe for you to go home, he/she  and 
his/her staff will ensure that you have appropriate transportation from the hospi[INVESTIGATOR_675738].  You should not drive yourself home so you should plan on having a friend, relative, or colleague be available to drive you home.   Also, you should plan on having 
someone stay with you for several days after you are discharged to help support your transition home and your recovery from this procedure.   The study doctor and his/her 
team will provide you with a Medical Alert Card as well as the following set of discharge instructions.   
 
Recovery & Symptoms 
 
The time that it takes for you to recover  from the Endobronchial Valve (EBV) procedure 
may vary depending on your age, physical well -being, and mental health.  It is important 
that you allow yourself the time to recover at your own pace.  Your regular doctor and 
the study doctor  (as appropriate) can help manage any symptoms and problems that 
you may experience following the procedure.  Such symptoms may include:  
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913696]-EBV Pro cedure Discharge Instructions for the Study Treatment Arm  
 
Version: June 23, 2017               CONFIDENTIAL                Page 2 of 5 
  
 
1) Fatigue/Lack of Energy  
 
You have just undergone a fairly significant procedure so you may feel tired and have a lack of energy in the days and weeks following the procedure as your body heals,  your general health status returns  to normal, and you regain your strength.   
You should  take it slow and easy and listen to your own body during this time so that 
you appropriately pace yourself and avoid overdoing it.  
 
2) Decrease in Appetite 
 
You may experience a temporary decrease in your appetite as the medicines from 
your procedure and pos t-procedure care wear off and your mouth and airways begin 
to recover from the bronchoscopy.  Your appetite should return to normal within 1- 2 
weeks following the procedure.  If your appetite is poor, attempt to eat smaller, 
nutrient -rich (high protein and high calorie), and frequent meals and ensure that you 
are drinking a lot of fluids throughout the day (6- 8 cups/day unless instructed 
otherwise by [CONTACT_4904]) .  Sometimes, a decrease in appetite can be accompanied 
by [CONTACT_675845]/or  dizziness.  If you should experience either  of these 
symptoms, please contact [CONTACT_458398].  
 
3) Pain/Discomfort  
 
You may experience some pain and discomfort in your nose, throat,  airways , and 
chest  in the days and weeks following the procedure as your body recovers from the 
bronchoscopy.  Normally, this pain and discomfort is only temporary and resolves within several days after the procedure.  It is important that you take any pain medication s that have  been prescribed for these symptoms as you may need them .  
If you should experience any sudden feelings of chest pain and/or tightness that are 
sharper and more severe than normal, please contact [CONTACT_458398].  
 
4) Breathing Changes  
 
As a result of this procedure, your breathing function may decrease, stay the same, 
or improve.  It is important that you realize that you may not notice dramatic changes in your breathing function immediately following the procedure and it is possible that it may even decrease a little as your body heals and you regain your strength after 
the procedure.  Hopefully, you will experience less shortness of breath in the weeks and months following the procedure but this cannot be guaranteed.  If you should 
experience significantly more shortness of breath than usual, please contact [CONTACT_675846].    
  
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913697]-EBV Pro cedure Discharge Instructions for the Study Treatment Arm  
 
Version: June 23, 2017               CONFIDENTIAL                Page 3 of 5 
  
 
5) Other Symptoms/Health Changes 
 
You may also experience increased shortness of breath that is accompanied by [CONTACT_675847]/or wheezing, increased sputum production, changes in sputum color, and fever, which may suggest that you are having a COPD exacerbation or an 
epi[INVESTIGATOR_270924].  Additionally, you may  cough up a lot of blood or one of the 
valves or experience an increased or irregular heartbeat following the procedure, which may suggest some changes in your heart function.  It is important that you call your family doctor and/or the study  doctor (as appropriate) as soon as you begin 
experiencing any of the symptoms above.  You should also call your family doctor and/or the study doctor (as appropriate) if you experience any other symptoms or changes in your health that seem out of the ordinary or worrisome to you.  
 
General Instructions 
 
It is important that you follow these general instructions as you continue your recovery 
from the EBV placement procedure at home in the days and weeks after this procedure.  If you have any questions or concerns regarding these instructions, please discuss them with the study doctor and his/her study team.  
 Activity 
 
In the days and week after discharge from the hospi[INVESTIGATOR_307], you should only engage in light 
physical activity as you are able and comfortable.  This means that you can participate 
in such activities as self -care, light household chores like cooking and laundry, 
socializing with friends and family, and light exercise like walking on a straight and level 
track.  For [ADDRESS_913698] and arm muscles.  This includes activities like vacuuming, carrying groceries, shoveling snow, lifting weights, jogging/running, swimming, playing tennis, or doing aerobics.  Additionally, you will not be able to start your post -procedure pulmonary 
rehabilitation program until your study doctor has completed a physical examination, performed a chest x -ray, and authorized you to resume your normal daily activities  
during your visit with him or her 1 week following your discharge from the hospi[INVESTIGATOR_307].  
 
Driving/Traveling 
 
You should not drive for the first few days after discharge.  This is the amount of time 
that is usually required for you to regain the necessary mobility and strength to safely 
navigate and steer a car.  Additionally, you should avoid travelling out of state and particularly by [CONTACT_675848] [ADDRESS_913699] 
easy  access to the treating hospi[INVESTIGATOR_675739] .  
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913700]-EBV Pro cedure Discharge Instructions for the Study Treatment Arm  
 
Version: June 23, [ADDRESS_913701] any questions or concerns or need special 
assistance regarding this instruction, please check with your study doctor.  
 
Medications 
 
After your procedure and prior to your discharge, your medications may change.  It is 
important that you take any new prescriptions and follow any new  medication 
instructions provided to you by [CONTACT_675849]/her team.  It is possible that 
you may need additional medications after you are discharged.  You should contact  
[CONTACT_675850] (as appropriate) if you have any questions or concerns or have additional medication requirements.  
 Problems after the Study Procedure  
 
You should ensure that your family doctor has been informed of your EBV placement 
procedure as he/she will continue to provide your ongoing regular medical care and management once you are discharged.   If you have any questions, concerns, or needs 
regarding your regular medical care after you are discharged, you should contact [CONTACT_675851].  If you have questions, concerns, or needs as they relate to this 
procedure or study, please contact [CONTACT_675849]/her study team.   
 
Please keep your study doctor and his/her study team informed of any changes in your 
health or medications regardless of their relationship to this procedure or study.  
Additionally, please ensure that you wear your study bracelet and place your Medical Alert Card for this  study in your wallet so that it is readily accessible to a health care 
professional(s) in the event that you experience a medical emergency.  
 
Calling the Study [CONTACT_675887] contact [CONTACT_675852]:  
 
• increased shortness of breath 
• nausea and/ or dizziness  
• sudden onset of sharp and severe chest pain/tightness  
• fever  
• increased cough and/or wheeze with or without increased sputum production and 
changes in color/thickness of sputum  
• coughing up significant amounts of blood  
LIBERATE Study  
Clinical Investigational Plan #[ADDRESS_913702]-EBV Pro cedure Discharge Instructions for the Study Treatment Arm  
 
Version: June 23, 2017               CONFIDENTIAL                Page 5 of 5 
 • coughing up valve(s)  
• irregular or increased heartbeat  
• any other worrisome problem or symptom  
 
   If you have any questions or concerns after you leave the hospi[INVESTIGATOR_307], please contact [CONTACT_6814]’s office or 24- hour number as follows:  
 
Dr.___[PI [CONTACT_5627] ]____  Office:_ _[PI [CONTACT_275583] # ]__ 24-hour:___[PI [CONTACT_275583] # ]___ 
 
Dr.__[Co-PI [CONTACT_5627] ]__ Office:_[ Co-PI [CONTACT_275583] # ]_ 24-hour: __[Co-PI [CONTACT_275583] # ]__ 
 
Dr.__[Sub-I Name ]__ Office:_[ Sub-I Office # ]_ 24-hour: __[Sub-I Office # ]__ 
 
  ___[SC Name ]__   _ Office:_   [SC Office  #]  _ 
    
  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 18 .  Management of Pneumothorax  
 
 
Version:  June 23, 2017                                                                            CONFIDENTIAL                   Page 1 of 2 
  Pneumothorax  
 Large  
 Symptomatic  
   Small  
 Asymptomatic  
  
Place Chest Drain  
• prefer small size  
• place with up to 20 cm of H 2O suction  
Stable with airleak 
continuing > 7 days  Unstable  
Remove all valves  Remove one valve 
(preferably most proximal)  
ITT Study Participant  
with no valves 2 º to 
complications  Airleak stops  
Discontinue drain  Airleak continues  > 48 hours  
Consider valve 
replacement in 6 weeks  Remove all valves  
Airleak continues  > 48 hours  
Consider pleurodesis  or 
surgical intervention   
ITT Study Participant  
with no valves 2 º to 
complications  Observe –  
repeat X -ray 2 -4 
hours  Symptomatic or 
enlarging  Stable with 
resolution  
Trapped lung collapse 
without airleak > 96 hrs  
Remove one valve 
(preferably most proximal)  
Re-expansion  
Discontinue drain  
Consider valve 
replacement in 6 weeks  Lack of re -expansion 
within 48 hrs  
Remove all valves  
Discontinue drain 
  
ITT Study Participant  
with no valves 2 º to 
complications  Airleak stops  
Discontinue drain  
Consider valve 
replacement in 6 weeks  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 18 .  Management of Pneumothorax  
Version:  June 23, [ADDRESS_913703] x -ray. Out of an 
abundance of caution in this situation, the clinician should consider the following:  
• Performing a CT scan of the chest without contrast to evaluate for pneumothorax 
that may not be visible on plain x -ray imaging 
• Keep chest drainage set easily accessible and consider placement of a small bore catheter if any size pneumothorax is identified  
• Application of oxygen (FiO2 of 100%)  
• Consider reducing patient’s exertion for 48 hours  
Consider the methods suggested in a recent publication (Herzog 2015) where patients 
following a modified post-EBV care that included [ADDRESS_913704] and, if needed, 
16 mg codeine up for cough to three times a day (TID), experienced statistically significant 
fewer pneumothoraces. 
Also, in the event of acute clinical deterioration, usual management protocols need to be 
followed. Placement of a chest tube should be considered if even a small pneumothorax is 
found on chest CT scanning following substantial atelectasis in the immediate post EBV 
procedure period. Additionally if clinical deterioration occurs that requires endotracheal 
intubation and positive pressure ventilation, bilateral chest drains should be placed if there 
is any suspi[INVESTIGATOR_675740].  
References  
1. Cormier Y, Laviolette M, Tardif A Prevention of pneumothorax in needle lung biopsy by 
[CONTACT_675853] 100% oxygen.  Thorax . 1980 Jan;35(1):37-41.  
 
2. Herzog D, Poellinger A, Doellinger F, Schuermann D, Temmesfeld-Wollbrueck B, Froeling 
V, Schreiter NF, Neumann K, Hippenstiel S, Suttorp N, Hubner RH. Modifying Post-
Operative Medical Care after EBV Implant May Reduce Pneumothorax Incidence.  PLoS 
One.2015 May 26;10(5):e0128097. 
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 1 of 14   
Analysis Summary  
  
Study Title: Lung Function Improvement after Bronchoscopic Lung Volume Reduction with 
Pulmonx Endobronchial Valves used in Treatment of Emphysema (Clinical Protocol 630 -0012). 
  
Patient Population:  Male and female patients with severe heterogeneous emphysema meeting 
the study eligibility criteria. 
 
 
Study Design: This will be a multi -center, prospective, randomized, controlled study with EBV 
treatment statistically evaluated using Intent-to-Treat (ITT) analyses.  A maximum of 183 ITT 
study participants, who meet study entry criteria, consisting of screening eligibility criteria, baseline eligibility criteria, and procedure eligibility criteria, will be enrolled.  Safety and 
effectiveness of bronchoscopic lung volume reduction (BLVR) using the Pulmonx EBV will be 
evaluated at [ADDRESS_913705]-approval.  
  
Primary Effectiveness Endpoint  
The percentage of s tudy p articipants in the Endobronchial Valve ( EBV) t reatment arm who meet 
the threshold of > 15% improved forced expi[INVESTIGATOR_31737] (FEV 1) as compared to 
the c ontrol arm at [ADDRESS_913706]-procedure for individual study participants.    
  
Secondary Effectiveness Endpoints   
 1) Treatment Lobe Volume Reduction (TLVR) for the Treatment Arm  
a. TLVR, measured as the ‘ absolute change from baseline’ for treated lobe volume as 
seen via HRCT (high resolution computed tomography), will be evaluated at 45 days and 1 year.   
b. TLVR, measured as the ‘percentage change from baseline’ for treated lobe volume as seen via HRCT, will be evaluated at 45 days and 1 year.    
2) St. George’s Respi[INVESTIGATOR_6015]  
a. Difference between study arms in ‘absolute change from baseline’ for  SGRQ score 
at 1 year.      
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 2 of 14  3) FEV [ADDRESS_913707] will be evaluated by [CONTACT_675796]  ‘absolute change from baseline’ for  FEV [ADDRESS_913708] will be evaluated by [CONTACT_675796] ‘percentage change from baseline’ for FEV 1 at 45 days, 6 
months, and 1 year.   
 
4) 6-Minute Walk Distance (6MWD)  
a. Difference between study arms in ‘absolute change from baseline’ for 6MWD at 1 year.    
b. Difference between study arms in ‘percentage change from baseline’ for 6MWD at 1 year.   
  
Safety Endpoint   
Evaluation of the short- and long-term adverse events profile of the EBV treatment arm during 
the treatment period, defined as the day of the study procedure until 45 days after the study procedure (short), and in the post-treatment period, defined as 46 days after the study procedure until the 1-year follow -up visit (long).  
  
Additional  Measures  
• Spi[INVESTIGATOR_038] , including FEV 1, forced vital capacity (FVC) and the ratio of FEV 1/FVC   
• Body plethysmography, including residual volume (RV ), inspi[INVESTIGATOR_14008] (IC), functional residual 
capacity (FRC),TLC, and the ratios of RV/TLC  and IC/TLC   
• SGRQ global  and domain (ie. ‘symptoms’, ‘activity’  and ‘impacts on daily life’)  scores  
• Modified Medical Research Council (mMRC ) Dyspnea Scale Score  
• BODE Index  
• Transitional Dyspnea Index (TDI) from Baseline Dyspnea Index (BDI)  
• COPD Assessment Test (CAT)  
• SF-36 Health Survey score 
• EQ-5D Health Survey score 
• Health Care Utilization Questionnaire 
• 6MWD test  
• Borg scale dyspnea scores  before and after 6MWD test  
• Change in use of ‘maintenance’ medications, including bronchodilators, corticosteroids, 
antibiotics, and anti -inflammatories   
• Pulmonary rehabilitation compliance diary responses  
• EXACT -PRO diary  responses  
• Health  s tatus c hange responses  
• Carbon Monoxide Diffusing Capacity ( DLCO) 
• Lung radiographic features  
 
 
Interim Analysis  
An interim data analysis designed to evaluate effectiveness for continuing crossover of control 
arm study participants at 1 year to EBV treatment will be performed when 74 (50% of the total 147) study participants have completed the 1 year follow -up.  The interim analysis will be 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, [ADDRESS_913709] of FEV 1 and adverse events . 
  
Definition of Study Success:  The study will be a success if the difference between the EBV 
Treatment arm and Control  arm for the percentage of s tudy p articipants meeting the threshold 
of >15% improved in FEV 1 differs significantly (two-sided test at p< 0.05) in favor of the 
treatment group at [ADDRESS_913710]-randomization.  
  
Number of Study Participants : 183   
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, [ADDRESS_913711] deviations, medians, and confidence intervals will be reported for all 
continuous variables. Dichotomous variables will be reported as percentages and the numerator and denominator will be reported and defined. The frequency of adverse events  
will be reported as percentage rates with computed 95% two-sided exact confidenc e 
intervals (upper and lower). 
 
II.  Analyses of the Patient Populations   
These analyses are intended to determine the similarity of two treatment groups and similarity of patients from different study sites with respect to important demographic or other 
varia bles, either known or suspected to have an influence on the outcome variables.  The 
absence of similarity for any variable will identify that variable as a potential covariate in subsequent analyses.  
 
A. Comparability of Treatment Groups – To assess the success of the randomization 
process, the demographic and prognostic variables measured at study entry will be compared between the Treatment and Control arms .  Continuous variables will be 
compared with the two-sample t-test or the Wilcoxon two-sample rank test, and 
categorical variables will be compared with the Fisher’s exact test or a Chi-square 
test.  Comparability analyses will be done with two-sided tests with significance level 
of 0.05. 
 B. Study Site Comparability – The appropriateness of pooling the data across study 
sites will be determined on a clinical basis, i.e., to ascertain if the sites used a 
common protocol, the sponsor adequately monitored the study to assure protocol 
compliance, and the data gathering and validation mechanisms were the same 
across all study sites (Meinert, 1986). 
 
An analysis will be done to determine if the magnitude of the clinical effect of the 
primary outcome is maintained if sites and/or site by [CONTACT_675854].  We expect the majority of sites  will 
show the treatment to be beneficial but statistically one would not expect all sites to 
show the treatment to be beneficial.  For those sites with contrary results , an analysis 
will be attempted to determine what factors at those sites led to the result (See 
expert statistical testimony from Dispute Resolution Panel transcript September 6, 
2001).   
 
C. In study sites with small numbers of patients, it will not be possible to evaluate site or 
site by [CONTACT_9866].  The reason is that what may appear to be a site by [CONTACT_675855] a small numbers phenomenon.  For example , if there 
were only three patients from a given study site with one in the control group and two 
in the treated group, one success in each arm will appear to be a site by [CONTACT_412050] (100% success in the controls but 50% success in the treated arm).  Hence, study sites with fewer than three patients in either treatment arm will be 
combined into one or more pseudo-sites to allow the comparison to be done.  The size of any pseudo-site created in this way will not exceed the size of the study site with the largest enrollment.   
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 5 of 14  III.       Analyses Populations  
A. Geographic Cohort:  This study will be conducted at clinical sites  inside and outside 
the U.S.   
B. Endpoint Analyses:  Primary and secondary s tudy endpoints will be analyzed utilizing 
an intent-to- treat (ITT) population defined as all randomized patients analyzed by [CONTACT_675856] (EBV treatment or control ).  
Consenting patients who qualify for the study and are randomized into the study will 
be included in the ITT population, regardless of the actual treatment received. Consented patients  who are found not to meet the study eligibility criteria prior to 
randomization will not be included in the intent-to -treat group.  
C. Secondary  Analyses : Secondary analyses will  also be performed on the study 
primary and secondary endpoints on a Completed Cases (CC)  basis and Per -
Protocol (PP) basis. The CC population is defined as all randomized and eligible patients who received study -directed treatment and had 1 year  of follow -up. The PP 
population is defined as all randomized patients who meet study eligibility criteria, 
who were treated as randomly assigned, and had follow -up for the endpoints.  Any 
visits where protocol violations occurred will be reviewed for possible exclusion from impacted analyses.  
D. Safety Analysis Population:  Both t he ITT analysis population and ‘As Treated’ (AT) 
analysis population will be used to assess the safety data.   For the AT analysis, 
study participants will be analyzed based on the treatment they actually received.       
E. Secondary Valve Procedures:  If applicable, statistical analyses will also be 
conducted after sorting patients by [CONTACT_84810], specifically valve 
removal, valve replacement, and valve adjustment.     
 
IV. Effectiveness Analys es  
There is one primary effectiveness variable, four  secondary effectiveness variables, and 
several additional effectiveness variables .  
 
A. Analysis of the Primary Effectiveness Endpoint  
Both an interim and an end of study analysis for  the primary effectiveness endpoint are 
planned.  The primary effectiveness endpoint is  the difference between the EBV 
treatment arm and control arm in percentage of study participants who reach a threshold 
of >15% improved FEV 1, collected post-bronchodilator, at 1 year  (see Table 1) .  The 
FEV [ADDRESS_913712]-procedure using:  ((FEV 1 at 1 year follow -up subtracted from 
FEV 1 at baseline) / FEV 1 at baseline)) for individual study participants.  The two arms will 
be compared using the standard normal Z-statistic.     
  
Table 1.  Primary Effectiveness Endpoint  
Variable  Unit Values Statistically Evaluated  
Forced Expi[INVESTIGATOR_117067] (FEV 1) >15% improved  percentage of participants  
 An interim data analysis designed to evaluate effectiveness for continuing crossover of 
control  arm study participants at the 1 year follow-up to EBV treatment will be performed 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 6 of 14  when 74 (50% of the total 147)  study participants have completed the 1 year follow -up.  
The interim analysis will be reviewed by [CONTACT_4318].   
 To account for the interim analysis, the power spending function, defined as :  
φα αt t=) (  
will be  used to preserve an overall type I error rate of 0.05 for the study.  Using the 
nTerim program (Statistical Solutions) to calculate the power spending function with:    
α=.05, φ=2.3  and t=.5, ) (tα =.01, 
the value of the Z-statistic must exceed 2.571 (nominal alpha <0.01) for the null 
hypothesis to be rejected at this interim look  (see Table 2 ).   
 
Table 2.  Power Spending Function for Interim Analysis  
Looks 1 2 
Time  0.5 1 
Lower Bound  -2.[ZIP_CODE]  -2.[ZIP_CODE]  
Upper Bound  2.[ZIP_CODE]  2.[ZIP_CODE]  
Nominal Alpha  0.[ZIP_CODE]  0.[ZIP_CODE]  
Incremental Alpha  0.[ZIP_CODE]  0.[ZIP_CODE]  
Cumulative Alpha  0.[ZIP_CODE]  0.0500  
Exit Probability  38.75  50.52  
Cumulative Exit Probability  38.75  89.28  
 
If Z>2.571 then continuing crossover of control arm study participants will be strongly 
justified since the p-value will be < 0.01.  This observation may provide evidence to stop 
the trial early.   
 The study hypothesis will be tested again at the end of the study.  The Z-statistic will be 
calculated again, and by [CONTACT_675857], will have a final critical boundary value of 2.004, per the nTer im program.  If the trial is not stopped as a result of 
the interim analysis , then the final Z-statistic must be greater than or equal to 2.[ADDRESS_913713]  the null hypothesis at the final analysis  (at the overall 2-sided 5% 
significance level ).  Test statistic is “Z” as defined as :   
Z = 



+ −−
C TC T
n np pp p
1 1) 1 ( 
 Where,  
Tpand Cpare the proportions of success for the primary endpoint in the treatment and 
control groups, respectively , p is the pooled estimate of the success rate, and  
Tnand Cn are the sample sizes obtained in the treatment and control groups, 
respectively.  Two sets of ( p,Tp,Cp, Tn,Cn) will be  obtained:  one at the interim 
analysis and one at end of the study.   
 
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 7 of 14   
B.  Analysis of the Secondary Effectiveness Endpoints 
 
a. Treatment Lobe Volume Reduction for the Study Treatment Arm   
i. TLVR measured as the ‘ absolute change from baseline’ in treated lobe 
volume as seen via HRCT (high resolution computed tomography), will be 
evaluated at 45 days. TLVR will be calculated for each study participant 
using: (treatment lobe volume at 45 days  follow -up subtracted from the 
treatment lobe volume at baseline).  Descriptive statistics will be 
calculated for the study treatment arm and will include the mean, 
standard deviation and 95% confidence interval.  A one-sample t-statistic 
will be used to quantify the magnitude of the difference. 
ii. TLVR measured as the ‘ percentage change from baseline’ in treated lobe 
volume as seen via HRCT, will be evaluated at 45 days.  TLVR will be 
calculated for each study participant using: (treatment lobe volume at 45 
days follow -up subtracted from the treatment lobe volume at baseline 
divided by [CONTACT_675858]).  Descriptive statistics will 
be calculated for the study treatment arm and will include the mean, standard deviation and 95% confidence interval.  A one-sa mple t-statistic 
will be used to quantify the magnitude of the difference. 
iii. TLVR measured as the ‘absolute change from baseline’ in treated lobe 
volume as seen via HRCT (high resolution computed tomography), will be 
evaluated at 1 year. TLVR will be calculated for each study participant using: (treatment lobe volume at 1 year  follow -up subtracted from the 
treatment lobe volume at baseline).  Descriptive statistics will be calculated for the study treatment arm and will include the mean, 
standard deviation and 95% confidence interval.  A one-sample t-statistic 
will be used to quantify the magnitude of the difference. 
iv. TLVR measured as the ‘percentage change from baseline’ in treated lobe volume as seen via HRCT, will be evaluated at 1 year.  TLVR will be 
calcul ated for each study participant using: (treatment lobe volume at 1 
year follow -up subtracted from the treatment lobe volume at baseline 
divided by [CONTACT_675858]).  Descriptive statistics will be calculated for the study treatment arm and will include the mean, standard deviation and 95% confidence interval.  A one-sample t-statistic will be used to quantify the magnitude of the difference.  
 
b. St. George’s Respi[INVESTIGATOR_6015] ( SGRQ)   
i. Difference between study arms in ‘absolute change from baseline’ for  
SGRQ score at [ADDRESS_913714] 
deviations and 95% confidence intervals. A two  sample t-statistic will be 
used to quantify the magnitude of the difference between study groups. 
ii. Difference between study arms in ‘ percentage change from baseline’ for 
SGRQ score at [ADDRESS_913715] 
deviations and 95% confidence intervals. A two sample t-statistic will be used to quantify the magnitude of the difference between study groups. 
 
  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, [ADDRESS_913716] will be evaluated by [CONTACT_675760]  ‘absolute change from baseline’ for 
FEV 1 at 45 days, 6 months, and 1 year. The FEV 1 value will be calculated 
using: ((FEV 1 at each of the follow-up time points ) subtracted from (FEV 1 
at baseline))  for individual study participants to determine the mean 
absolute change for each study arm .  At each of the three time points, 
descriptive statistics will include means, standard deviations and 95% confidence intervals .  A two-sample t-statistic will be used to quantify the 
magnitude of the difference between study groups . A repeated-measures 
model  (GEE with an identity  link function and exchangeable correlation 
structure) will be used to model the entire time course of outcomes as a 
function of baseline value and a main effect indicating treatment group 
membership.  
ii. Persistence of the treatment effect will be evaluated by [CONTACT_675859] ‘ percentage change from baseline’ for 
FEV1 at 45 days, 6 months, and 1 year. The FEV
1 values will be 
calculated using: ((FEV 1 at each of the follow-up times ) subtracted from 
(FEV 1 at baseline divided by [CONTACT_10266] 1 at baseline)) for individual study 
participants to determine the mean absolute change for each study arm.  At each of the three time points, descriptive statistics will include means, standard deviations and 95% confidence intervals.  A tw o-sample t-
statistic will be used to quantify the magnitude of the difference between study groups. A repeated-measures model (GEE with an identity link function and exchangeable correlation structure) will be used to model the entire time course of outcomes as a function of baseline value and a main effect indicating treatment group membership. 
 
d. 6-M inute Walk D istance (6MWD)  
i. Difference between study arms in ‘absolute change from baseline’ for 6MWD at [ADDRESS_913717] deviations and 95% confidence intervals. A two sample t-statistic will be 
used to quantify the magnitude of the difference between study groups. 
ii. Difference between study arms in ‘ percentage change from baseline’ for 
6MWD at [ADDRESS_913718] 
deviations and 95% confidence intervals. A two sample t-statistic will be used to quantify the magnitude of the difference between study groups.  
e. The secondary effectiveness endpoints are summarized in Table 3.   
 
Table 3. Secondary Effectiveness Endpoints  
Variable  Unit Values Statistically Assessed  
Target Lobe Volume Reduction 
(TLVR)  milliliters  mean absolute  change  
TLVR  percent  mean percent change  
SGRQ Global Score  Points  mean absolute change  
SGRQ  percent  mean percent change  
FEV 1 Liters mean absolute change  
FEV 1 percent  mean percent change  
6-Minute Walk Distance  Meters  mean absolute change  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 9 of 14  6MWD  percent  mean percent change  
  
C. Analysis of Additional Effectiveness Endpoints   
 
a. Supporting Evidence for Effectiveness  
 
The following additional effectiveness endpoints will be  measured for  both study 
arms .  These are expected to provide supporting evidence of the effectiveness of 
EBV treatment. Results will be described with summary statistics. These endpoints will be described for each study arm separately and comparatively between arms  by [CONTACT_675860], 
whichever is appropriate for the variable being analyzed.  The definitions for these  additional effectiveness endpoints are shown in Table 4.   
 
Table 4.  Additional Effectiveness Endpoints  
Spi[INVESTIGATOR_675741] 1 >12% 
improved  Percentage of participants  
Forced Vital Capacity ( FVC) liters  mean absolute and percent change  
FEV 1/FVC  ratio mean absolute change  
DLCO percentage  mean absolute and percent change  
 
Body Plesthysmography Measures  
Residual Volume (RV)  liters  mean absolute and percent change  
Inspi[INVESTIGATOR_10226] (IC)  liters  mean absolute and percent change  
Functional Residual Capacity 
(FRC)   mean absolute and percent change  
Total Lung Capacity (TLC)  liters  mean absolute and percent change  
RV/TLC  ratio mean absolute change  
IC/TLC  ratio mean absolute change  
 
Patient-Reported Health Status Measures  
SGRQ Global Score  >4 points improved  percent age of 
participants  
 >8 points improved  percent age of 
participants  
SGRQ Domain Scores    
   ‘Symptoms’  points  mean absolute change  
   ‘Activity’  points  mean absolute change  
   ‘Impacts Daily Life’  points  mean absolute change  
mMRC  Score  semi -quantitative 
scale score  mean absolute change  
COPD Assessment Test (CAT)  points  mean absolute change  
Transitional Dyspnea Index (TDI)  points  mean absolute change  
 <1 point improved  percent of participants  
Short Form (SF) -36 Health 
Survey  points  mean absolute change  
EQ-5D Health Survey  points  mean absolute change  
 
Other Measures  
BODE Index  semi -quantitative  scale 
score  mean absolute change  
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 10 of 14   <1, 0, >1 change  percent age of 
participants  
6MWD – subjects stratified by 
[CONTACT_675861]  
 >25 meters  improved  percent age of 
participants  
 >54 meters  improved  percent age of 
participants  
Borg Scale Dyspnea Score:  
Before 6MWD test  semi -quantitative scale 
score  mean absolute change  
Borg Scale Dyspnea Score:   
After 6MWD test  semi -quantitative scale 
score  mean absolute change  
 
 
b. Informational Purposes:  
The following additional effectiveness endpoints will be  measured in both 
treatment groups for informational  purposes. Results will be described with 
summary statistics  (see Table 5) . These endpoints will be described for each 
treatment group separately and comparatively between groups by [CONTACT_675862], whichever is appropriate for the variable being analyzed. 
   
 
Table 5.  Informational Variables  
Variable  Unit Values Statistically 
Assessed  
Maintenance Medications    
   Bronchodilators  change in medication regimen  percent age of participants  
   Corticosteroids  change in medication regimen  percent age of participants  
   Antibiotics  change in medication regimen  percent age of participants  
   Anti-Inflammatories  change in medication regimen  percent age of participants  
Pulmonary Rehabilitation 
Compliance Diary  reported adherence to 
program  percent age of participants  
   Adherence to program  number of  sessions / week  mean absolute number  
   Intensity of program  length of reported sessions  mean absolute number  
EXACT -PRO Diary Entries  points  mean absolute number  
Health Utilization  
Measures  frequency of use  percentage of participants  
Lung Radiographic 
Features    
   TLVR  volumetric change  mean percentage change  
   valve occlusion   qualitative assessment  percent age of participants  
   inter-lobar fissures  percent complete  percent age of participants  
  
V. Adjustment for Potential Confounders  
The covariates shown in Table [ADDRESS_913719] to the 
effectiveness endpoints .  If any of these covariates are found to be out of balance between 
the groups  (at the two-sided 0.10 level), they will be included in a multivariate analysis, 
along with an indicator of treatment group, to evaluate their potential effect on the study conclusions.   A multivariate logistic regression model will be used.  
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 11 of 14  Table 6.  Covariates  
 Baseline  Procedure  Follow-Up 
Gender  X   
Age X   
Clinical Site  X   
6MWD  X   
Patient -reported health status measures  (e.g. SGRQ)  X   
Body Mass Index  X   
BODE Index  X   
Medication Use  X   
Residual Volume (RV)  X   
RV % Predicted  X   
Total Lung Capacity (TLC)  X   
TLC %  Predicted  X   
RV/TLC  X   
IC/TLC  X   
Vital Capacity  X   
Forced Vital Capacity (FVC)  X   
FVC % Predicted  X   
FEV 1 X   
FEV 1 % Predicted  X   
FEV 1 / FVC  X   
Lobar Volume  X   
Lobar Destruction Scores  X   
Ipsilateral DS Heterogeneity  X   
Severity of  emphysema (GOLD classification)  X   
Co-Morbidities  X   
Target Treatment Lobe   X  
Treatment Group   X  
Target Lobe Volume Reduction    X 
Lobar Occlusion    X 
 
     
VI. Secondary Valve Procedures  
Secondary valve procedures will be evaluated by [CONTACT_675863], valve replacement, or  valve adjustment, and describing the reasons 
they occurred.  Data for these study participants will be contrasted to data for study participants who did not receive a secondary valve procedure.  
  
VII. Safety Analyses  Evaluation of the short- and long-term adverse events profile of the EBV treatment arm 
during the treatment period, defined as the day of the study procedure until 45 days after the 
study procedure (short), and in the post-treatment period, defined as 46 days after the study procedure until the 1-year follow -up visit (long).  Safety analyses will be performed by  
[CONTACT_675864].  
The rates and 95% exact confidence intervals will be presented on an event and on a per -
patient basis.   
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 12 of 14  Adverse events will be categorized into clinically relevant groups ( e.g.:  stable 
pneumothorax with no intervention, pneumothorax resolved with chest tube insertion in less 
than 7 days, prolonged air leak, etc.).  Adverse events  occurring in the treatment arm will be 
further categorized by [CONTACT_675865] -related, p rocedure-related, or neither , and by 
[CONTACT_675866][INVESTIGATOR_675742]- discharge.  
Rehospi[INVESTIGATOR_675743] a Per-Patient (PPt) basis and on a 
Per-Event (PE) basis.  In study participants who receive EBV treatment, adverse events will be evaluated by [CONTACT_675867].   
 
VIII. Mortality  
A Kaplan-Meier survival curve  for each study arm will graphically display  the time to 
death from the time of randomization and a log rank test will be used to compare 
Kaplan-Meier curves between study arms.  A Cox proportional hazards model will be 
used to control for study site along with other significant co-variates as appli cable. 
 
IX.      Patient Accountability and Missing Data 
Every effort will be made to collect all data points in the study. The sponsor plans to minimize the amount of missing data by [CONTACT_675868], proper screening of study subjects, and training of participating investigators, monitors and study coordinators.   
 
The analysis for the primary endpoint will be performed by [CONTACT_675869]. For study participant FEV
1 data that is ‘intermittent’, missing outcomes will be imputed by 
[CONTACT_675870] [ADDRESS_913720] non-missed data point after the missed data point. 
For study participants  with truncated data (e.g. participants  who drop out or are lost to 
follow -up), a multiple imputation strategy will be performed using the propensity score 
method. In brief, for a particular outcome, the propensities for study participants  to have 
missing data (for each treatment group separately), modeled by [CONTACT_51621], are 
grouped into strata based on percentiles of the logistic propensity score model. Within a 
stratum, a study participant with a missing observation has an imputed value assigned 
by [CONTACT_357606] a value from among the study participants  in the same stratum 
with non-missing observations. This procedure will be repeated 20 times on the entire 
dataset, resulting in 20 different ‘complete’ datasets allowing for estimation of the effect on the outcome of interest, accounting for missing data.   
An additional analysis for the primary endpoint will be performed based on not imputing 
data.  All partial data that is available on subjects who drop out during the course of the study will be included.  In addition, sensitivity analyses such as worse-case or best-case imputation will be performed although it is recognized that they are biased.    
X.      Comparison of Crossed-Over Control versus Study Treatment Outcomes  
a. Effectiveness Outcomes  
 
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, 2017   Page 13 of 14  Table 7.  Effectiveness Endpoints for Control Arm Crossovers   
(comparison based on paired Control versus EB V Treatment differences)   
Variable  Unit Values Statistically Evaluated  
Forced Expi[INVESTIGATOR_117067] (FEV 1) >15% improved  percentage of participants  
     FEV 1 Liters  mean absolute change  
     FEV 1 percent  mean percent change  
SGRQ Global Score  Points  mean absolute change  
mMRC Score  semi -quantitative 
scale score  mean absolute change  
6-Minute Walk Distance  Meters  mean absolute change  
     6MWD – subjects stratified by 
[CONTACT_675861]  
     6MWD  >25 meters  
improved  percent age of participants  
DLCO percentage  mean absolute and percent change  
Residual Volume (RV)  liters  mean absolute and percent change  
Inspi[INVESTIGATOR_10226] (IC)  liters  mean absolute and percent change  
Total Lung Capacity (TLC)  liters  mean absolute and percent change  
RV/TLC  ratio mean absolute change  
IC/TLC  ratio mean absolute change  
   
   
 
The time-course of outcomes will be described. A paired t-test statistic will be used to 
quantify the magnitude of the difference between treatment modalities for the quantitative outcomes. For binary outcomes, a McNemar test-statistic  will be used to 
quantify the magnitude of the difference between the two treatment modalities.  
 
b.  Safety Outcomes  
Evaluation of the short- and long-term adverse events profile of crossed -over 
participants during the second year of follow -up, when they have the EBV treatment, will 
be assessed as in Section VII above. Additionally, the time-course of occurrence of Serious Adverse Events (SAEs) will be contrasted and compared for  the first year 
(Control Treatment) versus second year (EBV Treatment) periods. For those SAEs that 
could occur with either Control or EBV Treatment, a McNemar test-statistic will be used 
to quantify the magnitude of the difference between the two treatment modalities.  
 
XI. Randomization  Assignment Method 
Study p articipants who are determined to meet screening, baseline, and procedure 
eligibility criteria will be randomly assigned to Study Treatment ( EBV or C ontrol ).  Random 
assignment will be performed using a stratified permuted block design, generated 
separately for each clinical site, with  assignment stratified by [CONTACT_675871] (e.g. right lung or left lung).  Mixed block sizes will be used. 
 
XII. Device Malfunction Analyses  
Results of any device malfunctions and their sequelae are to be presented descriptively.  
The rate and exact 95% confidence intervals will be computed.   
LIBERATE Study  
Clinical Investigational Plan #630 -0012-H 
Appendix 19.  Statistical Analysis Plan   
 
Version:  June 23, [ADDRESS_913721].    
  
 
References  
 
1. Meinert, C. (1986). Clinical Trials: Design, Conduct, and Analysis .  Oxford University Press, 
[LOCATION_001]. 
 
2. Medical Devices Dispute Resolution Panel Meeting of September 6, 2001 (Panel 
Transcript) 
 
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 1 of 16 
 
  
Investigator Name: ________________  Site ID#___________________ 
Institution: _______________________  Participant ID: ______________ ________________________________ 
________________________________  Telephone: _________________ 
 
Dear Patient:  
 
You are be ing asked to participate in the tr eatment portion of the LI BERATE study because  you have 
an impaired lifestyle as a result of emphy sema, have success fully completed one year of participation 
in the con trol arm of t he study and  still meet the eligibility requirem ents.  Emphy sema is a se rious 
disease that afflicts more t han four million people worldwide.  It is one form of Chronic Obs tructive 
Pulmonary Di sease, or COPD.  Emphysema causes  the lungs to lose t he ability to move air in and  
out normally and to efficiently absorb oxygen, making br eathing more 
difficult. What you should know about a r esearch study: 
• Someone w ill explain this r esearch study to you. 
• You volunt eer to be in a r esearch study. 
• Whether you take part is up to you. 
• You can  choose not to take part in the r esearch study. 
• You can  agree to take pa rt now and later change your mind. 
• Whatev er you decide, it will not affect your care. 
• Feel free to ask all the questions you w ant before and after you decide. 
 Purpose of the Study  
The purpose of this r esearch 
 is to study a m edical device that is designed to be placed by a doctor in a 
diseased section of t he lungs.  This devi ce is called the Pulmonx Endobr onchial Valve (EBV).  The 
EBV is a one-w ay valve that blocks off the di seased lung section to inhal ed air but lets the trapped air 
already inside the area escape.   With placement of the EBV, the diseased part of t he lung collapses; 
this allows the healthier parts of the lung to expand.   The aim of the EBV treatment is to help 
someone with emphy sema breathe more easily by [CONTACT_675872]
r.  This r esearch study is designed to investigate the safety and effectiveness of the Pulmonx 
EBV for treating emphy sema symptom s. 
The EBV is consi dered experimental.  This m eans that it has not yet been approved by [CONTACT_941] U.S. FD A 
(Food and  Drug Administration) for commercial use in the Unit ed States. 
Since you have  successfully completed the 1-year visit, you m ay consider cr ossover to the study 
treatment. In or der to qualify for crossover, you must have been followed up successfully through [ADDRESS_913722] udy schedu le for 
treatment arm pa rticipants. 
 
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, [ADDRESS_913723] EB V implanted in your lungs.  The study doctor w ill make the final 
determination of your e ligibility during the bronchoscopy pr ocedure.  If you are found to be e ligible to 
participate in the cross- over portion of the study, you will receive EBV . 
 
Blood Gas (PaO2 and PaCO2) and Blood Chemistry Analysis 
A blood sample will be taken to measure the amount of oxygen and carbon dioxide in the sample.  
This blood sample will need to be taken from an artery (as opposed to a vein).  An arterial blood sample may be mo re painful than a venous blood sample, which is usually done for more routine 
blood samples.  Standard compounds and the number of blood cells will also be measured from the blood sample.  You must have stopped smoking for at least [ADDRESS_913724].  
 
Lung Function Tests  
Spi[INVESTIGATOR_038]: During the test, you will be asked to breathe in and out of a mouthpi[INVESTIGATOR_675707] a machine 
measures the amount of air you are breathing into and out of your lungs.  These breathing maneuvers 
may be somewhat difficult and you may be come tired  during the test but you will be allowed to rest 
periodically.   
 
Plethysmography : This test is used to determine how much air you can hold in your lungs.  You will 
sit in a small box, comparable to the size of a telephone booth, to undergo breathing tests similar to 
those described above. There is a chance that y ou may experience claustrophobia in addition to 
fatigue.  
 
Diffusing Capacity :  This test is used to measure the ability o f your lungs to transfer carbon 
monoxide.  You will be asked to breathe a mixture of helium, oxygen, nitrogen and carbon 
monoxide and hold your breath for 10 seconds.  
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, [ADDRESS_913725] (High Resolution Computed Tomography) of Chest 
You will be asked to lie down on your back on an x- ray table that will slide into a large, tunnel -
shaped machine.  You must not move during the test and will be asked to relax and breathe 
normally. The technician will also ask you to do some breathing mane uvers such as take a deep 
breath in or out.    
Pregnancy Test  
If you are a woman of child-bearing potential, a urine or blood pregnancy test may be performed.  
Six Minute Walk Test  
You will be asked to walk back and forth between a start and end point as many times as possible 
within [ADDRESS_913726] y ou will be 
asked questions about how breathless  you feel you are.  
 
Questionnaires  
During the study, you will be asked to complete a few simple questionnaires. These questionnaires 
will ask you about your daily activities and your opi[INVESTIGATOR_675719]. You will also be asked about frequency of visits to health care providers, such as your regular 
physician, emergent care facilities, and the hospi[INVESTIGATOR_307].  
 Pulmonary Rehabilitation Program—to be Eligible for the Study  
In order to participate in th e cross-over portion of the study, you will have to :   
• Be regularly performing maintenance respi[INVESTIGATOR_248688] .   
 
Description of the Bronchoscopy  Procedure  
During the bronchoscopy procedure, your physician will measure some of the airways  in your lungs 
using a device called the Chartis ® Pulmonary Assessment System .  This system is designed to measure 
air pressure and flow in lung airways.  The air pressure and flow measurements that are collected using the Chartis System will help the physician decide if you are eligible to potentially have the EBV 
treatment. Your physician will plan t he areas that will be measured before the day of the bronchoscopy 
procedure using the results of your CT scan.      
 
If you are found to have air pressure and flow measurements that show you are NOT eligible to receive 
the EBV treatment , your physician and his or her team will stop the bronchoscopy procedure and you 
will not receive any further treatment during the bronchoscopy procedure.  
 If you are found to have air pressure and flow measurements that show you are eligible to receive the 
EBV treatment, you will have the EBV treatment.    
In rare instances, fluoroscopy m ay be used by [CONTACT_675873]/her to see your 
lung structures and anatomy using t he bronchoscope alone. Fluoroscopy is making a moving pi[INVESTIGATOR_675744] x-ray s. 
 
Personnel from the study sponsor (Pulmonx) will attend your bronchoscopy procedure.  The doctor’s view of the procedure (the inside of your lung) may also be videotaped or photographed.    
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 4 of 16 
 
  
Description of the Study Procedure  
 
The EBV Procedure 
A bronchoscope (a tube with a camera at the tip, connected to a monitor) will be guided down an access 
tube all the way to the point where the EBV  will be placed.  Once your physician can clearly see t he area 
where the EBV will be placed, he or she will guide a catheter (flexible tube) , with the EBV attached,  to 
the targeted treatment area.  Once the catheter  is in the proper position, he or she will implant the EBV 
in the lung. This may be done several times depending upon how many EBV  are to be placed in your 
lungs.    If there is a problem with the EBV at any time during or after the procedure that makes it difficult or 
inappropriate to continue with the study, your physician may remove the EBV .  In some cases, if the 
EBV is removed, it can be replaced.  In rare cases, the EBV may not have been placed in the original 
procedure as it wa s intended to be (to completely stop the airflow from the damaged part of the lung).  
This may initiate a discussion be tween you and your physician about having another procedure to adjust 
the placement  of the EBV .    
 After the Bronchoscopy Procedure  
After the procedure, you will be taken to a recovery area of the hospi[INVESTIGATOR_307].  If you are found to not be eligible for the study, you will be allowed to go home a few hours after the bronchoscopy procedure.  I f 
you had EBV placed , it is anticipated that you will remain in the hospi[INVESTIGATOR_34092] [ADDRESS_913727] x-ray to confirm you are 
not experiencing any complications .  Your study physician  may keep you in the hospi[INVESTIGATOR_675721]/she 
feels your health need s further monitoring.  
 If you received the EBV, a chest x -ray will be taken at [ADDRESS_913728] to 
give to any physician that may need to treat you informing him/her of the pneumothorax risk.  Additionally, you will be given post-discharge instructions by [CONTACT_675874].   
After Discharge  
 
You will return to your study physician’s office [ADDRESS_913729] x -ray will be taken of your lungs at this time.   At this visit, the study doctor will 
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, [ADDRESS_913730] for emphysema treatment and some are not.   
 
            
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 6 of 16 
 
 Table 1:  List of Tests/Assessments 
 
+ Pulmonary rehabilitation starts within [ADDRESS_913731]-bronchoscopy pulmonary 
rehabilitation program; * all of this testing but the CT scan were obtained at your 1 -year follow -up visit as a control; + X• serum fibrinogen and ABG on ly at day 1 hospi[INVESTIGATOR_4408], ‡for 
study participants who have a study procedure (valve) adjustment, a CT scan, chest x -ray, and body plethysmography will be collected at [ADDRESS_913732] or Assessment 
Baseline 
Eligibility & 
Assessme nt* 
Day 0 
Index- 
procedure 
 
Days 1-4 
Hospi[INVESTIGATOR_675745] 5 (or 
day of 
Discharge ) 
Daily phone 
contact [CONTACT_46431] 
10 days* 
 
7 Days after 
Discharge 
 
30 Days 
 
45 days 
 
3 months 
 
6 months 
 
9 months 
 
1 year 
Annual 
visits 
(2-5 years) 
 
Early 
Terminatio n 
Visit 
Vital Signs / Physical Exam X X  X  X X X X X  X  X 
Medications & Events Review X      X X X X X X  X 
Blood Work X  X•         X   
Arterial blood gases X  X•         X   
Pulse oximetry 24 hours after 
procedure    
X            
Spi[INVESTIGATOR_038] X       X  X  X X X 
Body Plethysmography X       X X‡   X   
Diffusing Capacity X       X    X   
Symptom checklist     X X         
[ADDRESS_913733] scan X       X X‡   X   
Chest x-ray  X X X  X X X X‡      
Electrocardiography  X           X   
Pulmonary rehab compliance X       X X X X X   
Pulmonary rehabilitation      X+         
Health status change X  X X X   X X X X X   
Adverse events  X X X X X X X X X X X X X 
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, [ADDRESS_913734] treatment for emphysema patients.   The EBV was previously 
tested in the [LOCATION_002] with a large study that included four hundred ninety-two (492) patients from both the [LOCATION_002] and Europe.  The results of this large (VENT) study are discussed below. 
The Endobronchial Valve for Em physema Palliation Trial (VENT study) was a multi- center, prospective, 
randomized, controlled study conducted in the [LOCATION_002] and Europe to evaluate safety and 
effectiveness of endobronchial valve treatment (along with optimal medical management) comp ared to 
optimal medical management alone (control group).  In the U.S. study, the endobronchial valve treatment was found to improve forced expi[INVESTIGATOR_31737] (FEV
1) by [CONTACT_675828] 6.8% and 
the [ADDRESS_913735] results by [CONTACT_675875] 5.8%.  These results were significantly better 
than the results seen with medical management alone.   The European patients had similar results.   
After the VENT study was finished, the data was further analyzed.  We found that patients who showed signs that the airflow in some parts of their lungs could be blocked off, had the best results with the EBV and procedure.  For the study you are considering taking part in, we are planning to select patients who show these same signs BEFORE they  have the study treatment.  This will be done using the Chartis System 
during the bronchoscopy procedure.  At the end of the study, we will then compare the results of the EBV treatment to the control treatment.   
 In the VENT study, some adverse events were seen. The type of major adverse events and the percentage of patients who had them are shown below:    Table 2.  Adverse events that were seen through 90 days in the EBV Treatment Group in VENT Study  
 
Event % of 
Patients  
COPD exacerbation (without hospi[INVESTIGATOR_059])  7.9% 
   COPD exacerbation (with hospi[INVESTIGATOR_059])  1.4% 
Hemoptysis (coughing up any amount of blood)   5.6% 
   Massive Hemoptysis (coughing up a large amount of blood)  0.5% 
Valve expectoration, aspi[INVESTIGATOR_1516], migration (valve moved from the place it was put by 
[CONTACT_099])  4.7% 
Pneumonia  2.3% 
   Pneumonia (distal, or behind, the valve)  0.9% 
Formation of bronchial granulation (scab -like) tissue with valve  2.3% 
Pulmonary infection (infection in the lung)  1.9% 
Respi[INVESTIGATOR_1399] (poor lung function --too much carbon dioxide or too little oxygen in 
your blood-- where you need to have assistance with breathing using a mechanical 
ventilator)  1.4% 
Pneumothorax (air leak in the lung)  that required  treatment for more than 7 days  1.4% 
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 8 of 16 
 
 Pneumothorax (air leak in the lung) that expanded, or got larger  1.4% 
Pneumothorax (air leak in the lung) that was stable, or stayed the same size  1.4% 
Hypoxemia (decreased oxygen in the blood)  1.4% 
Hypercapnia  (excess carbon dioxide in the blood)  0.9% 
Death 0.9% 
Noncardiac chest pain  0.5% 
Bronchial (airway) trauma  0.5% 
 
Removal of the EBV in the VENT Study  
In some instances, patients enrolled in the valve treatment study group who experienced an adverse event required that the valves be removed.  In the U.S. VENT study, 31 (14.5%) patients had valve(s) removed after the procedure. The reasons for removal included:  valve migration, pneumonia, bleeding (hemoptysis), granulation, increased dyspnea (breathlessness), continuing COPD exacerbations, and patient request.      
 Alternative Treatments for Emphysema  
Oxygen, drug therapy, nutrition and lifestyle changes are the standard therapi[INVESTIGATOR_675746].   An additional alternative treatment may be Lung Volume Reduction Surgery (LVRS).   
 Summary of Benefits a nd Risks of Participation in the LIBERATE  Study 
As the EBV is still an investigational devic e in the [LOCATION_002] , the actual benefits and risks are 
unknown at this time.  The investigators may learn from this study whether the EBV treatment and 
procedure is safe and effective.  There may or may not be direct benefit from your participation in this study.   
Potential Benefits  
Potential benefits you may experience as a participant in the cross -over portion of the study include 
having improved lung function and other improvements that may be associated with improved lung 
function, such as improved quality of life.    
 
Potential Risks  
The primary risks associated with use of the Pulmonx EBV are similar to other bronchoscopic and 
surgical procedures used to treat emphysema.  These are listed below.  While this list is comprehensive, 
there may be other risks that are still unknown.  The close monitoring that you will receive, as part of the study, should allow for detection of symptoms, should they be present.  This, in turn, should allow for early intervention by [CONTACT_675876].  Y our physician will review all of the risks 
below with you so that you understand them.    Previous c linical trial experience and experience from  other countries around the world, where the EBV 
device is commercially available, has shown that in some people EBV treatment is associated with having a pneumothorax as a potential complication . A pneumothorax is a condition in which air  leaks 
from the lung into the space between the lung and chest wall.  This prevents the healthy lung from 
working well and can cause chest pain and shortness of breath.  As many as 1 in 3 patients may 
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, [ADDRESS_913736] 
frequently, a treatment using a small tube to drain out the air is required.  In rare cases, a pneumothorax 
may require a surgical intervention.  In addition, there is a chance that it can  be a serious and life-
threatening complication.    
 
Specifically in this study, the observed rate of pneumothorax events for patients treated with valves to 
date (16 June 2017) is 58 events out of 159 patients ( 36%).  Forty-six (46) of the 58 pneumothorax 
events (79%) occurred during the first [ADDRESS_913737] year for patients treated with valves in the LIBER ATE 
Study is 5 events out of 128 patients ( 3.9%). In 2 cases, the patient had a “Do Not Resuscitate” (DNR) 
directive in place that prevented potential life -saving interventions by [CONTACT_88235]. 
 Based on new information gained from this study so far, if the valve is not placed in the most diseased area of your lung, there is a higher risk that you could experience a pneumothorax that may require surgical intervention or that could be serious and life threatening. Your physician will discuss with you the area of the lung that will be treated so that you can understand whether you are at a higher risk of experiencing such an event.  
 Potential Risks (Adverse Events )  
Acute bronchitis (inflammation or infection of the airways)  
Acute bronchospasm (spasm of the  airway; may result in wheezing or increased shortness of breath)  
Acute respi[INVESTIGATOR_1505] (sudden, severe injury to lungs)  
Airway blockage due to implant migration  
Airway perforation (hole in the airway wall)  
Airway stenosis (narrowing)  
Anxiety 
Aphonia (difficulty talking)  
Aspi[INVESTIGATOR_1516] (inhalation of vomit)  
Bowel function impairment  
Bronchial (airway) trauma or ulceration  
Chest pain  
COPD exacerbation (acute worsening of COPD symptoms)  
Death 
Depression  
Deep Vein Thromboembolism (DVT, blood clot)  
Dysphonia (hoarse or rough sounding voice)  
Empyema (presence of pus)  
Fever 
Formation of bronchial granulation (scab-like) tissue  near the valve(s)  
Fractured Rib  
Headache  
Heart arrhythmias (irregular heartbeats)  
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 10 of 16 
 
 Heart Attack  
Heart failure (heart function is impaired;  could result in increased breathlessness or fluid retention)  
Hemoptysis (coughing up blood)  
Hemothorax (accumulation of blood between the lungs and the chest wall  
Iatrogenic injuries (injury caused by [CONTACT_675829])  
Impaired lung function  
Increased cough  
Increased dyspnea (shortness of breath)  
Increased hypercapnea (excess carbon dioxide in the blood)  
Increased hypoxemia  (decreased oxygen in the blood ) 
Infection  
Laryngospasm (throat spasm)  
Lethargy and disorientation  
Lung cancer or lung mass  
Nausea 
Pleural effusion (collection of fluid around the lungs)  
Pleuritis (inflammation of chest lining)  
Pneumonia  
Pneumothorax (air leak in the lung)  
Pulmonary shunting (uneven blood flow through the lung) 
Pulmonary embolism (a blood clot in the lung which can lead to chest pain and shortness of breath)  
Respi[INVESTIGATOR_1399] (poor lung function ; could require you to have  assistance with breathing using a 
mechanical ventilator)  
Septicemia ( severe infection) 
Stroke or Transient Ischemic Attack (sudden temporary loss of neurological function)  
Valve expectoration, aspi[INVESTIGATOR_1516], or migration ( valve moves from the place it was put by [CONTACT_271519])  
Vomiting  
Wheeze or whistling of valve  
 
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 11 of 16 
 
 Other Potential Risks of Procedures that are Required by [CONTACT_675877]:  You will be exerting your self to your limits in these tests.  
Lightheadedness, dizziness, fainting, chest pain, irregular heartbeats, and rarely death have be en seen 
during exercise tests.  You should inform the technicians or physicians if performing these  tests makes  
you feel abnormal.  
 Vein or artery blood tests:  The risks of drawing blood include temporary pain and discomfort and/or tenderness form the needle stick, redness, or bruising at the site, bleeding, fainting, and lightheadedness.  While rare, there is a possibility of infection or a local blood clot with any procedure in which the skin is pi[INVESTIGATOR_675724] a needle.  
 Radiation:  This study involves a r adiation exposure from the CT scans and chest x- rays that is typi[INVESTIGATOR_675747].  The amount of radiation exposure received in this study is below the levels that are thought to r esult in a significant risk of harm ful effects.  If  you are especially 
concerned with radiation exposure, you should discuss this with your study doctor.    Antibiotics:  Antibiotics will be provided to you around the time of the procedure and afterwards to 
minimize possible side effects.  All pharmaceutical drugs have side effects.  Antibiotics may also have side effects, including diarrhea, allergic reactions, and overgrowth of dangerous bacteria such as C. 
difficile which can result in a serious infection.  However, antibiotics are used r outinely to treat COPD 
exacerbations.   
 Anesthesia:  The side effects of moderate procedural sedation or general anesthesia medications an d 
other medications required to perform bronchoscopy include, but are not limited to, allergic reaction, drowsiness, slurred speech, tremor, fatigue, low blood pressure, slowing of the heart rate, anxiety, confusion, dizziness, temporary loss of consciousness, and respi[INVESTIGATOR_2341].  Trained medical professionals with extensive experience and expertise will administ er the medications and will be 
responsible for your care during the course of the procedure.    
Voluntary Participation and Study Withdrawal 
Decisions regarding whether or not you should participate in this study are entirely voluntary.  If you 
decide not to participate, you will not lose any benefits to which you are entitled, nor will you be denied 
access to other available treatments for emphysema.  You will receive the standard treatment and care 
normally provided by [CONTACT_29591].  Information obtained in the operating room after anesthesia is given to you will affect whether or not 
you are eligible to receive treatment during the bronchoscopy procedure.  This will happen, for instance, if it is determined that the air pressure and flow measured in the airways in your lungs make you 
ineligible to meet the study entry criteria or that the anatomy of your lung passageways does not allow 
the physician to place the EBV Implant.  In such an event, you will be sent to  the recovery  room without 
the valve treat ment.   
 Significant new findings discovered during the course of this study, which may affect your willingness to continue participating in the study, will be provided to you in writing .  You may withdraw your 
consent to participate in this study at any time without penalty or loss of benefits .  Also, your 
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, [ADDRESS_913738] you from possible injury arising from excessive blood drawing, excess x-rays, and interactions with other research device s or drugs, or similar hazards.  
 
Pregnancy and Contraception (Birth Control) 
Pregnant women may not participate in this research study as the risk of the procedure on an embryo or 
unborn fetus is unknown.  Women of childbearing potential must actively utilize appropriate means of birth control to avoid becoming pregnant throughout the course of the study.  
 
Confidentiality  
Information derived from this study and from your medical record may be reviewed and photocopi[INVESTIGATOR_491603] (FDA) and/or state and federal regulatory agencies and by [CONTACT_352038], Pulmonx Inc., with protection of confide ntiality so far as permitted by [CONTACT_1289].  
Information resulting from this study and from your medical record may be used for research purposes and may be published; however, you will not be identified by [CONTACT_491609].    
 
Financial Responsibility  
The costs of any routine medical care administered during the study will be the responsibility of you and/or your health insurer. For such routine costs, you will be responsible for any co-payments or deductibles required under your insurance. You are not, however, expected to absorb the cost of any medical care specifically required by [CONTACT_50568]. The study Sponsor (Pulmonx) will pay 
for tests and procedures performed solely for the purpose of this study.    
Research Related Inj ury 
In the event that you believe participation in this research study has led to injury, contact [CONTACT_675831]. You should understand that neither _____________________ (hospi[INVESTIGATOR_307]) nor the Federal Government has any programs to provide compensation for persons participating in research projects who may experience injury. However, necessary facilities, emergency treatment and professional services will be available to you. You should not expect any one to pay you for pain, worry, lost income, or non- medical care costs that occur from taking part in this research study. 
No funds have been set aside by _________________ (hospi[INVESTIGATOR_307]) to pay you in case of injury, nor will the study Sponsor provide direct compensation to patients in the event of an injury.   
Study Information at www.clinicaltrials.gov
 
A description of this clinical trial will be available on the http:www.clinicaltrials.gov, as required by 
U.S. Law.  This web site w ill not include information that can identify you.  At most, the web site will 
include a summary of the results.  You can search this web site at any time.    
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 13 of 16 
 
 Add Financial Compensation Section as Applicable  
This section is s ite specific – include financial compensation information as needed. 
 
Questions  
If you have any questions about the study, its procedures, risks or benefits, your alternatives or your rights, or if you experience a potentially research related injury you should contact  [CONTACT_4904]. If you 
cannot reach your doctor, contact [CONTACT_675832].  
Physician Contact [CONTACT_7171] (24 hour):  
 
Name:   ______________________ 
 
Phone Number:______________________ Alternate Contact [CONTACT_7171] (24 hour):  
 
Name:   ______________________ 
 
Phone Number:______________________ 
  
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 14 of 16 
 
 Authorization to Use and Disclose Health Information 
I agree to permit ____________________ (physician) and his/her staff (“Researchers”) to use and disclose 
health information that identifies me for the purposes described below.  I also agree to permit 
________________________ (hospi[INVESTIGATOR_307]), my doctors, and my other health care providers to disclos e health 
information in my medical records to the Researchers for the purposes described below.    
1. The health information that may be used and disclosed includes all information collected during the research described in this document and health information in my medical records that is relevant to the research described.  
2. The researchers and Pulmonx may use and share my health information to conduct research; 
disclose my health information to Pulmonx to confirm the research results; disclose my health 
information as required by [CONTACT_675833], effectiveness and the conduct of the research; and remove from my health information my name [CONTACT_675883].  
3. Once information that could be used to identify me has been removed, the information that remains is no longer subject to this authorization and may be used and disclosed by [CONTACT_675878] f or other research purposes. 
4. Once my health information has been disclosed to a third party,  federal privacy laws may no longer 
protect it from further disclosure.  However, the researchers and Pulmonx agree to protect my 
health information by [CONTACT_675835].  Also, no publication about the research will reveal my identity without my specific written permission.  These limitations continue even if I revoke this Authorization.   
5. Please not e that you do not have to sign this authorization, but if you do not, you may not be 
allowed to participate in this research study.  You may change your mind and revoke this authorization at any time.  However, if you revoke this authorization, you may no longer be allowed to participate in this research study.  Also, even if you revoke this authorization, the 
information already obtained may remain part of the research.  To revoke this authorization, you must write to: 
 
 
 
 While the research is in progress, you will not be allowed to see your health information that is created or collected in the course of the research.  After the research is finished, however, you may see this information as described in (hospi[INVESTIGATOR_307]) Notice o f Information practices.     
 
6. This authorization does not have an expi[INVESTIGATOR_320]. 
 
 
  
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, [ADDRESS_913739] titled:  Lung Function Improvement after Bronchoscopic Lung Volume Reduction 
with Pulmonx Endobronchial Valves used in Emphysema . 
1) The nature, purpose, and contemplated effects of the project, so far as it affects me, have been fully 
explained to my satisfaction  by [CONTACT_675879].  My consent is informed and given voluntarily.  
2) The details of the procedure proposed have also been explained to me. 
3) It has been explained to me that the purpose of this research project is to improve the quality of 
medical care, and that my involvement may not be of any benefit to me.  
4) I have been given the opportunity to have a member of my family or a friend present while the 
project is explained to me.  
5) I am informed that no information regarding my medical history will be divulged, other than tha t 
described in the consent form, and that my identity will be kept confidential in all published results 
of the study. 
6) I have been informed that my involvement in the project will not affect my relationship with my 
medical advisors in their management of m y health.  I have also been told  that I am free to withdraw 
from the project at any stage without prejudice for future treatment at this hospi[INVESTIGATOR_307], and if I so choose, I can ask for any information collected up to that point to be withheld from use in the 
research. 
7) I declare that all of my questions have been answered to my satisfaction.  
 
If I agree to participate in the research study and if my questions are answered, I should sign this form.  
If I wish to refuse to participate in the study , I may do so without any loss of medical care or benefits.  
Once I have consented, I still have the right to withdraw at any time.  To withdraw, all I have to do is 
complete the Revocation of Consent portion of the form below and provide to or simply tell Dr. 
________________________. 
 
I will be given a copy of this form to keep and to refer to as needed. 
 
Printed Name [CONTACT_2385] (or legal representative):         
 
Signature:        [CONTACT_1782]:      
 I declare that I have been present when the research study was explained to the above participant and I 
believe that the participant has an application and understanding of the explanation given.  
Witness:       Date:      
  
LIBERATE Study  
Clinical In vestigational Plan #630-0012-H 
Appendix 20.  Example Crossover Informed Consent 
 
 
Version:  June 23, 2017               CONFIDENTIAL                Page 16 of 16 
 
  
 
 
REVOCATION OF CONSENT  
I hereby [CONTACT_675880].  
Withdrawal WILL NOT jeopardize any treatment or my relationship with _________________ 
Hospi[INVESTIGATOR_307]. 
 
Printed Name [CONTACT_2385] (or legal representative):        
 
Signature:        [CONTACT_1782]:      
 
 